logotest1logotest1logotest1logotest1
  • WHICH BLENDS ARE BEST FOR ME?
  • 88/8: EXTREME WEIGHTLOSS PROTOCOL (MESSAGE FOR PASSWORD)
  • TESTIMONIALS
  • SHOP
  • CART
  • SAMPLES
  • COMBOS
  • HOME
  • MAILING LIST
  • CONTACT SHIPPING
  • CONTACT GAVIN
  • SCIENCE
  • ABOUT
  • INGREDIENTS
  • TEXT SIGN UP
  • TELEGRAM PORTAL (MESSAGE ORDER NUMBER)
  • INTERSTELLAR BLOGS
  • ULTIMATE DRY FASTING RESOURCE
  • MY ACCOUNT
  • RESET PASSWORD
0
    ✕
              No results See all results
              E K G (Cardioprotective)
              November 16, 2020
              TITANIUM (Anti-Osteoporosis, Bone Health)
              December 19, 2020
              On Sale
              STOMACH RESET COMBO (Fix Virtually All Gastrointestinal Problems) Featuring: PURGE/ PARASLAYER/ HELICO

              STOMACH RESET COMBO (Fix Virtually All Gastrointestinal Problems) Featuring: PURGE/ PARASLAYER/ HELICO

              Rated 5.00 out of 5 based on 14 customer ratings
              (14 customer reviews)

              $825.00 Original price was: $825.00.$495.00Current price is: $495.00.

              SKU: COM-RESETCOMBO Categories: Combos, Exclusive Products Tag: Featured
              Share
              0
              • Description
              • Additional information
              • Reviews 14

              DIRECTIONS: Mix 1/2 teaspoon HELICO and PARASLAYER morning and night in plain unsweetened kefir.


              PURGE dosage is 1/8 – 1/4 tsp as needed and be sure to stay near a toilet!!!! Be careful it’s POTENT!!! 


              100g bag PARASLAYER, HELIC0 & PURGE

              200:1 Concentration


              HELICOBACTER PYLORI

              1 out of 2 people has IT

              Heartburn? Indigestion? Irritable bowel syndrome? Gas? Nutrient absorption issues? Ulcers? Stomach problems in general? There’s a high probability you have this resistant little bacteria camping out in your stomach wreaking havoc.

              “Helicobacter pylori, previously known as Campylobacter pylori, is a gram-negative, helically-shaped, microaerophilic bacterium usually found in the stomach.[6] Its helical shape (from which the genus name, helicobacter, derives) is thought to have evolved in order to penetrate the mucoid lining of the stomach and thereby establish infection.[7][8] The bacterium was first identified in 1982 by Australian doctors Barry Marshall and Robin Warren, who found that it was present in a person with chronic gastritis and gastric ulcers, conditions not previously believed to have a microbial cause.[9][10][11] H. pylori has also been linked to the development of duodenal ulcers, polyps, i. e. benign growths, in the small intestine, large intestine, and rectum, and malignancies of the stomach’s secretory glands (termed stomach adenocarcinoma),[12] of the mucosa-associated lymphoid tissue in the stomach, esophagus, colon, rectum, or tissues around the eye (termed extranodal marginal zone B-cell lymphoma of the cited organ),[13][14][15] and of lymphoid tissue in the stomach (termed diffuse large B-cell lymphoma).[16]

              Many investigators have proposed causal associations between H. pylori and a wide range of other diseases (e.g. idiopathic thrombocytopenic purpura, iron deficiency anemia, atherosclerosis, Alzheimer’s disease,[17] multiple sclerosis, coronary artery disease, periodontitis,[18] Parkinson’s disease, Guillain–Barré syndrome, rosacea, psoriasis, chronic urticaria, spot baldness, various autoimmune skin diseases, Henoch–Schönlein purpura, low blood levels of vitamin B12, autoimmune neutropenia, the antiphospholipid syndrome, plasma cell dyscrasias, central serous chorioretinitis, open angle glaucoma, blepharitis, diabetes mellitus, the metabolic syndrome, various types of allergies, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, hepatic fibrosis, and liver cancer[19]). The bacterial infection has also been proposed to have protective effects for its hosts against infections by other pathogens, asthma, obesity,[17] celiac disease, inflammatory bowel disease,[18] rhinitis, atopic dermatitis,[20] gastroesophageal reflux disease,[21] and esophageal cancer.[21] However, these deleterious and protective effects have frequently been based on correlative rather than direct relationship studies[18] and have often been contradicted by other studies that show either the opposite or no effect on the cited disease.[19] Consequently, many of these relationships are currently regarded as questionable and in need of more definitive studes.[17] They are not considered further here.

              Some studies suggest that H. pylori plays an important role in the natural stomach ecology, e.g. by influencing the type of bacteria that colonize the gastrointestinal tract.[22][19] Other studies suggest that non-pathogenic strains of H. pylori may be beneficial, e.g., by normalizing stomach acid secretion,[23] and may play a role in regulating appetite, since the bacterium’s presence in the stomach results in a persistent but reversible reduction in the level of ghrelin, an hormone that increases appetite.[23]

              In general, over 50% of the world’s population has H. pylori in their upper gastrointestinal tracts[5] with this infection (or colonization) being more common in developing countries.[4] In recent decades, however the prevalence of H. pylori colonization of the gastrointestinal tract has declined in many countries. This is attributed to improved socioeconomic conditions: in the United States of America, for example, the prevalence of H. pylori, as detected by endoscopy conducted on a referral population, fell from 65.8 to 6.8% over a recent 10 year period while over the same time period in some developing countries H. pylori colonization remained very common with prevalence levels as high as 80%.[24] In all events, H. pylori infection is usually asymptomatic, being associated with overt disease (commonly gastritis or peptic ulcers rather than the relatively very rarely occurring cancers) in less than 20% of cases.[25].” – WIKI

               


              Inflammation, DNA Damage, Helicobacter pyloriand Gastric Tumorigenesis


              Helicobacter pylori (H. pylori) is a Gram negative bacterium that colonizes the stomach of almost half human population. It has evolved to escape immune surveillance, establishes lifelong inflammation, predisposing to genomic instability and DNA damage, notably double strand breaks. The epithelial host cell responds by activation of DNA damage repair (DDR) machinery that seems to be compromised by the infection. It is therefore now accepted that genetic damage is a major mechanism operating in cases of H. pylori induced carcinogenesis. Here, we review the data on the molecular pathways involved in DNA damage and DDR activation during H. pylori infection.


              Helicobacter pylori-induced premature senescence


              Helicobacter pylori, one of the most frequently observed bacterium in the human intestinal flora, has been widely studied since Marshall and Warren documented a link between the presence of H. pylori in the gastrointestinal tract and gastritis and gastric ulcers. Interestingly, H. pylori has also been found in several other epithelial tissues, including the eyes, ears, nose and skin that may have direct or indirect effects on host physiology and may contribute to extragastric diseases, e.g. chronic skin diseases. More recently, it has been shown that H. pylori cytotoxin CagA expression induces cellular senescenceof human gastric nonpolarized epithelial cells that may lead to gastrointestinal disorders and systemic inflammation. Here, we hypothesize that also chronic skin diseases may be promoted by stress-induced premature senescence (SIPS) of skin cells, namely fibroblasts and keratinocytes, stimulated with H. pylori cytotoxins. Future studies involving cell culture models and clinical specimens are needed to verify the involvement of H. pylori in SIPS-based chronic skin diseases.


              H. pylori infection leads to an increased rate of diabetes


              CONCLUSIONS We demonstrated for the first time that H. pylori infection leads to an increased rate of incident diabetes in a prospective cohort study. Our findings implicate a potential role for antibiotic and gastrointestinal treatment in preventing diabetes.


              Proton Pump Inhibitors Accelerate Endothelial Senescence


              Rationale: Proton pump inhibitors (PPIs) are popular drugs for gastroesophageal reflux, which are now available for long-term use without medical supervision. Recent reports suggest that PPI use is associated with cardiovascular, renal, and neurological morbidity.

              Objective: To study the long-term effect of PPIs on endothelial dysfunction and senescence and investigate the mechanism involved in PPI-induced vascular dysfunction.

              Methods and Results: Chronic exposure to PPIs impaired endothelial function and accelerated human endothelial senescence by reducing telomere length.

              Conclusions:Our data may provide a unifying mechanism for the association of PPI use with increased risk of cardiovascular, renal, and neurological morbidity and mortality.

              A new paradigm for GERD pathogenesis. Not acid injury, but cytokine-mediated inflammation driven by HIF-2α: a potential role for targeting HIF-2α to prevent and treat reflux esophagitis.


              Traditionally, reflux esophagitis was assumed to develop as a caustic, chemical injury inflicted by refluxed acid. Recently, however, studies in rats and humans suggest that reflux esophagitis develops as a cytokine-mediated inflammatory injury, with hypoxia inducible factor (HIF)-2α playing a major role. In response to the reflux of acid and bile, HIF-2α in esophageal epithelial cells becomes stabilized, thereby increasing production of pro-inflammatory cytokines that attract T lymphocytes and other inflammatory cells to damage the esophagus. Recent studies have identified small molecule inhibitors of HIF-2α that demonstrate exquisite isoform selectivity, and clinical trials for treatment of HIF-2α-driven kidney cancers are ongoing. It is conceivable that a HIF-2α-directed therapy might be a novel approach to prevention and treatment of reflux esophagitis.


              The Helicobacter pylori Urease Virulence Factor Is Required for the Induction of Hypoxia-Induced Factor-1α in Gastric Cells


              Chronic Helicobacter pylori infection increases the risk of gastric cancer and induction of hypoxia-induced factor (HIF), which is frequently associated with the development and progression of several types of cancer. We recently showed that H. pylori activation of the PI3K-AKT-mTOR pathway in gastric cells increased HIF-1α expression. Here, we identified the H. pylori virulence factor responsible for HIF-1α induction. A mutant of the H. pylori 84-183 strain was identified with reduced ability to induce HIF-1α. Coomassie blue staining of extracts from these bacteria separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) revealed poor expression of urease subunits that correlated with reduced urease activity. This finding was confirmed in the 26695 strain, where urease mutants were unable to induce HIF-1α expression. Of note, HIF-1α induction was also observed in the presence of the urease inhibitor acetohydroxamic acid at concentrations (of 20 mM) that abrogated urease activity in bacterial culture supernatants, suggesting that enzymatic activity of the urease is not required for HIF-1α induction. Finally, the pre-incubation of the human gastric adenocarcinoma cell line AGS with blocking antibodies against Toll-like receptor-2 (TLR2), but not TLR4, prevented HIF-1α induction. In summary, these results reveal a hitherto unexpected role for the urease protein in HIF-1α induction via TLR2 activation following H. pylori infection of gastric cells.

              INGREDIENTS:

              Abrus cantoniensis (Fabaceae)
              • Impact Of Abrus Cantoniensis Ethanolic Extract On The Growth Inhibition Of Helicobacter Pylori
              • In Vitro Anti-Helicobacter Pylori Action Of 30 Chinese Herbal Medicines Used To Treat Ulcer Diseases
              • Progress In Use Of Natural Products And Their Active Components Against Helicobacter Pylori
              • Pharmacological ins and outs of medicinal plants against Helicobacter pylori: A review

                Chinese conducted the antibacterial action of thirty herbal medicines, which have been frequently used since ancient times for the treatment of gastritis-like disorders (Li et al., 2005). Among those thirty tested Chinese herbs, the ethanol extracts of Saussurea lappa (Asteraceae), Abrus cantoniensis (Fabaceae) and Eugenia caryophyllata (Myrtaceae) had the most strongly bacteriostatic effect (MICs: approximately 40 mg/ml).

              Agaricus bisporus extract
              • Anti-Helicobacter pyloriactivity of mushrooms
              • Antimicrobial properties of the button mushroom, Agaricus bisporus: A mini-review

              Ageratum conyzoides extract

              • In-vitro antimicrobial activity of Ageratum conyzoides (Linn) on clinical isolates of Helicobacter pylori
              • Pharmacological ins and outs of medicinal plants against Helicobacter pylori: A review

                Ndip et al screened ten medicinal plants from Cameron against 15 clinical isolates by disk diffusion method and determine MIC and minimum bactericidal concentration (MBC) values. All the tested plants showed anti-H.pylori activity with inhibition zone diameters of 0-30 mm. Out of these, Ageratum conyzoides, Scleria striatinux and Lycopodium cernua showed potent anti-H. pylori activity with the lowest MIC and MBC of 0.032 mg/mL and 0.098 mg/mL respectively (Ndip et al., 2007).


              Allicin
              • A Comprehensive Review on Pharmacotherapeutics of Three Phytochemicals, Curcumin, Quercetin, and Allicin, in the Treatment of Gastric Cancer
              • Activities of Garlic Oil, Garlic Powder, and Their Diallyl Constituents against Helicobacter pylori
              • Allicin as a potent antibiotic against Escherichia coli, Proteus vulgaris and Helicobacter pylori
              • Allicin as add-on therapy for Helicobacter pylori infection: A systematic review and meta-analysis.
              • Allicin possess significant activity against Helicobacter Pylori
              • Allyl‐thiosulfinates, the Bacteriostatic Compounds of Garlic against Helicobacter pylori
              • Antibacterial effect of garlic and omeprazole on Helicobacter pylori
              • Assessment of antibacterial effect of garlic in patients infected with Helicobacter pylori using urease breath test
              • Helicobacter pylori eradication with beta carotene, ascorbic acid and allicin
              • In Vitro Inhibition of the Growth of Helicobacter pylori by Oil-Macerated Garlic Constituents
              • Thermal degradation of allicin in garlic extracts and its implication on the inhibition of the in‐vitro growth of Helicobacter pylori

              Angelica sinensis extract
              • Beneficial effect of Burdock complex on asymptomatic Helicobacter pylori‐infected subjects: A randomized, double‐blind placebo‐controlled clinical trial
              • Effectiveness of great burdock essence compounds in the adjuvant treatment of gastric ulcer patients infected with Helicobacter pylori

              Artemisia annua Extract
              • Anti-Helicobacter pylori Potential of Artemisinin and Its Derivatives

              Bifidobacterium bifidum
              • Bacterium belonging to the genus Bifidobacterium and utilization of the same
              • Bifidobacterium bifidum BF-1 suppresses Helicobacter pylori-induced genes in human epithelial cells
              • Construction of recombinant Bb-hpaA-vacA vaccine of Helicobacter pylori [J]
              • Effect of Bifidobacterium bifidum fermented milk on Helicobacter pylori and serum pepsinogen levels in humans
              • Effect of Lactobacillus acidophilus and Bifidobacterium bifidum supplementation to standard triple therapy on Helicobacter pylori eradication and dynamic changes …
              • Effect of probiotics on preventing disruption of the intestinal microflora following antibiotic therapy: a double-blind, placebo-controlled pilot study
              • Fermented milk that contains Bifidobacterium bifidum BF-1 (BF-1), a probiotic strain, and Streptococcus thermophilus YIT 2021 (ST) is known to improve Helicobacter pylori -associated gastritis in humans.
              • Living cells of probiotic Bifidobacterium bifidum YIT 10347 detected on gastric mucosa in humans
              • Method for obtaining a novel strain of bifidobacterium bifidum with activity against infection by helicobacter pylori
              • Novel Probiotic Bifidobacterium bifidum CECT 7366 Strain Active against the Pathogenic Bacterium Helicobacter pylori
              • The use of probiotics in Helicobacter pylori eradication therapy

              Bombax malabaricum DC. Extract
              • Screening of anti-Helicobacter pylori herbs deriving from Taiwanese folk medicinal plants

              Broccoli sprouts (sulforaphane)
              • A Comparative Study Of Broccoli Sprouts Powder And Standard Triple Therapy On Cardiovascular Risk Factors Following H.Pylori Eradication: A Randomized Clinical Trial In Patients With Type 2 Diabetes
              • Anti-Bacterial Properties Of Herbs Against Helicobacter Pylori Infection: A Review
              • Clinical And Molecular Evidence Of The Consumption Of Broccoli, Glucoraphanin And Sulforaphane In Humans
              • Daily Intake Of Sulforaphane-Rich Broccoli Sprouts Prevents Progression Of High Salt Diet-Induced Gastric Atrophy In H. Pylori-Infected C57/Bl6 Mice In Vivo
              • Dietary Sulforaphane-Rich Broccoli Sprouts Reduce Colonization And Attenuate Gastritis In Helicobacter Pylori–Infected Mice And Humans
              • Efficacy Of Sulforaphane In Eradicating Helicobacter Pylori In Human Gastric Xenografts Implanted In Nude Mice
              • High-Sulforaphane Broccoli Sprout Powder Reduces Serum Nitric Oxide Metabolites In Helicobacter Pylori Infected Patients
              • It Was Found That Foods With Measurable Anti‐H. Pylori Activity Have An Effect Greater In Combination Than The Sum Of Foods Tested Singly, And That This Was Most Noticeable With A Combination Of Broccoli Sprouts And Blackcurrant Oil.
              • Oral Broccoli Sprouts For The Treatment Of Helicobacter Pylori Infection: A Preliminary Report
              • Sulforaphane Inhibits Extracellular, Intracellular, And Antibiotic-Resistant Strains Of Helicobacter Pylori And Prevents Benzo [A] Pyrene-Induced Stomach Tumors
              • Sulforaphane Is A Very Potent And Highly Selective Antibiotic Against Helicobacter Pylori. Sulforaphane Is Bacteriostatic Against Many Clinical Isolates Of H. Pylori Including Those That Are Resistant To Conventional Antibiotics.
              • The Chemopreventive Power Of Crucifers: Isothiocyanates And Glucosinolates
              • The Effects Of Broccoli Sprout Extract Containing Sulforaphane On Lipid Peroxidation And Helicobacter Pylori Infection In The Gastric Mucosa
              • Using Food To Reduce H. Pylori‐Associated Inflammation

              Capsaicin
              • Abstract A77: Gastric Cancer Risk In Relation To Capsaicin Intake, H. Pylori Caga Status, And Il1B-31 C> T Genotypes
              • Anti‐Inflammatory Effect Of Capsaicin In Helicobacter Pylori‐Infected Gastric Epithelial Cells
              • Anti‐Inflammatory Effects Of Capsaicin And Piperine On Helicobacter Pylori‐Induced Chronic Gastritis In Mongolian Gerbils
              • Approach To Role Of Capsaicin-Sensitive Afferent Nerves In The Development And Healing In Patients With Chronic Gastritis
              • Capsaicin As An Inhibitor Of The Growth Of The Gastric Pathogen Helicobacter Pylori
              • Capsaicin As New Orally Applicable Gastroprotective And Therapeutic Drug Alone Or In Combination With Nonsteroidal Anti-Inflammatory Drugs In Healthy Human Subjects …
              • Capsaicin Consumption, Helicobacter Pylori Caga Status And Il1B-31C> T Genotypes: A Host And Environment Interaction In Gastric Cancer
              • Capsaicin-Induced Immunomodulation Results In Reduced …
              • Capsaicin-Sensitive Afferentation In Helicobacter Pylori Positive Gastritis Before And After Eradication
              • Capsaicin-Sensitive Afferentation Represents An Indifferent Defensive Pathway From Eradication In Patients With H. Pylori Gastritis
              • Inhibitory Effect Of Capsaicin On Interleukin-8 Production By Helicobacter Pylori-Infected Mkn-45 Cells
              • Oral Capsaicin Test And Functional Dyspepsia: Any Consideration For Helicobacter Pylori Infection And Concomitant Medications?
              • Re: Peppers At Treatment For Helicobacter Pylori Infection

              Carthamus tinctorious extract
              • In vitro Inhibition of Helicobacter pylori by Some Spices and Medicinal Plants Used in Iran


              Cassia twig extract
              • Cinnamomi Ramulus ethanolic extract showed the potent antioxidant activity and cytotoxicity of Helicobacter pylori (H. pylori) and acid-neutralizing capacity.
              • Comparison of the antibacterial activities according to the extracting methods of Cinnamomum cassia against Helicobacter pylori
              • These results demonstrate that it can be successfully cured against H. pylori infection and protected from H. pylori-induced pathology with Cinnamomum cassia.

              Celery Seed (novel unnamed component)
              • A Novel Compound From Celery Seed With A Bactericidal Effect Against Helicobacter Pylori
              • An Extract Of The Seed From Celery (Apium Graviolens) (Cse), And Fractions Thereof, Have Been Found To Possess Anti-Inflammatory Activity, Gastro-Protective Activity, And Anti-Helicobacter Pylori Activity.
              • Celery Seed And Related Extracts With Antiarthritic, Antiulcer, And Antimicrobial Activities

              Coptis chinensis extract
              • Bactericidal Action Of 5 Kinds Of Traditional Herbal Drugs For Helicobacter Pylori
              • Combined Antibacterial Activity Of Three Chinese Drugs Against Helicobacter Pylori
              • Coptis Chinensis Is Better Than Berberine Gydrogchloride In Inhibiting H.Pylori.
              • Coptis Chinensis, Known As ‘Huanglian’ In Chinese, Is Traditionally Used In China For The Treatment Of Diarrhea And H. Pylori-Related Gastrointestinal Diseases
              • Coptis Chinensis,Scutellaria Baicalensis And Rheum Officinale Present A Certain Hp Inhibition
              • Inhibitory Activities Of Palmatine From Coptis Chinensis Against Helicobactor Pylori And Gastric Damage
              • Protective Effects And Its Mechanisms Of Total Alkaloids From Rhizoma Coptis Chinensis On Helicobacter Pylori Lps Induced Gastric Lesion In Rats
              • Protective Effects And Its Mechanisms Of Total Alkaloids From Rhizoma Coptis Chinensis On Helicobacter Pylori Lps Induced Gastric Lesion In Rats
              • Relation Between Helicobacter Pylori And Pathogenesis Of Chronic Atrophic Gastritis And The Research Of Its Prevention And Treatment
              • The Lineweaver-Burk Plot Analysis Indicated That The Inhibition Pattern Of C. Chinensis Against Urease Was Noncompetitive For Both H. Pylori Urease And Jack Bean Urease.
              • The Traditional Chinese Combination Has Special Curative Effects On Gastric Ulcer And Duodenal Ulcer And Has Inhibiting Effect On Helicobacter Pylori.
              • Traditional Chinese Medicine Composition For Treating Helicobacter Pylori Disease

              Cranberry (Vaccinium macrocarpon)
              • A High Molecular Mass Constituent Of Cranberry Juice Inhibits Helicobacter Pylori Adhesion To Human Gastric Mucus
              • Addition Of Cranberry To Proton Pump Inhibitor-Based Triple Therapy For Helicobacter Pylori Eradication
              • Cranberry Extract Suppresses Interleukin-8 Secretion From Stomach Cells Stimulated By Helicobacter Pylori In Every Clinically Separated Strain But Inhibits Growth In Part Of The Strains
              • Cranberry Juice Cocktail For Prevention And Treatment Of Helicobacter Pylori Infection In Mice Model
              • Cranberry Synergies For Dietary Management Of Helicobacter Pylori Infections
              • Effect Of Cranberry Juice On Eradication Of Helicobacter Pylori In Patients Treated With Antibiotics And A Proton Pump Inhibitor
              • Efficacy Of Cranberry Juice On Helicobacter Pylori Infection: A Double‐Blind, Randomized Placebo‐Controlled Trial
              • Enrichment Of Phenolic Antioxidants And Anti-Helicobacter Pylori Properties Of Cranberry Pomace By Solid-State Bioprocessing
              • Growth Inhibitory Action Of Cranberry On Helicobacter Pylori
              • Inhibition Of Helicobacter Pylori Adhesion To Human Gastric Mucus By A High-Molecular-Weight Constituent Of Cranberry Juice
              • Inhibition Of Helicobacter Pylori And Associated Urease By Oregano And Cranberry Phytochemical Synergies
              • Is Cranberry Juice Effective In The Treatment And Prevention Of Helicobacter Pylori Infection Of Mice?
              • Modulation Of Helicobacter Pylori Colonization With Cranberry Juice And Lactobacillus Johnsonii La1 In Children
              • Potential Of Cranberry For Suppressing Helicobacter Pylori, A Risk Factor For Gastric Cancer
              • Pp80 Modulation Of Helicobacter Pylori Colonization With Cranberry Juice Plus Lactoferrin In Asymptomatic Children
              • Susceptibility Of Helicobacter Pylori Isolates To The Antiadhesion Activity Of A High-Molecular-Weight Constituent Of Cranberry

              Dateplum persimmon extrat
              • Fresh Ginger, Turmeric Extract And Dark Plum Extract Product Composition For Improving Helicobacter Pylori In Gastrointestinal Tracts
              • Method For Testing Antimicrobial Activity, Medicine Against Antimicrobial Helicobacter Pylori, Method For Preventing Occurrence Of Helicobacter Pylori And Method For Using Plum Extract
              • Preparation Method Of Active Dark Plum Extract And Application In Inhibition Of Helicobacter Pylori

              Decursin
              • Decursin And Decursinol Angelate Selectively Inhibit Nadh-Fumarate Reductase Of Ascaris Suum
              • Decursin Inhibits Tumor Growth, Migration, And Invasion In Gastric Cancer By Down-Regulating Cxcr7 Expression
              • Pharmacological ins and outs of medicinal plants against Helicobacter pylori: A review

                First study of screening medicinal plants against H. pylori was published by Korean researchers who screened several medicinal plants against H. pylori and found extracts of Eugenia caryophyllata (flower), Coptidis japonica (rhizoma), Magnolia officinalis (cortex), Rheum palmatum (rhizoma) and Rhus javanica (galla rhois) had bacteriostatic effect on H. pylori. On further isolation of active constituents, the effects of decursinol angelate and decursin on bacterial inhibition were the most potent with minimum inhibitory concentrations (MICs) values of 6-20 mg/ml (Bae et al., 1998).


              EGCG
              • Detouring The Undesired Route Of Helicobacter Pylori-Induced Gastric Carcinogenesis
              • Growth Inhibitory, Bactericidal, And Morphostructural Effects Of Dehydrocostus Lactone From Magnolia Sieboldii Leaves On Antibiotic-Susceptible And -Resistant Strains Of Helicobacter Pylori
              • In Mongolian Gerbils, Green Tea Catechins, Such As Egcg, Strongly Inhibited H. Pylori Urease Activity In Vitro And Suppressed H. Pylori-Induced Gastritis, While Garlic And Its Diallyl Sulfur Compounds Showed Potential Effects On H. Pylori Elimination
              • In Vitro And In Vivo Activities Of Tea Catechins Against Helicobacter Pylori
              • Inhibition Of Bacterial Toxin Recognition Of Membrane Components As An Anti-Virulence Strategy
              • Natural Products And Food Components With Anti-Helicobacter Pylori Activities
              • Preparation Of Epigallocatechin Gallate-Loaded Nanoparticles And Characterization Of Their Inhibitory Effects On Helicobacter Pylori Growth In Vitro And In Vivo
              • Prevention Of Gastric Cancer: Eradication Of Helicobacter Pylori And Beyond

              Eugenia caryophyllata (CLOVES)

              • In vitro anti-Helicobacter pylori action of 30 Chinese herbal medicines used to treat ulcer diseases
              • Pharmacological ins and outs of medicinal plants against Helicobacter pylori: A review.

                Chinese conducted the antibacterial action of thirty herbal medicines, which have been frequently used since ancient times for the treatment of gastritis-like disorders (Li et al., 2005). Among those thirty tested Chinese herbs, the ethanol extracts of Saussurea lappa (Asteraceae), Abrus cantoniensis (Fabaceae) and Eugenia caryophyllata (Myrtaceae) had the most strongly bacteriostatic effect (MICs: approximately 40 mg/ml).

              • Eugenol: a potential phytochemical with multifaceted therapeutic activities

              Fructus amomi extract
              • Killing H Pylori Capsule Containing More Than Ten Kinds Of Chinese Herbs Such As Radix Salviae Miltiorrhizae, Poria Coccus, Atractylodes Macrocephala, Saussurea Lappa, Magnolia Officinalis, Fructus Amomi, Wu Mei, Etc Has Been Proved, In Animal Experiments And Clinical Trials, To Have The Efficacy Of Improving Mucosal Lesions
              • Volatile Oil From Amomi Fructus Attenuates 5-Fluorouracil-Induced Intestinal Mucositis

               

              GALANGIN (Alpinia officinarum extract)
              • Anti-Helicobacter pylori diarylheptanoid identified in the rhizome of Alpinia officinarum
              • Taken together, some spices, like Myristica fragrans and Alpinia officinarum, have been demonstrated to effectively inhibit H. pylori
              • Diarylheptanoid from the rhizome of Alpinia officinarum inhibited three standard H. pylori strains in vitro with MICs of 48, 24, and 24 μg/mL, respectively, which were comparable to that of metronidazole
              GENIPOSIDE (Fructus Gardeniae)
              • The Suppressive Effects of Geniposide and Genipin on Helicobacter pylori Infections In Vitro and In Vivo
              Ganoderma lucidum extract
              • Anti-Helicobacter Pylori Activity Of Mushrooms
              • Ganoderma Lucidum Pharmacopuncture For Teating Ethanol-Induced Chronic Gastric Ulcers In Rats
              • Ganoderma Lucidum Pharmacopuncture For The Treatment Of Acute Gastric Ulcers In Rats
              • Interaction Of Helicobacter Pylori With C-Type Lectin Dendritic Cell-Specific Icam Grabbing Nonintegrin
              • Mechanism Of The Antiulcerogenic Effect Of Ganoderma Lucidum Polysaccharides On Indomethacin-Induced Lesions In The Rat
              • The Solid-State Fermentation Of Artemisia Capillaris Leaves With Ganoderma Lucidum Enhances The Anti-Inflammatory Effects In A Model Of Atopic Dermatitis

              Golden cypress Cortex Phellodendri Chinensis) extract
              • Comparison of Helicobacter pylori urease inhibition by Rhizoma Coptidis, Cortex Phellodendri and Berberine: mechanisms of interaction with the sulfhydryl group
              • Screening test for anti-Helicobacter pylori activity of traditional Chinese herbal medicines
              • Gastroprotective effect of alkaloids from cortex phellodendri on gastric ulcers in rats through neurohumoral regulation
              • Studied Chinese herbs on Helicobacter pylori
              • Potent anti‐microbial activity of traditional Chinese medicine herbs against Candida species

              Hawthorn (Crataegus pinnatifida) Extract
              • Anti-inflammatory, gastroprotective, free-radical-scavenging, and antimicrobial activities of hawthorn berries ethanol extract
              • Comparative studies on the regulatory effects of raw and charred hawthorn on functional dyspepsia and intestinal flora
              • Study on the antimicrobial activities of herbal extracts against Helicobacter pylori
              Juglans regia extract
              • Anti‐Helicobacter Pylori Activities Of Six Iranian Plants
              • In Vitro Antibacterial Activity Of Some Iranian Medicinal Plant Extracts Against Helicobacter Pylori
              Korean Red Ginseng extract
              • Abstract B45: Inhibitory Effects Of Fermented Korean Red Ginseng On Helicobacter Pylori-Induced Gastric Inflammation And Carcinogenesis
              • Effect Of Korean Red Ginseng On Helicobacter Pylori-Induced Expression Of Inflammatory Mediators In Gastric Mucosa Of Mongolian Gerbil
              • Efficacy Of Korean Red Ginseng Supplementation On Eradication Rate And Gastric Volatile Sulfur Compound Levels After Helicobacter Pylori Eradication Therapy
              • Helicobacter Pylori Infection And Halitosis–Evidence, Hypothesis, And Korean Red Ginseng To Mitigate Its Effect
              • Inhibitory Effect Of Korean Red Ginseng Extract On Dna Damage Response And Apoptosis In Helicobacter Pylori–Infected Gastric Epithelial Cells
              • Korean Red Ginseng Extract Inhibits P53-Dependent Apoptosis In Helicobacter Pylori-Infected Gastric Epithelial Cells
              • Korean Red Ginseng: Qualitative And Quantitative Benefits On Helicobacter Pylori Infection
              • Protective Effect Of Korean Red Ginseng Extract Against Helicobacter Pylori-Induced Gastric Inflammation In Mongolian Gerbils

              L. rhamnosus GG
              • Baicalin, Baicalein, And Lactobacillus Rhamnosus Jb3 Alleviated Helicobacter Pylori Infections In Vitro And In Vivo
              • Characterization Of The Immunomodulatory And Anti-Helicobacter Pylori Properties Of The Human Gastric Isolate Lactobacillus Rhamnosus Uco-25A
              • Honey-Derived Lactobacillus Rhamnosus Alleviates Helicobacter Pylori-Induced Gastro-Intestinal Infection And Gastric Inflammation In C57Bl/6 Mice: An Immuno …
              • Lactobacillus Rhamnosus Gg Supplementation To Reduce Side-Effects Of Anti-Helicobacter Pylori Treatment
              • The Anti-Helicobacter Pylori Effects Of Lactobacillus Acidophilus, L. Plantarum, And L. Rhamnosus In Stomach Tissue Of C57Bl/6 Mice
              • The Probiotic Lactobacillus Rhamnosus For Alleviation Of Helicobacter Pylori-Associated Gastric Pathology In East Africa

              Lactobacillus reuteri
              • Analysis Of The Microbial Ecology Between Helicobacter Pylori And The Gastric Microbiota Of Mongolian Gerbils
              • Evidence Base Of Lactobacillus Reuteri Efficacy In The Treatment Of Diseases Associated With Helicobacter Pylori
              • Evidence Base Of Lactobacillus Reuteri Efficacy In The Treatment Of Diseases Associated With Helicobacter Pylori.
              • Helicobacter Pylori Eradication: Sequential Therapy And Lactobacillus Reuteri Supplementation
              • Impact Of Lactobacillus Reuteri Supplementation On Anti-Helicobacter Pylori Levofloxacin-Based Second-Line Therapy
              • Inclusion Of Lactobacillus Reuteri In The Treatment Of Helicobacter Pylori In Sardinian Patients: A Case Report Series
              • Inhibition Of Binding Of Helicobacter Pylori To The Glycolipid Receptors By Probiotic Lactobacillus Reuteri
              • Inhibition Of Helicobacter Pylori Infection In Humans By Lactobacillus Reuteri Atcc 55730 And Effect On Eradication Therapy: A Pilot Study
              • Lactobacillus Reuteri Improves The Eradication Rate Of Helicobacter Pylori
              • Lactobacillus Reuteri In Management Of Helicobacter Pylori Infection In Dyspeptic Patients: A Double-Blind Placebo-Controlled Randomized Clinical Trial
              • Lactobacillus Reuteri In The Treatment Of Helicobacter Pylori Infection
              • Lactobacillus Reuteri Strain Combination In Helicobacter Pylori Infection: A Randomized, Double-Blind, Placebo-Controlled Study
              • Lactobacillus Reuteri Tablets Can Suppress Helicobacter Pylori Infection: A Double-Blind, Randomised, Placebo-Controlled Cross-Over Clinical Study: 98
              • Lactobacillus Reuteri Therapy To Reduce Side‐Effects During Anti‐Helicobacter Pylori Treatment In Children: A Randomized Placebo Controlled Trial
              • Lactobacillus Reuteri Versus Triple Therapy For The Eradication Of Helicobacter Pylori In Functional Dyspepsia
              • Lactobacillus Reuteri–An Alternative In The First-Line Of Helicobacter Pylori Eradication
              • No Significant Impact Of Lactobacillus Reuteri On Eradication Of Helicobacter Pylori In Children (Double-Blind Randomized Clinical Trial)
              • Non-Viable Lactobacillus Reuteri Dsmz 17648 (Pylopass™) As A New Approach To Helicobacter Pylori Control In Humans
              • Role Of Probiotics In Helicobacter Pylori Eradication: Lessons From A Study Of Lactobacillus Reuteri Strains Dsm 17938 And Atcc Pta 6475 (Gastrus®) And A Proton …
              • Significant Reduction In Helicobacter Pylori Load In Humans With Non-Viable Lactobacillus Reuteri Dsm17648: A Pilot Study
              • Some Studies Found That Lacobacillus Reuteri Is Able To Prevent Helicobacter Pylori Adhesion To Cell Receptor Molecules In Vitro.
              • The Effect Of Lactobacillus Reuteri Supplementation In Helicobacter Pylori Infection: A Placebo-Controlled, Single-Blind Study
              • The Efficacy And The Safety Of Lactobacillus Reuteri Dsmz17648 In The Treatment Of Helicobacter Pylori Positive Patients
              • The Elongation Factor Tu From Lactobacillus Reuteri Inhibits The Adhesion Of Helicobacter Pylori To Porcine Gastric Mucin
              • Twice‐A‐Day Ppi, Tetracycline, Metronidazole Quadruple Therapy With Pylera® Or Lactobacillus Reuteri For Treatment Naïve Or For Retreatment Of Helicobacter Pylori. Two Randomized Pilot Studies

              Lions Mane Mushroom
              • Anti-Helicobacter Pylori Activity Of Bioactive Components Isolated From Hericium Erinaceus
              • In Vitro And In Vivo Inhibition Of Helicobacter Pylori By Ethanolic Extracts Of Lions Mane Medicinal Mushroom Hericium Erinaceus (Agaricomycetes)
              • In Vitro Anti-Helicobacter Pylori Effects Of Medicinal Mushroom Extracts, With Special Emphasis On The Lion’S Mane Mushroom, Hericium Erinaceus (Higher …
              • Preparation, Characterization, And Anti-Helicobacter Pylori Activity Of Bi3+-Hericium Erinaceus Polysaccharide Complex

              Luteolin
              • In Silico Molecular Modeling and Docking Studies on Luteolin Derivatives as Novel Helicobacter Pylori β-hydroxyacyl-acyl carrier protein dehydratase Inhibitor from Biebersteinia multifida DC.
              • Inhibitory Actions Of Luteolin On The Growth And Arylamine N-Acetyltransferase Activity In Strains Of Helicobacter Pylori From Ulcer Patients
              • Luteolin isolate from the methanol extract identified as the single-carbon compound responsible for broad antiulcer activities of Cassia singueana Leaves.
              • Suppressive Effects Of Selected Food Phytochemicals On Cd74 Expression In Nci-N87 Gastric Carcinoma Cells

              Lycopodium cernua
              • In Vitro Anti-Helicobacter Pylori Activity Of Extracts Of Selected Medicinal Plants From North West Cameroon
              • In Vitro Anti-Helicobacter Pylori Activity Of Lycopodium Cernuum (Linn) Pic. Serm
              • Preliminary Phytochemical Screening And In Vitro Anti-Helicobacter Pylori Activity Of Extracts Of The Stem Bark Of Bridelia Micrantha (Hochst., Baill., Euphorbiaceae)
              • Role Of Phosphate Solubilizing Burkholderia Spp. For Successful Colonization And Growth Promotion Of Lycopodium Cernuum L.(Lycopodiaceae) In Lateritic Belt …
              • Pharmacological ins and outs of medicinal plants against Helicobacter pylori: A review

                Ndip et al screened ten medicinal plants from Cameron against 15 clinical isolates by disk diffusion method and determine MIC and minimum bactericidal concentration (MBC) values. All the tested plants showed anti-H.pylori activity with inhibition zone diameters of 0-30 mm. Out of these, Ageratum conyzoides, Scleria striatinux and Lycopodium cernua showed potent anti-H. pylori activity with the lowest MIC and MBC of 0.032 mg/mL and 0.098 mg/mL respectively (Ndip et al., 2007).


              Mangnolia officinalis extract
              • Anti-Helicobacter pylori activity and inhibition of gastritis by Magnolia officinalis extract

              Mastic Gum extract
              • Antimicrobial Activity Of The Essential Oil Isolated From Pistacia Lentiscus Leaves Against Helicobacter Pylori Algerian Clinical Isolates
              • Bactericidal Activity Of Pistacia Lentiscus Mastic Gum Against Helicobacter Pylori
              • Chemical Composition Of The Essential Oil Of Mastic Gum And Their Antibacterial Activity Against Drug-Resistant Helicobacter Pylori
              • Experimental Study On Mastic Gum Therapy For Helicobacter Pylori Infection [J]
              • Helicobacter Pylori In Ice Cream And Its Control Using Mastic Gum Essential Oil
              • In Vitro And In Vivo Activities Of Chios Mastic Gum Extracts And Constituents Against Helicobacter Pylori
              • Mastic Gum Has No Effect On Helicobacter Pylori Load In Vivo
              • Mastic Gum Kills Helicobacter Pylori
              • Selection Of Effective Composition Of Mastic Gum Against Helicobacter Pylori In Vitro [J]
              • The Effect Of Mastic Gum On Helicobacter Pylori: A Randomized Pilot Study
              Oregano
              • Inhibition Of Helicobacter Pylori And Associated Urease By Oregano And Cranberry Phytochemical Synergies
              • Phenolic Antioxidants From Clonal Oregano (Origanum Vulgare) With Antimicrobial Activity Against Helicobacter Pylori
              • Binary and Tertiary Mixtures of Satureja hortensis and Origanum vulgare Essential Oils as Potent Antimicrobial Agents Against Helicobacter pylori

              Plumbago zeylanica L. extract
              • Anti-Helicobacter Pylori Activity Of Plumbago Zeylanica L.
              • Anti-Helicobacter Pylori And Cytotoxic Activity Of Detoxified Root Of Plumbago Auriculata, Plumbago Indica And Plumbago Zeylanica
              • High-Performance Liquid Chromatography For Quantification Of Plumbagin, An Anti-Helicobacter Pylori Compound Of Plumbago Zeylanica L.
              • Pharmacological ins and outs of medicinal plants against Helicobacter pylori: A review.

                Researchers from Taiwan conducted a large scale study and employed fifty medicinal plants against H. pylori. While half of the employed plants showed bactericidal activity, five plants namely Anisomeles indica (L.) O. Kuntze, Bombax malabaricum DC., Paederia scandens (Lour.) Merr., Plumbago zeylanica L., and Alpinia speciosa (J. C. Wendl.) K. Schum demonstrated strong anti-H. pylori activities.

              Polygonum cuspidatum extract

              • Anti-Helicobacter pylori compounds from Polygonum cuspidatum

                Anti-Helicobacter pylori activity guided fractionation led to the isolation of five anthraquinones, two stilbenes and one naphthoquinone from the EtOAc fraction of Polygonum cuspidatum, using silica gel column chromatography, Sephadex-LH20, MPLC and recrystallization. The chemical structures were identified to be physcion (1), emodin (2), anthraglycoside B (3), trans-resveratrol (4), anthraglycoside A (5), polydatin (6), 2-methoxy-6-acetyl-7-methyljuglone (7) and citreorosein (8) by UV, 1H-NMR, 13C-NMR and mass spectrometry. Anti-Helicobacter pylori activity including MIC values of each compound was evaluated. All of the isolates exhibited anti-H. pylori activity of which MIC values were lower than that of a positive control, quercetin. Compounds 2 and 7 showed potent growth inhibitory activity. Especially, a naphthoquinone, compound 7 displayed most potent antibacterial activity with MIC50 value of 0.30 µM and MIC90 value of 0.39 µM. Although anti–H. pylori activity of this plant was previously reported, this is the first report on that of compounds isolated from this species. From these findings, P. cuspidatum roots or its isolates may be useful for H. pylori infection and further study is needed to elucidate mechanism of action.


              Punica granatum peel extract
              • Effects of Punica granatum pericarps and Quercus infectoria nutgalls on cell surface hydrophobicity and cell survival of Helicobacter pylori
              • Punica granatum is more effective to prevent gastric disorders induced by Helicobacter pylori or any other stimulator in humans
              • Study of In Vitro Inhibition Effect of Pomegranate Rind on H.pylori
              • In vitro Inhibition of Helicobacter pylori by Some Spices and Medicinal Plants Used in Iran

                Helicobacter pylori is the most common cause of gastric infections worldwide. The antibacterial activity of methanol extracts of Satureja hortensis L. (Lamiaceae), Artemisia dracunculus L. (Asteraceae), Carthamus tinctorius L. (Asteraceae), Apium petroselinum L. (Apiaceae), Citrus sinensis L. (Rutaceae) and Punica granatum L. (Punicaceae) were evaluated against H. pylori. Inhibition tests were carried out using the disc diffusion method against 27 clinical isolates of H. pylori for initial screening and then agar dilution method to determine minimum inhibitory concentration (MIC). Among the crude extracts, P. granatum showed the highest inhibition (27.96±0.97mm) and the MICs of its butanol and aqueous fractions were 156 and 195.12 µg/mL, respectively. While its chloroform fraction had no activity against tested H. pylori isolates. All extracts except safflower preserved their anti-Helicobacter pylori activity at 121°C. All the extracts were capable of inhibiting the in in vitro growth of H. pylori and the butanol fraction of P. granatum, showed excellent anti-H. pylori activity

              Resveratrol
              • Anti-Helicobacter Pylori And Urease Inhibitory Activities Of Resveratrol And Red Wine
              • Effect Of Resveratrol On Helicobacter Pylori-Induced Interleukin-8 Secretion, Reactive Oxygen Species Generation And Morphological Changes In Human Gastric Epithelial …
              • In Vitro Activity Of Wine Compounds (Resveratrol, Methyl Gallate And Other Phenolic Compounds) Against Helicobacter Pylori Clinical Isolates
              • Increased Susceptibility To Resveratrol Of Helicobacter Pylori Strains Isolated From Patients With Gastric Carcinoma
              • Resveratrol And Red Wine Extracts Inhibit The Growth Of Caga+ Strains Of Helicobacter Pylori In Vitro
              • Resveratrol Inhibits The Growth Of Helicobacter Pylori In Vitro
              • Resveratrol Protects Against Helicobacter Pylori-Associated Gastritis By Combating Oxidative Stress
              • The Synergy Of Resveratrol And Alcohol Against Helicobacter Pylori And Underlying Anti‐Helicobacter Pylori Mechanism Of Resveratrol

              Rheum officinale extract
              • Four compounds of anthraquinone in Rheum officinale on Helicobacter pylori inhibition
              • A Study on the antigastritic effects of Rheum species extracts and their active components

              Rhizoma coptidis extract
              • Comparison of Helicobacter pylori urease inhibition by Rhizoma Coptidis, Cortex Phellodendri and Berberine: mechanisms of interaction with the sulfhydryl group

              Rottlerin (Mallotus philippinensis Muell. Arg (Euphorbiaceae)
              • Among the isolated compounds, rottlerin exhibited most potent bactericidal activity with minimum bactericidal concentration (MBC) value of 3.12-6.25 mg/l against several clinical H. pylori isolates including Japanese and Pakistani strains, nine clarithromycin resistant (CR), and seven metronidazole resistant (MR) strains.
              • Pharmacological ins and outs of medicinal plants against Helicobacter pylori: A review

                We have conducted a study of fifty medicinal plants including twenty-five spices that are commonly prescribed for the treatment of gastrointestinal disorders in Unani medical practice in Pakistan (Zaidi et al., 2009a). MBC values determined were at the concentration range of 7.8 to 500 µg/ml using seven H. pylori clinical isolates and one ATCC reference H. pylori strain (ATCC 43504). It was interesting to note that >50% of herbs at the concentration of 500 µg/ml inhibited the growth of all H. pylori strains. Extracts of Mallotus phillipinesis (Lam) Muell., Curcuma amada Roxb., Psoralea corylifolia L. and Myrisctica fragrans Houtt showed strong anti-H. pylori activity (MBC: 15.6-62.5 µg/ml). The most potent extract (Mallotus phillipinesis (Lam) Muell) was further evaluated for active constituents and found rottlerin to possess strong MBC value range of 3.12-6.25 µg/ml even against geographically distinct Japanese strains and antibiotic resistant strains (Zaidi et al., 2009b).


              Saccharomyces boulardii
              • Saccharomyces boulardii in Helicobacter Pylori eradication in children: a randomized trial from Iran
              • EFFECT OF SACCHAROMYCES BOULARDII CNCM I-745 ON THE GUT MICROBIOME AS A COMPLEMENTARY TREATMENT AGAINST HELICOBACTER PYLORI …
              • Comparison of the Effects of Saccharomyces boulardii Sachets and Bismuth Agent both Combined with Triple Therapy on Helicobacter pylori Eradication
              • Saccharomyces boulardii as an adjuvant therapy for Helicobacter pylori eradication: A systematic review and meta‐analysis with trial sequential analysis
              • Treatment of Quadruple Therapy Combined with Saccharomyces boulardii Sachets on Helicobacter pylori Infection: A Report of 125 Cases
              • Influence of Saccharomyces boulardii Sachets combined with bismuth quadruple therapy for initial Helicobacter pylori eradication
              • Saccharomyces boulardii CNCM I-745 plus sequential therapy for Helicobacter pylori infections: a randomized, open-label trial
              • Effect of Saccharomyces boulardii on Rescue Therapy of Helicobacter pylori Infection

              Saussurea lappa (Asteraceae) Costus Root extract
              • Pharmacological ins and outs of medicinal plants against Helicobacter pylori: A review.

                Chinese conducted the antibacterial action of thirty herbal medicines, which have been frequently used since ancient times for the treatment of gastritis-like disorders (Li et al., 2005). Among those thirty tested Chinese herbs, the ethanol extracts of Saussurea lappa (Asteraceae), Abrus cantoniensis (Fabaceae) and Eugenia caryophyllata (Myrtaceae) had the most strongly bacteriostatic effect (MICs: approximately 40 mg/ml).

              • Anti-microbial activity of Saussurea lappa CB Clarke Roots

              Scutellaria baicalensis extract
              • Study of Scutellaria baicalensis and Baicalin against antimicrobial susceptibility of Helicobacter pylori strains in vitro
              • Biological evaluation and molecular docking of baicalin and scutellarin as Helicobacter pylori urease inhibitors
              • Antigastritic and Anti Helicobacter pylori Effects of Baicalein from Scutellaria Baicalensis
              Smilax glabra rhizome extract
              • anti-Helicobacter pylori activity of traditional Chinese herbal medicines
              • Three new flavonoid glycosides from Smilax glabra and their anti-inflammatory activity

              Smoked plum (Fructus Pruni Mume) fruit extract
              • anti-Helicobacter pylori activity of traditional Chinese herbal medicines
              • Chinese herbal decoction as a complementary therapy for atrophic gastritis: a systematic review and meta-analysis

              Tabebuia impetiginosa Martius ex DC dried inner bark (Menadione and plumbagin)

              • Antibacterial activity of Tabebuia impetiginosa Martius ex DC (Taheebo) against Helicobacter pylori.

                The growth-inhibiting activity of Tabebuia impetiginosa Martius ex DC dried inner bark-derived constituents against Helicobacter pylori ATCC 43504 was examined using paper disc diffusion and minimum inhibitory concentration (MIC) bioassays. The activity of the isolated compounds was compared to that of the commercially available anti-Helicobacter pylori agents, amoxicillin, metronidazole, and tetracycline. The biologically active components of Tabebuia impetiginosa dried inner bark (taheebo) were characterized by spectroscopic analysis as 2-(hydroxymethyl)anthraquinone, anthraquinone-2-carboxylic acid, and 2-hydroxy-3-(3-methyl-2-butenyl)-1,4-naphthoquinone (lapachol). With the paper disc diffusion assay 2-(hydroxymethyl)anthraquinone exhibited strong activity against Helicobacter pylori ATCC 43504 at 0.01 mg/disc. Anthraquinone-2-carboxylic acid, lapachol and metronidazole were less effective, exhibiting moderate anti-Helicobacter pylori activity at 0.1 mg/disc. Amoxicillin and tetracycline were the most potent compounds tested, displaying very strong activity at 0.005 mg/disc. 2-(Hydroxymethyl)anthraquinone exhibited moderate activity at this dose. Tetracycline still had strong activity at 0.001 mg/disc while amoxicillin had little activity at this dose. In the MIC bioassay, 2-(hydroxymethyl)anthraquinone (2 microg/mL), anthraquinone-2-carboxylic acid (8 microg/mL), and lapachol (4 microg/mL) were more active than metronidazole (32 microg/mL) but less effective than amoxicillin (0.063 microg/mL) and tetracycline (0.5 microg/mL). The anti-Helicobacter pylori activity of seven 1,4-naphthoquinone derivatives (structurally related to lapachol), 1,4-naphthoquinone, 5,8-dihydroxy-1,4-naphthoquinone (naphthazarin), 2-methyl-1,4-naphthoquinone (menadione), 2-hydroxy-1,4-naphthoquinone (lawsone), 5-hydroxy-2-methyl-1,4-naphthoquinone (plumbagin), 5-hydroxy-1,4-naphthoquinone (juglone), and 2,3-dichloro-1,4-naphthoquinone (dichlone) was also evaluated using the paper disc assay. Menadione and plumbagin were the most potent compounds tested with the later still exhibiting very strong activity at 0.001 mg/disc. Menadione, juglone and tetracycline had strong activity at this low dose while the latter two compounds and amoxicillin had very strong activity at 0.005 mg/disc. Lawsone was unusual in that it had very strong activity at 0.1 and 0.05 mg/disc but weak activity at doses of 0.01 mg/disc and lower. Naphthazalin, lapachol and dichlone had similar activities while metronidazole had the lowest activity of all compounds tested. These results may be an indication of at least one of the pharmacological actions of taheebo. The Tabebuia impetiginosa dried inner bark-derived materials, particularly 2-(hydroxymethyl)anthraquinone, merit further study as potential Helicobacter pylori eradicating agents or lead compounds.

              tyrosol-elenolic acid dialdehyde (Ty-EDA or Ty-DEA) from Olive oil

              • In vitro activity of olive oil polyphenols against Helicobacter pylori.

                Helicobacter pylori is linked to a majority of peptic ulcers and to some types of gastric cancer, and resistance of the microorganism to antibiotic treatment is now found worldwide. Virgin olive oil is an unrefined vegetable oil that contains a significant amount of phenolic compounds. Under simulated conditions, we have demonstrated that these substances can diffuse from the oil into the gastric juice and be stable for hours in this acidic environment. In vitro, they exerted a strong bactericidal activity against eight strains of H. pylori, three of them resistant to some antibiotics. Among the phenolic compounds, the dialdehydic form of decarboxymethyl ligstroside aglycon showed the strongest bactericidal effect at a concentration as low as 1.3 microg/mL. Although the experimental conditions are different from other reported works, this bactericidal concentration is much lower than those found for phenolic compounds from tea, wine, and plant extracts. These results open the possibility of considering virgin olive oil a chemopreventive agent for peptic ulcer or gastric cancer, but this bioactivity should be confirmed in vivo in the future.


              Wasabi (Wasabia japonica) extract
              • Improvement Effects of Wasabi (Wasabia japonica) Leaves and Allyl Isothiocyanate on Stomach Lesions of Mongolian Gerbils Infected with Helicobacter pylori
              • The antimicrobial effects of Wasabia japonica and Armoracia rusticana, J Marine Biology and Aquascape
              • Leaf extract of Wasabia japonica relieved oxidative stress induced by Helicobacter pylori infection

                Infection with Helicobacter pylori (H. pylori) can induce gastric disorders, and though its presence cannot explain disease pathogenesis and does not have associations with other factors, it is well known that H. pylori infection causes stomach inflammation following oxidative stress. We examined the suppressive effects of a leaf extract of Wasabia japonica on H. pylori infection and on stress loading in Mongolian gerbils. Following oral administration of wasabi extract of 50 and 200 mg/kg B.W./d for 10 d, the animals were exposed to restraint stress for 90 and 270 min. As for the results, the level of 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG) in the stomach and oxidative DNA damage in peripheral erythrocytes at 270 min significantly increased. That elevation was significantly suppressed by the addition of the leaf extract. We concluded that the simultaneous loading of H. pylori infection and physical stress loading might induce oxidative DNA damage additively, while a leaf extract attenuated this DNA damage in the stomach as well as the peripheral erythrocytes.


              • Pharmacological ins and outs of medicinal plants against Helicobacter pylori: A review

                Shin et al from Japan reported anti-H. pylori activity of wasabi (Wasabia japonica) and demonstrated higher bactericidal activity of leaves than root of wasabi (Shin et al., 2004).


              Zinc Carnosine
              • A modified sequential regimen of Helicobacter pylori treatment enforced by Bacillus clausii and Zinc Carnosine complex yields high eradication rates

                Introduction: Over the past decade a worldwide trend of decline in the cure rates of Helicobacter pylori is observed. Current eradication rates achieved by the standard triple therapy are below 70%. Sequential therapy had provided a potential alternative that would compensate for the unmet performance of triple therapy. Despite its superiority to triple therapy, the excellent results reported initially were not reproduced by other investigators work. Adding adjuvant agents was also found to improve further the success rate of eradication. Probiotics emerged as a useful adjunct in treatment and prophylaxis of Helicobacter pylori infection. The nutritional supplement Zinc carnosine complex is another adjuvant which is believed to add value to the treatment. Patients and method: an open label randomized observational clinical study designed to compare the efficacy of a modified sequential regimen enforced by two adjuvants the probiotic Bacillus clausii and the nutritional Zinc Carnosine supplement. Patients who fulfilled the inclusion and exclusion criteria were randomized to one of two groups who were given the same components of the regimen of treatment either with clarithromycin (group A, n=131) or levofloxacin replacing it (group B, n=137) and were compared against the current reported response to triple therapy in our area (67.9%). Results: This regimen of eradication had yielded a Per protocol cure rate of 96.4% and an ITT rate of 89.9% for the levofloxacin based therapy. The Per protocol eradication rate for the clarithromycin based treatments was 93.4% and the ITT rate was 90%. The response was not significantly affected by previous exposure to the antibiotics used. Patient satisfaction and compliance were remarkable with most patients having a significant feeling of wellbeing and improvement of their symptoms. Side effects to the components of the regimen were unremarkable. The addition of Bacillus clausii and the nutritional supplement Zinc Carnosine had added great value to the eradication response.


              Scientific Studies:
              1. Helicobacter pylori Infection
              2. Helicobacter pylori and gastric carcinogenesis.
              3. Schistosomes, liver flukes and Helicobacter pylori.
              4. Helicobacter pylori Infection and Gastric Lymphoma
              5. Helicobacter pylori and gastrointestinal tract adenocarcinomas
              6. The prevalence of Helicobacter pylori infection in different countries.
              7. Helicobacter pylori Infection and the Development of Gastric Cancer
              8. Helicobacter pylori Infection and the Risk of Gastric Carcinoma
              9. Pathogenesis of Helicobacter pylori Infection
              10. Helicobacter pylori Virulence and Genetic Geography
              11. The epidemiology of Helicobacter pylori infection.
              12. The incidence of Helicobacter pylori infection.
              13. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma
              14. Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori
              15. Isolation of Helicobacter pylori from human faeces
              16. The Cohort Effect and Helicobacter pylori
              17. Helicobacter pylori and Peptic Ulcer Disease
              18. Helicobacter pylori persistence: biology and disease
              19. Carcinogenesis of Helicobacter pylori
              20. Long-term sequelae of Helicobacter pylori gastritis
              21. Free recombination within Helicobacter pylori
              22. The complete genome sequence of the gastric pathogen Helicobacter pylori
              23. Traces of Human Migrations in Helicobacter pylori Populations
              24. Epidemiology of Helicobacter pylori infection.
              25. The protein–protein interaction map of Helicobacter pylori
              26. Relation of Helicobacter pylori infection and coronary heart disease.
              27. Helicobacter pylori: the African enigma.
              28. Helicobacter pylori infection induces gastric cancer in Mongolian gerbils
              29. Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report
              30. The prevalence of Helicobacter pylori in peptic ulcer disease.
              31. Helicobacter pylori: Epidemiology and Routes of Transmission
              32. Helicobacter pylori Infection and Gastric Carcinoma among Japanese Americans in Hawaii
              33. Intrafamilial Clustering of Helicobacter pylori Infection
              34. Cure of duodenal ulcer associated with eradication of Helicobacter pylori
              35. Helicobacter pylori and gastric diseases
              36. An international association between Helicobacter pylori infection and gastric cancer
              37. Current concepts in the management of Helicobacter pylori infection—The Maastricht 2‐2000 Consensus Report
              38. Helicobacter pylori: gastric cancer and beyond
              39. Epidemiology of Helicobacter pylori Infection
              40. Helicobacter pylori in Health and Disease
              41. Helicobacter pylori and the Pathogenesis of Gastroduodenal Inflammation
              42. Helicobacter pylori and gastric cancer.
              43. Epidemiology of Helicobacter pylori Infection
              44. Helicobacter pylori Infection in Children: A Consensus Statement
              45. Epidemiology of Helicobacter pylori infection
              46. Helicobacter pylori Vacuolating Cytotoxin Inhibits T Lymphocyte Activation
              47. Helicobacter pylorir Current Status
              48. Eradication of Helicobacter pylori for non‐ulcer dyspepsia
              49. Helicobacter pylori infection and chronic gastric acid hyposecretion
              50. Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori
              51. Hypotheses on the pathogenesis and natural history of Helicobacter pylori-induced inflammation
              52. The primary transcriptome of the major human pathogen Helicobacter pylori
              53. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report
              54. Childhood living conditions and Helicobacter pylori seropositivity in adult life
              55. Transfer of Campylobacter pylori and Campylobacter mustelae to Helicobacter gen. nov. as Helicobacter pylori comb. nov. and Helicobacter mustelae comb. nov., Respectively
              56. Helicobacter pylori and Atrophic Gastritis: Importance of the cagA Status
              57. Development of Helicobacter pylori-induced Gastric Carcinoma in Mongolian Gerbils
              58. Helicobacter pylori treatment in the era of increasing antibiotic resistance
              59. Host-Bacterial Interactions in Helicobacter pylori Infection
              60. Gastric Adenocarcinoma and Helicobacter pylori Infection
              61. Heightened inflammatory response and cytokine expression in vivo to cagA+ Helicobacter pylori strains.
              62. Helicobacter pylori Adhesin Binding Fucosylated Histo-Blood Group Antigens Revealed by Retagging
              63. Helicobacter pylori SabA Adhesin in Persistent Infection and Chronic Inflammation
              64. Translocation of Helicobacter pylori CagA into Gastric Epithelial Cells by Type IV Secretion
              65. Factors influencing the eradication of Helicobacter pylori with triple therapy
              66. Disruption of the Epithelial Apical-Junctional Complex by Helicobacter pylori CagA
              67. The vacuolating cytotoxin of Helicobacter pylori
              68. Microbiology of Helicobacter pylori.
              69. Seroconversion for Helicobacter pylori
              70. SHP-2 Tyrosine Phosphatase as an Intracellular Target of Helicobacter pylori CagA Protein
              71. Isolation of Helicobacter pylori from saliva.
              72. Mechanisms of disease: Helicobacter pylori virulence factors
              73. Helicobacter pylori infection
              74. Nod1 responds to peptidoglycan delivered by the Helicobacter pylori cag pathogenicity island
              75. An African origin for the intimate association between humans and Helicobacter pylori
              76. Attachment of Helicobacter pylori to human gastric epithelium mediated by blood group antigens
              77. Helicobacter pylori in Peptic Ulcer Disease
              78. Epidemiology of Helicobacter pylori Infection and Public Health Implications
              79. Kyoto global consensus report on Helicobacter pylori gastritis
              80. Helicobacter pylori and antibiotic resistance
              81. Pathogenicity of Helicobacter pylori: a perspective.
              82. Analyses of the cag pathogenicity island of Helicobacter pylori
              83. Transmission of Helicobacter pylori among siblings
              84. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer
              85. Helicobacter pylori Detection and Antimicrobial Susceptibility Testing
              86. Anti-Helicobacter pylori flavonoids from licorice extract
              87. Helicobacter pylori and Probiotics
              88. Purification and characterization of the vacuolating toxin from Helicobacter pylori.
              89. A standardized mouse model of Helicobacter pylori infection: Introducing the Sydney strain
              90. Natural history and epidemiology of Helicobacter pylori infection
              91. Accuracy of invasive and noninvasive tests to diagnose Helicobacter pylori infection
              92. Helicobacter pylori in the drinking water in Peru
              93. Antibiotic resistance in Helicobacter pylori: Implications for therapy
              94. cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors
              95. Helicobacter pylori: Its Role in Disease
              96. Helicobacter pylori VacA, a paradigm for toxin multifunctionality
              97. Geographic distribution of vacA allelic types of Helicobacter pylori
              98. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis
              99. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori
              100. Activation of β-catenin by carcinogenic Helicobacter pylori
              101. Complex polysaccharides as PCR inhibitors in feces: Helicobacter pylori model.
              102. A whole-genome microarray reveals genetic diversity among Helicobacter pylori strains
              103. Determinants of Helicobacter pylori pathogenicity.
              104. Expanding Allelic Diversity of Helicobacter pylori vacA
              105. Water source as risk factor for Helicobacter pylori infection in Peruvian children
              106. Prevalence of Helicobacter pylori Infection and Histologic Gastritis in Asymptomatic Persons
              107. Helicobacter pylori Infection: Genetic and Environmental Influences: A Study of Twins
              108. Ecology of Helicobacter pylori in the Human Stomach
              109. Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori.
              110. Treatment of Helicobacter pylori infection
              111. Mastic Gum Kills Helicobacter pylori
              112. Eradication Therapy for Helicobacter pylori
              113. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation.
              114. European Multicentre Survey of in Vitro Antimicrobial Resistance in Helicobacter pylori
              115. Helicobacter pylori and Gastric Cancer: Factors That Modulate Disease Risk
              116. Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection
              117. Clinical relevance of the cagA, vacA, and iceA status of Helicobacter pylori
              118. Effect of Treatment of Helicobacter pylori Infection on the Long-term Recurrence of Gastric or Duodenal Ulcer: A Randomized, Controlled Study
              119. Genome-Scale Metabolic Model of Helicobacter pylori 26695
              120. Second Asia–Pacific Consensus Guidelines for Helicobacter pylori infection
              121. DNA diversity among clinical isolates of Helicobacter pylori detected by PCR-based RAPD fingerprinting
              122. Helicobacter pylori and Gastric Cancer
              123. Helicobacter pylori and gastric inflammation
              124. RECENT DEVELOPMENTS IN THE EPIDEMIOLOGY OF Helicobacter pylori
              125. Symptomatic Benefit from Eradicating Helicobacter pylori Infection in Patients with Nonulcer Dyspepsia
              126. Characterization of a Helicobacter pylori neutrophil-activating protein.
              127. Helicobacter pylori and gastric adenocarcinoma
              128. Serologic detection of infection with cagA+ Helicobacter pylori strains.
              129. Sequential Therapy versus Standard Triple-Drug Therapy forHelicobacter pyloriEradication
              130. A Report Card to Grade Helicobacter pylori Therapy
              131. When is Helicobacter pylori infection acquired?
              132. Mucosal IgA recognition of Helicobacter pylori 120 kDa protein, peptic ulceration, and gastric pathology
              133. Living dangerously: how Helicobacter pylori survives in the human stomach
              134. Helicobacter pylori genetic diversity and risk of human disease
              135. Local Cytokine Response in Helicobacter pylori-Infected Subjects
              136. Helicobacter pylori infection and duodenal ulcer disease.
              137. Comparative proteome analysis of Helicobacter pylori
              138. Screening dyspepsia by serology to Helicobacter pylori
              139. Helicobacter pylori, Gastroduodenal Disease, and Recurrent Abdominal Pain in Children
              140. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption
              141. THE PATHOGENESIS OF Helicobacter pylori–INDUCED GASTRO-DUODENAL DISEASES
              142. Helicobacter pylori eradication can induce platelet recovery in idiopathic thrombocytopenic purpura
              143. Changes in the gastric mucosa following eradication of Helicobacter pylori.
              144. Helicobacter pylori and gastric carcinogenesis
              145. Helicobacter pylori and Gastroduodenal Disease
              146. Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population
              147. Seroprevalence of Helicobacter pylori Infections in Thailand
              148. Duodenal ulcer treated with Helicobacter pylori eradication: seven-year follow-up
              149. Transmission of Helicobacter pylori: faecal-oral versus oral-oral route.
              150. Resistance of Helicobacter pylori to antibiotics
              151. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection
              152. Diagnosis of Helicobacter pylori infection.
              153. Plasma ghrelin following cure of Helicobacter pylori
              154. Purification and characterization of urease from Helicobacter pylori.
              155. Clinical relevance of the Helicobacter pylori gene for blood-group antigen-binding adhesin
              156. Supramolecular assembly and acid resistance of Helicobacter pylori urease
              157. Age-Specific Incidence of Helicobacter pylori
              158. Helicobacter pylori Infection and Dyspepsia
              159. Molecular characterization of the 128-kDa immunodominant antigen of Helicobacter pylori associated with cytotoxicity and duodenal ulcer
              160. Helicobacter pylori infection and gastric cancer: systematic review of the epidemiological studies.
              161. Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report
              162. Epithelial attachment alters the outcome of Helicobacter pylori infection
              163. Mechanisms involved in Helicobacter pylori—Induced inflammation
              164. Development of a mouse model of Helicobacter pylori infection that mimics human disease
              165. Helicobacter pylori Infection and the Risk for Duodenal and Gastric Ulceration
              166. Helicobacter pylori stimulates antral mucosal reactive oxygen metabolite production in vivo.
              167. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts
              168. Inverse Associations of Helicobacter pylori With Asthma and Allergy
              169. Helicobacter pylori Caga Protein Can Be Tyrosine Phosphorylated in Gastric Epithelial Cells
              170. A Mr 34,000 proinflammatory outer membrane protein (oipA) of Helicobacter pylori
              171. Amoxicillin and omeprazole to eradicate Helicobacter pylori
              172. Molecular Hydrogen as an Energy Source for Helicobacter pylori
              173. Tyrosine phosphorylation of the Helicobacter pylori CagA antigen after cag-driven host cell translocation
              174. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: A review
              175. Coadaptation of Helicobacter pylori and humans: ancient history, modern implications
              176. Infection with Helicobacter pylori Strains Possessing cagA Is Associated with an Increased Risk of Developing Adenocarcinoma of the Stomach
              177. Colonization of gnotobiotic piglets by Helicobacter pylori deficient in two flagellin genes.
              178. Clinical and pathological importance of heterogeneity in vacA, the vacuolating cytotoxin gene of Helicobacter pylori
              179. Diagnosing Helicobacter pylori In Vivo by Confocal Laser Endoscopy
              180. The coccoid forms of Helicobacter pylori. Criteria for their viability
              181. Increased Oxidative DNA Damage in Helicobacter pylori-infected Human Gastric Mucosa
              182. Chemoprevention of Gastric Dysplasia: Randomized Trial of Antioxidant Supplements and Anti-Helicobacter pylori Therapy
              183. Helicobacter pylori Infection Has No Role in the Pathogenesis of Reflux Esophagitis
              184. Sensitive detection of Helicobacter pylori by using polymerase chain reaction.
              185. Helicobacter pylori-Negative Duodenal Ulcer.
              186. Importance of childhood socioeconomic status on the current prevalence of Helicobacter pylori infection.
              187. Helicobacter pylori catalase
              188. Inhibition of Helicobacter pylori by garlic extract ( Allium sativum)
              189. Helicobacter pylori Eradication to Prevent Gastric Cancer in a High-Risk Region of ChinaA Randomized Controlled Trial
              190. Association of Virulent Helicobacter pylori Strains With Ischemic Heart Disease
              191. The urea breath test for Helicobacter pylori.
              192. Helicobacter pylori infection: Independent risk indicator of gastric adenocarcinoma
              193. Lack of Effect of Treating Helicobacter pylori Infection in Patients with Nonulcer Dyspepsia
              194. Essential role of urease in pathogenesis of gastritis induced by Helicobacter pylori in gnotobiotic piglets.
              195. Helicobacter pylori in the pediatric patient.
              196. Clinical Relevance of Helicobacter pylori cagA and vacA Gene Polymorphisms
              197. Antibacterial Treatment of Gastric Ulcers Associated with Helicobacter pylori
              198. Diagnosis of Helicobacter pylori infection with a new non-in vasive antigen-based assay
              199. Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors
              200. Duodenal ulcer promoting gene of Helicobacter pylori
              201. Helicobacter pylori Infection in Intestinal- and Diffuse-Type Gastric Adenocarcinomas
              202. Treatment of Helicobacter pylori Infection: A Review of the World Literature
              203. Helicobacter pylori gastritis and primary gastric non-Hodgkin’s lymphomas.
              204. Eradication of Helicobacter pylori with clarithromycin and omeprazole.
              205. Fecal and Oral Shedding of Helicobacter pylori From Healthy Infected Adults
              206. Helicobacter pylori Colonization Is Inversely Associated with Childhood Asthma
              207. Helicobacter pylori infection causes antral gastritis
              208. Helicobacter pylori infection and chronic gastritis in gastric cancer.
              209. Helicobacter pylori infection activates NF-kappa B in gastric epithelial cells
              210. Atrophic Gastritis and Helicobacter pylori Infection in Patients with Reflux Esophagitis Treated with Omeprazole or Fundoplication
              211. Optimal therapy for Helicobacter pylori infections
              212. Helicobacter pylori-induced gastric inflammation and gastric cancer
              213. Transmission and Epidemiology of Helicobacter pylori
              214. The clinical relevance of strain types of Helicobacter pylori.
              215. Gastric mucosal inflammatory responses to Helicobacter pylori.
              216. Divergence of genetic sequences for the vacuolating cytotoxin among Helicobacter pylori strains.
              217. Long term follow up of patients treated for Helicobacter pylori infection
              218. Clarithromycin-Resistant Genotypes and Eradication ofHelicobacter pylori
              219. Factors Influencing the Epidemiology of Helicobacter pylori Infection in Children
              220. Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole.
              221. Altered states: Involvement of phosphorylated CagA in the induction of host cellular growth changes by Helicobacter pylori
              222. A H+-Gated Urea Channel: The Link Between Helicobacter pylori Urease and Gastric Colonization
              223. Establishment of gastric Helicobacter pylori infection in Mongolian gerbils.
              224. Helicobacter pylori: microbiology of a ‘slow’ bacterial infection
              225. Meta-Analysis of the Efficacy of Antibiotic Therapy in Eradicating Helicobacter pylori.
              226. Helicobacter pylori and gastric carcinoma
              227. The Treatment of Helicobacter pylori Infection in the Management of Peptic Ulcer Disease
              228. Epidemiological Features of Helicobacter pylori Infection in Developing Countries
              229. Mosaicism in Vacuolating Cytotoxin Alleles of Helicobacter pylori
                ASSOCIATION OF SPECIFIC vacA TYPES WITH CYTOTOXIN PRODUCTION AND PEPTIC ULCERATION
              230. A small animal model of human Helicobacter pylori active chronic gastritis
              231. Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse
              232. Restriction and Modification Systems.
              233. Low biological activity of Helicobacter pylori lipopolysaccharide.
              234. Seroprevalence of Helicobacter pylori in South Korea
              235. The response of cells from low-grade B-cell gastric lymphomas of mucosa-associated lymphoid tissue to Helicobacter pylori
              236. Helicobacter pylori in Developing Countries. World Gastroenterology Organisation Global Guideline
              237. Possible role of Helicobacter pylori infection in early gastric cancer development
              238. Gastroretentive dosage forms: Overview and special case of Helicobacter pylori
              239. Epidemiology of Helicobacter pylori in an asymptomatic population in the United States: Effect of age, race, and socioeconomic status
              240. Epidemiology of Helicobacter pylori Infection
              241. The Complete Genome Sequence of Helicobacter pylori Strain G27
              242. Helicobacter pylori Infection in Children: Recommendations for Diagnosis and Treatment
              243. Mucosal tumour necrosis factor alpha and interleukin-6 in patients with Helicobacter pylori associated gastritis.
              244. Treatment of Peptic Ulcers Caused by Helicobacter pylori
              245. Pathophysiology of Helicobacter pylori Infection
              246. How is Helicobacter pylori Transmitted?
              247. Helicobacter pylori Genotypes May Determine Gastric Histopathology
              248. Hyperemesis Gravidarum Associated With Helicobacter pylori Seropositivity
              249. Helicobacter pylori CagA targets PAR1/MARK kinase to disrupt epithelial cell polarity
              250. Helicobacter pylori in Human Carotid Atherosclerotic Plaques
              251. Oral immunization against Helicobacter pylori.
              252. Anti-Helicobacter pylori Activity of Hearbal Medicines
              253. Review article: Helicobacter pylori and gastro-oesophageal reflux disease-clinical implications and management.
              254. Eradication of Helicobacter pylori Infection in Primary Low-Grade Gastric Lymphoma of Mucosa-Associated Lymphoid Tissue
              255. Interleukin-8 expression in Helicobacter pylori infected, normal, and neoplastic gastroduodenal mucosa.
              256. Helicobacter pylori increases proliferation of gastric epithelial cells.
              257. Susceptibility of Helicobacter pylori to the antibacterial activity of manuka honey.
              258. Antibacterial activity of black myrobalan (Terminalia chebula Retz) against Helicobacter pylori
              259. Gene structure of the Helicobacter pylori cytotoxin and evidence of its key role in gastric disease.
              260. Screening of Turkish anti-ulcerogenic folk remedies for anti-Helicobacter pylori activity
              261. Immunization of BALB/c mice against Helicobacter felis infection with Helicobacter pylori urease
              262. Immune and Inflammatory Responses to Helicobacter pylori Infection
              263. Mutation frequency and biological cost of antibiotic resistance in Helicobacter pylori
              264. Helicobacter pylori and gastric carcinoma: Serum antibody prevalence in populations with contrasting cancer risks
              265. Stable amoxicillin resistance in Helicobacter pylori
              266. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease
              267. New concepts of resistance in the treatment of Helicobacter pylori infections
              268. Role of type IV secretion in Helicobacter pylori pathogenesis
              269. Helicobacter pylori outer membrane proteins and gastroduodenal disease
              270. Recombination and clonal groupings within Helicobacter pylori from different geographical regions
              271. Cure of duodenal ulcer after eradication of Helicobacter pylori
              272. Eradication of Helicobacter pylori Using One‐week Triple Therapies Combining Omeprazole with Two Antimicrobials: The MACH I Study
              273. Nodular gastritis and Helicobacter pylori.
              274. Neutrophil activation by Helicobacter pylori.
              275. Absence of Benefit of Eradicating Helicobacter pylori in Patients with Nonulcer Dyspepsia
              276. The gastric cardia in Helicobacter pylori infection
              277. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis
              278. Helicobacter pylori and MALT Lymphom
              279. Prevention of Helicobacter pylori infection by lactobacilli in a gnotobiotic murine model.
              280. The spatial orientation of Helicobacter pylori in the gastric mucus
              281. Epidemiology and mechanism of antibiotic resistance in Helicobacter pylori
              282. Therapy for Helicobacter pylori in Patients with Nonulcer Dyspepsia: A Meta-Analysis of Randomized, Controlled Trials
              283. I. Helicobacter pylori: Its epidemiology and its role in duodenal ulcer disease
              284. Lymphocytes in the human gastric mucosa during Helicobacter pylori have a T helper cell 1 phenotype
              285. A new highly effective short-term therapy schedule for Helicobacter pylori eradication.
              286. Grb2 Is a Key Mediator of Helicobacter pylori CagA Protein Activities
              287. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy
              288. Review article: the treatment of refractory Helicobacter pylori infection
              289. Beneficial Effects of Helicobacter pylori Eradication on Idiopathic Chronic Urticaria
              290. The MACH2 study: Role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies
              291. Global burden of gastric cancer attributable to Helicobacterpylori
              292. Helicobacter pylori Colonization in Early Life
              293. Helicobacter pylori and Esophageal Cancer Risk: A Meta-analysis
              294. Effect of Helicobacter pylori on gastric somatostatin in duodenal ulcer disease
              295. An Inverse Relation between cagA+ Strains of Helicobacter pylori Infection and Risk of Esophageal and Gastric Cardia Adenocarcinoma
              296. Helicobacter pylori infection in childhood: risk factors and effect on growth
              297. Risk Factors for Helicobacter pylori Resistance in the United States: The Surveillance of H. pylori Antimicrobial Resistance Partnership (SHARP) Study, 1993–1999
              298. Helicobacter pylori—Is It a Novel Causative Agent in Vitamin B12 Deficiency?
              299. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis
              300. Long-Term Follow-up of Voluntary Ingestion of Helicobacter pylori
              301. Distinctiveness of Genotypes of Helicobacter pylori in Calcutta, India
              302. Effect of Ranitidine and Amoxicillin plus Metronidazole on the Eradication of Helicobacter pylori and the Recurrence of Duodenal Ulcer
              303. Helicobacter pylori motility
              304. Natural Antibiotic Function of a Human Gastric Mucin Against Helicobacter pylori Infection
              305. Helicobacter pylori CagA: a new paradigm for bacterial carcinogenesis
              306. Suppressive effect of Lactobacillus gasseri OLL 2716 (LG21) on Helicobacter pylori infection in humans
              307. Mucosal Tumor Necrosis Factor-or, Interleukin-1/3, and Interleukin-8 Production in Patients with Helicobacter pylori Infection
              308. Non-human reservoirs of Helicobacter pylori.
              309. Helicobacter pylori virulence factors in gastric carcinogenesis
              310. Does Helicobacter pylori protect against asthma and allergy?
              311. Review article: the global emergence of Helicobacter pylori antibiotic resistance
              312. Endoscopic transmission of Helicobacter pylori
              313. Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications
              314. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer.
              315. Relationship between Helicobacter pylori iceA, cagA, and vacA Status and Clinical Outcome: Studies in Four Different Countries
              316. Helicobacter pyloriINFECTION IN GASTRIC CANCEROGENES
              317. A Community-Based Seroepidemiologic Study of Helicobacter pylori Infection in Mexico
              318. Helicobacter pylori infection
              319. Helicobacter pylori moves through mucus by reducing mucin viscoelasticity
              320. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia
              321. NF-κB activation and potentiation of proinflammatory responses by the Helicobacter pylori CagA protein
              322. Activities of Garlic Oil, Garlic Powder, and Their Diallyl Constituents against Helicobacter pylori
              323. Association of Helicobacter pylori infection with elevated serum lipids
              324. One week eradication regimen for Helicobacter pylori
              325. Meta-analysis: Can Helicobacter pylori Eradication Treatment Reduce the Risk for Gastric Cancer?
              326. A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: The QUADRATE study
              327. Helicobacter pylori: the size of the problem
              328. Helicobacter pylori cagA + Strains and Dissociation of Gastric Epithelial Cell Proliferation From Apoptosis
              329. Helicobacter pylori isolated from the domestic cat: public health implications.
              330. Cytokine gene expression in Helicobacter pylori associated antral gastritis.
              331. Induction of Gastric Epithelial Cell Apoptosis by Helicobacter pylori Vacuolating Cytotoxin
              332. Thyroxine in Goiter, Helicobacter pylori Infection, and Chronic Gastritis
              333. Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review
              334. Treatment of Helicobacter pylori Reduces the Rate of Rebleeding in Peptic Ulcer Disease
              335. Comparison of biopsy sites for the histopathologic diagnosis of Helicobacter pylori: a topographic study of H. pylori density and distribution
              336. Antibiotic resistance in Helicobacter pylori infection
              337. ChronicUrticariaandHelicobacterpylori
              338. Helicobacter pylori in Gambian children with chronic diarrhoea and malnutrition.
              339. Helicobacter pylori secretes a chemotactic factor for monocytes and neutrophils
              340. Helicobacter pylori in gastric cancer established by CagA immunoblot as a marker of past infection
              341. Protection against Helicobacter pylori and Other Bacterial Infections by Garlic
              342. Helicobacter pylori cagA gene and expression of cytokine messenger RNA in gastric mucosa
              343. Helicobacter pylori: a poor man’s gut pathogen?
              344. Dental Plaque: A Permanent Reservoir of Helicobacter pylori?
              345. Age at acquisition of Helicobacter pylori infection: a follow-up study from infancy to adulthood
              346. Helicobacter pylori evolution and phenotypic diversification in a changing host
              347. Global Transposon Mutagenesis and Essential Gene Analysis of Helicobacter pylori
              348. Phenolic antioxidants from clonal oregano (Origanum vulgare) with antimicrobial activity against Helicobacter pylori
              349. Symptoms and risk factors of Helicobacter pylori infection in a cohort of epidemiologists
              350. Simple sequence repeats in the Helicobacter pylori genome
              351. Review article: exploring the link between Helicobacter pylori and gastric cancer
              352. Helicobacter pylori urease activity is toxic to human gastric epithelial cells.
              353. Cyclooxygenase-2 Expression in Helicobacter pylori-Associated Premalignant and Malignant Gastric Lesions
              354. Effect of gastric pH on urease-dependent colonization of gnotobiotic piglets by Helicobacter pylori.
              355. Interleukin-8 response of gastric epithelial cell lines to Helicobacter pylori stimulation in vitro.
              356. Gastric Interleukin‐8 and IgA IL‐8 Autoantibodies in Helicobacter pylori Infection
              357. Helicobacter pylori and reflux disease
              358. Regulation of Gastric Carcinogenesis by Helicobacter pylori Virulence Factors
              359. Acid-Adaptive Genes of Helicobacter pylori
              360. IV. Helicobacter pylori and peptic ulceration: Histopathological aspects
              361. Determinants of Helicobacter pylori Infection and Chronic Gastritis.
              362. The Disease Spectrum of Helicobacter pylori: The Immunopathogenesis of Gastroduodenal Ulcer and Gastric Cancer
              363. Helicobacter pylori and Interleukin 1 Genotyping: An Opportunity to Identify High-Risk Individuals for Gastric Carcinoma
              364. Review article: pathogenesis of Helicobacter pylori‐induced gastric inflammation
              365. Virulence Factors of Helicobacter pylori Responsible for Gastric Diseases in Mongolian Gerbil
              366. Purification and N-terminal analysis of urease from Helicobacter pylori.
              367. Hyperhomocysteinaemia, Helicobacter pylori, and coronary heart disease.
              368. Long-Term Follow-Up of Gastric MALT Lymphoma After Helicobacter pylori Eradication
              369. Differences in Genotypes of Helicobacter pylori from Different Human Populations
              370. What Role Does Helicobacter pylori Play in Gastric Cancer?
              371. Helicobacter mustelae-associated gastritis in ferrets
              372. Motility as a factor in the colonisation of gnotobiotic piglets by Helicobacter pylori
              373. The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease
              374. Helicobacter pylori Diagnosis and Management
              375. Extradigestive manifestations of Helicobacter pylori gastric infection
              376. High eradication rates of Helicobacter pylori with a new sequential treatment
              377. Reversal of Iron Deficiency Anemia after Helicobacter pylori Eradication in Patients with Asymptomatic Gastritis
              378. Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium
              379. Age at Establishment of Helicobacter pylori Infection and Gastric Carcinoma, Gastric Ulcer, and Duodenal Ulcer Risk
              380. Helicobacter pylori genetic diversity within the gastric niche of a single human host
              381. Preventing Recurrent Upper Gastrointestinal Bleeding in Patients with Helicobacter pylori Infection Who Are Taking Low-Dose Aspirin or Naproxen
              382. Coccoid Forms of Helicobacter pylori in the Human Stomach
              383. Coccoid forms of Helicobacter pylori are the morphologic manifestation of cell death.
              384. Systemic and mucosal humoral responses to Helicobacter pylori in gastric cancer.
              385. Helicobacter pylori genome evolution during human infection
              386. The life and death of Helicobacter pylori
              387. Helicobacter pylori infection: A clinical overview
              388. Antibacterial Activity of Hydrolyzable Tannins Derived from Medicinal Plants against Helicobacter pylori
              389. Helicobacter pylori Update: Gastric Cancer, Reliable Therapy, and Possible Benefits
              390. Treatment of Helicobacter pylori Infection 2010
              391. Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors
              392. Induction of host signal transduction pathways by Helicobacter pylori
              393. Selective Inhibition of Ii-dependent Antigen Presentation by Helicobacter pylori Toxin VacA
              394. Helicobacter pylori infection in children: potential clues to pathogenesis.
              395. Life in the human stomach: persistence strategies of the bacterial pathogen Helicobacter pylori
              396. CagA/cytotoxic strains of Helicobacter pylori and interleukin-8 in gastric epithelial cell lines.
              397. Helicobacter pylori eradication reduces the rate of rebleeding in ulcer hemorrhage
              398. A critique of therapeutic trials in Helicobacter pylori-positive functional dyspepsia
              399. Isolation of Helicobacter pylori from feces of patients with dyspepsia in the United Kingdom
              400. Natural history of Helicobacter pylori infection
              401. The prevalence of Helicobacter pylori-positive serology in asymptomatic children.
              402. Turmeric (Curcuma longa) and curcumin inhibit the growth of Helicobacter pylori, a group 1 carcinogen.
              403. Seroprevalence of Helicobacter pylori in Chile: Vegetables May Serve as One Route of Transmission
              404. Gastric lymphoid follicles in Helicobacter pylori infection: Frequency, distribution, and response to triple therapy
              405. Coccoid Helicobacter pylori Not Culturable In Vitro Reverts in Mice
              406. Relationship between Helicobacter pylori infection and Alzheimer disease
              407. Interobserver variation in the histopathological assessment of Helicobacter pylori gastritis
              408. Sequential Therapy for Helicobacter pylori Eradication: A Critical Review
              409. Pathogenesis of Helicobacter pylori Infection
              410. Helicobacter pylori CagA protein targets the c-Met receptor and enhances the motogenic response
              411. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis
              412. Helicobacter pylori: comparison of DNA fingerprints provides evidence for intrafamilial infection.
              413. The Epidemiology of Helicobacter pylori
              414. Pathobiology of Helicobacter pylori–Induced Gastric Cancer
              415. Helicobacter pylori induced interleukin-8 expression in gastric epithelial cells is associated with CagA positive phenotype.
              416. Shuttle cloning and nucleotide sequences of Helicobacter pylori genes responsible for urease activity.
              417. Pathogenic mechanisms of Helicobacter pylori.
              418. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients
              419. A new look at anti-Helicobacter pylori therapy
              420. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer
              421. Isolation and Genotyping of Helicobacter pylori from Untreated Municipal Wastewater
              422. Beneficial effects of Helicobacter pylori eradication on migraine.
              423. Helicobacter pylori‐Related Iron Deficiency Anemia: A Review
              424. Helicobacter pylori-Specific CD4+ CD25high Regulatory T Cells Suppress Memory T-Cell Responses to H. pylori in Infected Individuals
              425. The role of probiotics in the treatment and prevention of Helicobacter pylori infection
              426. Hypothesis: The Changing Relationships of Helicobacter pylori and Humans: Implications for Health and Disease
              427. Serum anti‐Helicobacter pylori antibody and gastric carcinoma among young adults
              428. Eradication of Helicobacter pylori reduces the possibility of rebleeding in peptic ulcer disease
              429. Helicobacter pylori and autoimmune pancreatitis: role of carbonic anhydrase via molecular mimicry?
              430. Helicobacter pylori: Pathology and Diagnostic Strategies
              431. Helicobacter pylori—in vitro susceptibility to garlic (Allium sativum) extract
              432. Helicobacter pylori eradication treatment reduces the severity of rosacea
              433. Helicobacter pylori
              434. Prospective screening of dyspeptic patients by Helicobacter pylori serology
              435. Gastric Lymphoma and Helicobacter pylori
              436. The Transmission of Helicobacter pylori. A Critical Review of the Evidence
              437. Role of cytokines in pathogenesis of Helicobacter pylori-induced mucosal damage.
              438. Helicobacter pylori Gastric Infection and Sideropenic
              439. Epidemiology of Helicobacter pylori in Southern China: Identification of Early Childhood as the Critical Period for Acquisition
              440. Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease
              441. Src Is the Kinase of the Helicobacter pylori CagA Protein in Vitro and in Vivo
              442. Helicobacter pylori Flagellin Evades Toll-Like Receptor 5-Mediated Innate Immunity
              443. Schönlein-Henoch purpura associated with gastric Helicobacter pylori infection
              444. Oral immunization with Helicobacter pylori urease B subunit as a treatment against Helicobacter infection in mice
              445. Immunobiology of Helicobacter pylori infection
              446. Autoimmune Thrombocytopenic Purpura and Helicobacter pylori Infection
              447. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection
              448. Biofilm formation by Helicobacter pylori
              449. Epidemiology of Helicobacter pylori Infection
              450. Emergence of recombinant strains of Helicobacter pylori during human infection
              451. Biological activity of the Helicobacter pylori virulence factor CagA is determined by variation in the tyrosine phosphorylation sites
              452. Helicobacter pylori and gastric acid: Biological and therapeutic implications
              453. Helicobacter pylori infection and dental care.
              454. Cholesterol glucosylation promotes immune evasion by Helicobacter pylori
              455. The neutrophil-activating protein of Helicobacter pylori promotes Th1 immune responses
              456. Helicobacter pylori infection induces antibodies cross-reacting with human gastric mucosa
              457. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers
              458. AN INTERNATIONAL ASSOCIATION BETWEEN HELICOBACTER-PYLORI INFECTION AND GASTRIC-CANCER.
              459. Comparative Genomics of Helicobacter pylori: Analysis of the Outer Membrane Protein Families
              460. In Vitro and In Vivo Activities of Tea Catechins against Helicobacter pylori
              461. Antimicrobial Activity of Essential Oils against Helicobacter pylori
              462. Cinnamon extracts’ inhibitory effect on Helicobacter pylori
              463. Adherence to gastric epithelial cells induces expression of a Helicobacter pylori gene, iceA, that is associated with clinical outcome.
              464. A New Helicobacter pylori Vacuolating Cytotoxin Determinant, the Intermediate Region, Is Associated With Gastric Cancer
              465. Helicobacter pylori Uses Motility for Initial Colonization and To Attain Robust Infection
              466. Geographic association of Helicobacter pylori antibody prevalence and gastric cancer mortality in rural China
              467. Evaluation of treatment regimens to cure Helicobacter pylori infection—a meta‐analysis
              468. Helicobacter pylori reinfection with identical organisms: transmission by the patients’ spouses.
              469. Helicobacter pylori Infection in Skin Diseases
              470. Guidelines for the Management of Helicobacter pylori Infection in Japan: 2009 Revised Edition
              471. Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection
              472. Smoking Increases the Treatment Failure for Helicobacter pylori Eradication
              473. Systematic review and meta‐analysis: levofloxacin‐based rescue regimens after Helicobacter pylori treatment failure
              474. Effect of Genetic Differences in Omeprazole Metabolism on Cure Rates for Helicobacter pylori Infection and Peptic Ulcer
              475. Inappropriate hypergastrinaemia in asymptomatic healthy subjects infected with Helicobacter pylori.
              476. Helicobacter pylori Persistence: an Overview of Interactions between H. pylori and Host Immune Defenses
              477. Isolation of Helicobacter pylori from dental plaques in healthy volunteers.
              478. Antibiotic resistance problems with Helicobacter pylori
              479. Helicobacter pylori Infection in the Colombian Andes: A Population-based Study of Transmission Pathways
              480. Seroprevalence of Helicobacter pylori infection in couples.
              481. Role of Helicobacter pylori in the Pathogenesis of Gastritis, Peptic Ulcer and Gastric Cancer
              482. Inducible Nitric Oxide Synthase, Nitrotyrosine, and Apoptosis in Helicobacter pylori Gastritis: Effect of Antibiotics and Antioxidants
              483. Systematic review: are probiotics useful in controlling gastric colonization by Helicobacter pylori?
              484. Chemokines in the gastric mucosa in Helicobacter pylori infection
              485. Helicobacter pylori Infection is the Major Risk Factor for Atrophic Gastritis.
              486. Duodenal ulcer healing by eradication of Helicobacter pylori without anti-acid treatment: randomised controlled trial
              487. Why Helicobacter pylori has Lewis antigens
              488. Simultaneous visualization of Helicobacter pylori and gastric morphology: A new stain
              489. Diagnosis of Helicobacter pylori: Invasive and non-invasive tests
              490. Helicobacter pylori infection in children: clinical, endoscopic, and histologic correlations.
              491. Treatment of Helicobacter pylori
              492. Challenge model for Helicobacter pylori infection in human volunteers
              493. Effect of Proton-Pump Inhibitor Therapy on Diagnostic Testing for Helicobacter pylori
              494. Helicobacter pylori and peptic ulcers: the present position.
              495. Role of Helicobacter pylori Eradication in the Prevention of Peptic Ulcer Bleeding Relapse
              496. Mechanisms of Helicobacter pylori Infection: Bacterial Factors
              497. c‐Src/Lyn kinases activate Helicobacter pylori CagA through tyrosine phosphorylation of the EPIYA motifs
              498. Helicobacter pylori Infection Enhances N-Methyl-N-nitrosourea-induced Stomach Carcinogenesis in the Mongolian Gerbil
              499. Effect of interleukin 1 polymorphisms on gastric mucosal interleukin 1β production in Helicobacter pylori infection
              500. Epidemiology of Helicobacter pylori infection and gastric cancer in Asia
              501. The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice
              502. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication
              503. Heterogeneity of Helicobacter pylori.
              504. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study
              505. Update on Helicobacter pylori Treatment.
              506. Helicobacter pylori infection as a cause of gastritis, duodenal ulcer, gastric cancer and nonulcer dyspepsia: a systematic overview.
              507. Characterization of Monospecies Biofilm Formation by Helicobacter pylori
              508. The Helicobacter pylori Vacuolating Toxin Inhibits T Cell Activation by Two Independent Mechanisms
              509. Intestinal metaplasia and Helicobacter pylori: an endoscopic bioptic study of the gastric antrum.
              510. Detection of Helicobacter pylori in Stool Specimens by PCR and Antigen Enzyme Immunoassay
              511. Treatment of Helicobacter pylori
              512. Iron Deficiency and Helicobacter pylori Infection in the United States
              513. Soluble surface proteins from Helicobacter pylori activate monocytes/macrophages by lipopolysaccharide-independent mechanism.
              514. Helicobacter pylori arginase inhibits nitric oxide production by eukaryotic cells: A strategy for bacterial survival
              515. In vitro anti-Helicobacter pylori action of 30 Chinese herbal medicines used to treat ulcer diseases
              516. Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials
              517. Seven‐day therapy for Helicobacter pylori in the United States
              518. Review article: 13C‐urea breath test in the diagnosis of Helicobacter pylori infection – a critical review
              519. Helicobacter pylori Infection and Related Gastrointestinal Diseases
              520. Identification and Characterization of Helicobacter pylori Genes Essential for Gastric Colonization
              521. Risk factors for coronary heart disease and infection with Helicobacter pylori: meta-analysis of 18 studies
              522. Rapid eradication of Helicobacter pylori infection
              523. The Interrelationship between Cytotoxin-Associated Gene A, Vacuolating Cytotoxin, and Helicobacter pylori-Related Diseases
              524. Hepatoprotective and anti-Helicobacter pylori activities of constituents from Brazilian propolis
              525. Oligomeric and subunit structure of the Helicobacter pylori vacuolating cytotoxin.
              526. Helicobacter pylori in the Natural Environment
              527. Helicobacter pylori causes DNA damage in gastric epithelial cells
              528. Influence of Oral Helicobacter pylori on the Success of Eradication Therapy Against Gastric Helicobacter pylori
              529. In vitro selection of resistant Helicobacter pylori.
              530. Long-Term Follow-up of Helicobacter pylori Serology after Successful Eradication.
              531. The diverse antioxidant systems of Helicobacter pylori
              532. Detection of Chlamydia pneumoniae but not Helicobacter pylori in atherosclerotic plaques of aortic aneurysms.
              533. Cloning and expression of a high-molecular-mass major antigen of Helicobacter pylori: evidence of linkage to cytotoxin production.
              534. Characterization of and human serologic response to proteins in Helicobacter pylori broth culture supernatants with vacuolizing cytotoxin activity.
              535. Prevalence of Helicobacter pylori–Associated Gastritis in Chronic Urticaria
              536. Surface localization of Helicobacter pylori urease and a heat shock protein homolog requires bacterial autolysis.
              537. Drug Therapy for Helicobacter pylori Infection: Problems and Pitfalls.
              538. Potential role of molecular mimicry between Helicobacter pylori lipopolysaccharide and host Lewis blood group antigens in autoimmunity.
              539. A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates
              540. Relationship Between Helicobacter pylori Infection and Esophageal Neoplasia: A Meta-analysis
              541. Patient Factors Affecting Helicobacter pylori Eradication with Triple Therapy.
              542. Management Strategies for Helicobacter pylori-Seropositive Patients with Dyspepsia: Clinical and Economic Consequences
              543. Interleukin 1 Polymorphisms, Lifestyle Factors, and Helicobacter pylori Infection
              544. OralHelicobacter pylori: Can We Stomach It?
              545. Helicobacter pylori and gastric cancer
              546. PCR-based subtractive hybridization and differences in gene content among strains of Helicobacter pylori
              547. Effect of urease on HeLa cell vacuolation induced by Helicobacter pylori cytotoxin.
              548. Transmission of Helicobacter pylori Infection Studies in Families of Healthy Individuals
              549. Antimicrobial Resistance Incidence and Risk Factors among Helicobacter pylori–Infected Persons, United States
              550. In vitro inhibition of Helicobacter pylori NCTC 11637 by organic acids and lactic acid bacteria
              551. Evidence-based Guidelines From ESPGHAN and NASPGHAN for Helicobacter pylori Infection in Children
              552. Familial clustering of Helicobacter pylori infection: population based studyCommentary: Helicobacter pylori—the story so far
              553. Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole.
              554. Extragastric Manifestations of Helicobacter pylori Infection
              555. PCR-based RFLP analysis of DNA sequence diversity in the gastric pathogen Helicobacter pylori
              556. Cellular vacuoles induced by Helicobacter pylori originate from late endosomal compartments
              557. Long-term nonsteroidal antiinflammatory drug use and Helicobacter pylori infection
              558. Probiotics and Helicobacter pylori
              559. Antibacterial effect of plant extracts against Helicobacter pylori
              560. In Vitro and In Vivo Inhibition of Helicobacter pylori by Lactobacillus casei Strain Shirota
              561. Is Helicobacter pylori Infection a Necessary Condition for Noncardia Gastric Cancer?
              562. Favourable effect of an acidified milk (LC-1) on Helicobacter pylori gastritis in man
              563. Role of Helicobacter pylori in the pathogenesis of atrophic gastritis.
              564. Rational Helicobacter pylori Therapy: Evidence-Based Medicine Rather Than Medicine-Based Evidence
              565. GASTRIC CANCER AND Helicobacter pylori INFECTION
              566. Increased expression and cellular localization of inducible nitric oxide synthase and cyclooxygenase 2 in Helicobacter pylori gastritis
              567. Helicobacter pylori infection prevents allergic asthma in mouse models through the induction of regulatory T cells
              568. Helicobacter pylori GASTRITIS AND GASTRIC PHYSIOLOGY
              569. Effects of ingesting Lactobacillus- and Bifidobacterium-containing yogurt in subjects with colonized Helicobacter pylori
              570. Evidence for the essential role of Helicobacter pylori in gastric ulcer disease.
              571. SagA of CagA in Helicobacter pylori pathogenesis
              572. Difference in expression of Helicobacter pylori gastritis in antrum and body
              573. Construction of isogenic urease-negative mutants of Helicobacter pylori by allelic exchange.
              574. Not all Helicobacter pylori strains are created equal: should all be eliminated?
              575. Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment—Helicobacter pylori positive (CADET-Hp) randomised controlled trial
              576. Local acid production and Helicobacter pylori: a unifying hypothesis of gastroduodenal disease.
              577. Helicobacter pylori and Gastric Cancer: A New Paradigm For Inflammation-Associated Epithelial Cancers
              578. One week triple therapy for Helicobacter pylori: a multicentre comparative study
              579. Inhibitory effect of natural honey on Helicobacter pylori.
              580. Apoptosis in gastric epithelium induced by Helicobacter pylori infection: implications in gastric carcinogenesis
              581. Detection of Helicobacter pylori in dental plaque by reverse transcription-polymerase chain reaction.
              582. Helicobacter pylori infection in functional dyspepsia
              583. Helicobacter pylori and Duodenal Ulcer Recurrence.
              584. T helper 1 effector cells specific for Helicobacter pylori in the gastric antrum of patients with peptic ulcer disease.
              585. Helicobacter pylori–associated iron-deficiency anemia in adolescent female athletes
              586. The Design of Vaccines Against Helicobacter pylori and Their Development
              587. Helicobacter pylori infection and gastric function in patients with chronic idiopathic dyspepsia
              588. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial
              589. 7 – Phase Variation in Helicobacter pylori Lipopolysaccharide
              590. Relation between infection with Helicobacter pylori and living conditions in childhood: evidence for person to person transmission in early life
              591. Regulation of gastric epithelial cell growth by Helicobacter pylori: Offdence for a major role of apoptosis
              592. Helicobacter pylori strain-specific differences in genetic content, identified by microarray, influence host inflammatory responses
              593. High Levels of Aberrant DNA Methylation in Helicobacter pylori–Infected Gastric Mucosae and its Possible Association with Gastric Cancer Risk
              594. Helicobacter pylori and extragastric diseases
              595. Is Helicobacter pylori the cause of dyspepsia?
              596. Molecular mimicry by Helicobacter pylori CagA protein may be involved in the pathogenesis of H. pylori‐associated chronic idiopathic thrombocytopenic purpura
              597. Helicobacter pylori infection prevents erosive reflux oesophagitis by decreasing gastric acid secretion
              598. Histological identification of Helicobacter pylori: comparison of staining methods
              599. Analysis of metronidazole, clarithromycin and tetracycline resistance of Helicobacter pylori isolates from Korea
              600. Antigenic mimicry between Helicobacter pylori and gastric mucosa in the pathogenesis of body atrophic gastritis
              601. Mucosal FOXP3-Expressing CD4+ CD25high Regulatory T Cells in Helicobacter pylori-Infected Patients
              602. pH-Regulated Gene Expression of the Gastric Pathogen Helicobacter pylori
              603. Therapy of Helicobacter pylori: current status and issues
              604. Helicobacter pylori infection: Detection, investigation, and management
              605. Catalase, a novel antigen for Helicobacter pylori vaccination.
              606. Immunoproteomics of Helicobacter pylori infection and relation to gastric disease
              607. Secondary Resistance Among 554 Isolates of Helicobacter pylori After Failure of Therapy
              608. Helicobacter pylori–Related Disease
              609. Meta-analysis of Risk Factors for Peptic Ulcer: Nonsteroidal Antiinflammatory Drugs, Helicobacter pylori, and Smoking
              610. Helicobacter pylori infection in perforated peptic ulcer disease
              611. Helicobacter pylori infection and gastric cancer
              612. Gastric bacteria other than Helicobacter pylori.
              613. Mucosal interleukin-8 and Helicobacter pylori-associated gastroduodenal disease.
              614. Helicobacter pylori-associated ammonia production enhances neutrophil-dependent gastric mucosal cell injury
              615. Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer
              616. Disease‐specific Helicobacter pylori Virulence Factors: The Unfulfilled Promise
              617. Induction of various cytokines and development of severe mucosal inflammation by cagA gene positive Helicobacter pylori strains
              618. Importance of Helicobacter pylori oipA in clinical presentation, gastric inflammation, and mucosal interleukin 8 production
              619. Helicobacter pylori infection and gastric cancer
              620. How Does Helicobacter pylori Cause Mucosal Damage? Direct Mechanisms
              621. Helicobacter pylori — Not a Good Bug after All
              622. Role of metronidazole resistance in therapy of Helicobacter pylori infections.
              623. Serum ferritin, hemoglobin, and Helicobacter pylori infection: A seroepidemiologic survey comprising 2794 Danish adults
              624. Pathological significance and molecular characterization of the vacuolating toxin gene of Helicobacter pylori.
              625. Gastritis due to spiral shaped bacteria other than Helicobacter pylori: clinical, histological, and ultrastructural findings.
              626. An investigation into factors associated with Helicobacter pylori infection
              627. Cell proliferation in Helicobacter pylori associated gastritis and the effect of eradication therapy.
              628. Gastric Dysplasia and Gastric Cancer: Helicobacter pylori, Serum Vitamin C, and Other Risk Factors
              629. Antimicrobial Activity of Curcumin against Helicobacter pylori Isolates from India and during Infections in Mice
              630. Burden of Helicobacter pylori and H. pylori-related diseases in developed countries: recent developments and future implications
              631. Low rates of Helicobacter pylori reinfection in children
              632. Helicobacter pylori CagA Phosphorylation-Independent Function in Epithelial Proliferation and Inflammation
              633. Helicobacter pylori Eradication in Functional Dyspepsia
              634. How Should Helicobacter pylori Infection Be Diagnosed?
              635. Inhibition of Helicobacter pylori binding to gastrointestinal epithelial cells by sialic acid-containing oligosaccharides.
              636. Seroprevalence of Helicobacter pylori infection in an asymptomatic Turkish population
              637. Canadian Helicobacter Study Group Consensus Conference: Update on the approach to Helicobacter pylori infection in children and adolescents–an evidence-based evaluation.
              638. A systematic review of Helicobacter pylori eradication therapy—the impact of antimicrobial resistance on eradication rates
              639. Helicobacter pylori in North and South America before Columbus
              640. Choosing the Best Anti-Helicobacter pylori Therapy: Effect of Antimicrobial Resistance.
              641. Treatment strategies for Helicobacter pylori infection.
              642. Direct polymerase chain reaction test for detection of Helicobacter pylori in humans and animals.
              643. Amoxycillin tolerance in Helicobacter pylori
              644. Epidemiology and diagnosis of Helicobacter pylori infection
              645. Inhibition of binding of Helicobacter pylori to the glycolipid receptors by probiotic Lactobacillus reuteri
              646. [Diagnosis and treatment guidelines for Helicobacter pylori infection in Korea].
              647. High incidence of reflux oesophagitis after eradication therapy for Helicobacter pylori: impacts of hiatal hernia and corpus gastritis.
              648. Effects of Helicobacter pylori Eradication on Early Stage Gastric Mucosa–Associated Lymphoid Tissue Lymphoma
              649. Acute perforated duodenal ulcer is not associated with Helicobacter pylori infection.
              650. Helicobacter pylori Infection and Iron Stores: A Systematic Review and Meta‐analysis
              651. Antibacterial effect of garlic and omeprazole on Helicobacter pylori
              652. Use of autoradiography to assess viability of Helicobacter pylori in water.
              653. The Epidemiology of Helicobacter pylori in Peruvian Children between 6 and 30 Months of Age.
              654. MicroRNA signatures in Helicobacter pylori‐infected gastric mucosa
              655. Anti-Helicobacter pylori Agents from the Cashew Apple
              656. Iron acquisition by Helicobacter pylori: importance of human lactoferrin.
              657. Helicobacter pylori and gastric cancer
              658. Concordance of Helicobacter pylori Strains within Families
              659. Helicobacter pylori impairs iron absorption in infected individuals
              660. The Gastric Biology of Helicobacter pylori*
              661. Oral Carriage of Helicobacter pylori: A Review
              662. Helicobacter pylori urease is a potent stimulus of mononuclear phagocyte activation and inflammatory cytokine production
              663. Helicobacter pylori induced apoptosis
              664. Helicobacter pylori gastritis—Epidemiology
              665. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review
              666. Detection of Helicobacter pylori gene expression in human gastric mucosa.
              667. Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial
              668. Serodiagnosis of Helicobacter pylori: comparison of enzyme-linked immunosorbent assays.
              669. Inactivation of Helicobacter pylori by chlorination.
              670. Effect of Helicobacter pylori eradication on sideropenic refractory anaemia in adolescent girls with Helicobacter pylori infection
              671. Long-Term Course and Consequences of Helicobacter pylori gastritis Results of a 32-Year Follow-up Study
              672. Density of Helicobacter pylori Infection In Vivo as Assessed by Quantitative Culture and Histology
              673. Helicobacter pylori virulence factors—one part of a big picture
              674. CD25+/Foxp3+ T Cells Regulate Gastric Inflammation and Helicobacter pylori Colonization In Vivo
              675. Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind placebo controlled trial with 12 months’ follow up
              676. Improvement in Atrophic Gastritis and Intestinal Metaplasia in Patients in Whom Helicobacter pylori Was Eradicated
              677. Epidemiology of Helicobacter pylori infection
              678. Meta-analysis: Sequential Therapy Appears Superior to Standard Therapy for Helicobacter pylori Infection in Patients Naive to Treatment
              679. Surface proteins from Helicobacter pylori exhibit chemotactic activity for human leukocytes and are present in gastric mucosa.
              680. Effect of Helicobacter pylori and its eradication on gastric juice ascorbic acid.
              681. Salty Food Intake and Risk of Helicobacter pylori Infection
              682. Cytokine gene polymorphisms influence mucosal cytokine expression, gastric inflammation, and host specific colonisation during Helicobacter pylori infection
              683. Gastric epithelium in the duodenum: its association with Helicobacter pylori and inflammation.
              684. Horizontal versus Familial Transmission of Helicobacter pylori
              685. MALT-type lymphoma of the stomach is associated with Helicobacter pylori strains expressing the CagA protein
              686. Elimination of Helicobacter pylori under treatment with omeprazole.
              687. Translocation of the Helicobacter pylori CagA protein in gastric epithelial cells by a type IV secretion apparatus
              688. Association between Helicobacter pylori Infection and Pancreatic Cancer
              689. Bugs on trial: the case of Helicobacter pylori and autoimmunity
              690. Helicobacter pylori Infection and Gastric Adenocarcinoma
              691. Compositional analysis of Helicobacter pylori rough-form lipopolysaccharides.
              692. Survival of Helicobacter pylori in a Natural Freshwater Environment
              693. The link between Helicobacter pylori infection and rosacea
              694. Fifteen-Year Effects of Helicobacter pylori, Garlic, and Vitamin Treatments on Gastric Cancer Incidence and Mortality
              695. Helicobacter pylori virulence factors: facts and fantasies
              696. Acid Acclimation by Helicobacter pylori
              697. Cag pathogenicity island-specific responses of gastric epithelial cells to Helicobacter pylori infection
              698. Bactericidal Activity of Pistacia lentiscus Mastic Gum Against Helicobacter pylori
              699. The prevalence of Helicobacter pylori infection in gastric cancer.
              700. Mechanisms involved in Helicobacter pylori-induced interleukin-8 production by a gastric cancer cell line, MKN45.
              701. Diagnosis of Helicobacter pylori infection
              702. Helicobacter pylori infection and gastric lymphoma
              703. Gastric T lymphocyte responses to Helicobacter pylori in patients with H pylori colonisation.
              704. In vitro inhibition of Helicobacter pylori by extracts of thyme
              705. Regression of gastric MALT lymphoma after eradication of Helicobacter pylori is predicted by endosonographic staging. MALT Lymphoma Study Group
              706. Effect of eradication of Helicobacter pylori on gastric juice ascorbic acid concentrations.
              707. Did the inheritance of a pathogenicity island modify the virulence of Helicobacter pylori?
              708. Meta-analysis: Duration of First-Line Proton-Pump Inhibitor–BasedTriple Therapy forHelicobacter pyloriEradication
              709. Helicobacter pylori-induced gastritis in the domestic cat.
              710. Helicobacter pylori enter and survive within multivesicular vacuoles of epithelial cells
              711. High prevalence of Helicobacter pylori in saliva demonstrated by a novel PCR assay.
              712. Helicobacter pylori Urease: Properties and Role in Pathogenesis
              713. Mutation discovery in bacterial genomes: metronidazole resistance in Helicobacter pylori
              714. A Comprehensive Review of the Natural History of Helicobacter pylori Infection in Children
              715. Molecular Characterization of Two-Component Systems of Helicobacter pylori
              716. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study
              717. BCA-1 is highly expressed in Helicobacter pylori–induced mucosa-associated lymphoid tissue and gastric lymphoma
              718. Effect of Pretreatment Antibiotic Resistance to Metronidazole and Clarithromycin on Outcome of Helicobacter pylori Therapy
              719. Could Helicobacter pylori infection increase the risk of coronary heart disease by modifying serum lipid concentrations?
              720. In vitro anti-Helicobacter pylori activity of Greek herbal medicines
              721. DISCOVERY BY JAWORSKI OF Helicobacter pyloriAND ITS PATHOGENETIC ROLE IN PEPTIC ULCER, GASTRITIS AND GASTRIC CANCER
              722. Helicobacter pylori-induced epithelial cell signalling in gastric carcinogenesis
              723. Effect of different probiotic preparations on anti-Helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study
              724. Helicobacter pylori eradication therapy
              725. Structure of the Neutrophil-activating Protein from Helicobacter pylori
              726. Lactobacillus acidophilus Autolysins Inhibit Helicobacter pylori In Vitro
              727. Expression of 120 kilodalton protein and cytotoxicity in Helicobacter pylori.
              728. Helicobacter pylori Strain-specific Genotypes and Modulation of the Gastric Epithelial Cell Cycle
              729. VacA from Helicobacter pylori: a hexameric chloride channel
              730. Free-living Amoebae Promote Growth and Survival of Helicobacter pylori
              731. Occurrence of Helicobacter pylori in surface water in the United States
              732. Helicobacter pylori and molecular events in precancerous gastric lesions
              733. Analysis and typing of the vacA gene from cagA-positive strains of Helicobacter pylori isolated in Japan.
              734. Helicobacter pylori Infection Is Associated With an Increased Rate of Diabetes
              735. Metronidazole resistance in Helicobacter pylori
              736. GASTRIC PATHOLOGY ASSOCIATED WITH Helicobacter pylori
              737. Ulcer risk factors: Interactions between Helicobacter pylori infection, nonsteroidal use, and age
              738. Prospective relations between Helicobacter pylori infection, coronary heart disease, and stroke in middle aged men.
              739. Helicobacter pylori among Preschool Children and Their Parents: Evidence of Parent-Child Transmission
              740. Canadian Helicobacter pylori Consensus Conference Update: Infections in Adults
              741. Relationship between Helicobacter pylori infection and glaucoma
              742. Gain and Loss of Multiple Genes During the Evolution of Helicobacter pylori
              743. The Neutrophil-Activating Protein (Hp-Nap) of Helicobacter pylori Is a Protective Antigen and a Major Virulence Factor
              744. Early Helicobacter pylori Eradication Decreases Risk of Gastric Cancer in Patients With Peptic Ulcer Disease
              745. Evaluation of Helicobacter pylori in reflux oesophagitis and Barrett’s oesophagus.
              746. Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori.
              747. Pathogenesis of Helicobacter pylori Infection
              748. Helicobacter pylori Gastritis in Children Is Associated With a Regulatory T-Cell Response
              749. Helicobacter pylori-associated gastroduodenal disease in childhood.
              750. Probiotics and Helicobacter pylori eradication
              751. Unique cholesteryl glucosides in Helicobacter pylori: composition and structural analysis.
              752. Disappearance of Hyperplastic Polyps in the Stomach after Eradication of Helicobacter pylori: A Randomized, Controlled Trial
              753. Tolerance Rather Than Immunity Protects From Helicobacter pylori–Induced Gastric Preneoplasia
              754. Prospective multicentre study on antibiotic resistance of Helicobacter pylori strains obtained from children living in Europe
              755. Helicobacter pylori: present status and future prospects in Japan
              756. Intact Gram-Negative Helicobacter pylori, Helicobacter felis, and Helicobacter hepaticus Bacteria Activate Innate Immunity via Toll-Like Receptor 2 but Not Toll-Like Receptor 4
              757. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults
              758. Management of Helicobacter pylori infection.
              759. Selective increase of the permeability of polarized epithelial cell monolayers by Helicobacter pylori vacuolating toxin.
              760. Acid survival of Helicobacter pylori: how does urease activity trigger cytoplasmic pH homeostasis?
              761. Helicobacter pylori Physiology Predicted from Genomic Comparison of Two Strains
              762. Cure of Helicobacter pylori Infection and Duration of Remission of Low-Grade Gastric Mucosa-Associated Lymphoid Tissue Lymphoma
              763. Stool Antigen Test for the Diagnosis of Helicobacter pylori Infection: a Systematic Review
              764. Positive serum antibody and negative tissue staining for Helicobacter pylori in subjects with atrophic body gastritis
              765. Helicobacter pylori and the Birth Cohort Effect: Evidence of a Continuous Decrease of Infection Rates in Childhood.
              766. Metabolism and Genetics of Helicobacter pylori: the Genome Era
              767. Helicobacter pylori infection in children: relation with current household living conditions.
              768. Helicobacter pylori-coccoid forms and biofilm
              769. Prevention of ulcer recurrence after eradication of Helicobacter pylori: A prospective long-term follow-up study
              770. The inflammatory and immune response to Helicobacter pylori infection
              771. Helicobacter pylori infection with iron deficiency anaemia and subnormal growth at puberty
              772. Helicobacter pylori infection and growth delay in older children
              773. Low Prevalence of Helicobacter pylori‐negative Gastric Cancer among Japanese
              774. Chronic Helicobacter pylori infections induce gastric mutations in mice
              775. Reversal of Long-Standing Iron Deficiency Anaemia after Eradication of Helicobacter pylori Infection
              776. Treatment of Helicobacter pylori
              777. Typing of Helicobacter pylori vacA Gene and Detection of cagA Gene by PCR and Reverse Hybridization
              778. Epidemiology and diagnosis of Helicobacter pylori infection
              779. Importance of Helicobacter pylori cagA and vacAstatus for the efficacy of antibiotic treatment
              780. Helicobacter pylori: an invading microorganism? A review
              781. Helicobacter pylori independent chronological change in gastric acid secretion in the Japanese
              782. Gastric Atrophy and Intestinal Metaplasia before and after Helicobacter pylori Eradication: A Meta-Analysis
              783. Age of the Association between Helicobacter pylori and Man
              784. The complete genome sequence of a chronic atrophic gastritis Helicobacter pylori strain: Evolution during disease progression
              785. Cloning and genetic characterization of the Helicobacter pylori and Helicobacter mustelae flaB flagellin genes and construction of H. pylori flaA- and flaB-negative mutants by electroporation-mediated allelic exchange.
              786. Tooth loss, pancreatic cancer, and Helicobacter pylori
              787. Acute Helicobacter pylori infection: clinical features, local and systemic immune response, gastric mucosal histology, and gastric juice ascorbic acid concentrations.
              788. Population genetic analysis of Helicobacter pylori by multilocus enzyme electrophoresis: extensive allelic diversity and recombinational population structure.
              789. Helicobacter pylori was recovered from sheep milk, suggesting a role for animals in transmission. H pylori may be a commensal in the sheep, which may be H pylori’s ancestral host.
              790. Expression of interleukin 8 and CD54 by human gastric epithelium after Helicobacter pylori infection in vitro
              791. Helicobacter pylori Associated with Glossitis and Halitosis
              792. Eradicating Helicobacter pylori infection lowers gastrin mediated acid secretion by two thirds in patients with duodenal ulcer.
              793. Resveratrol inhibits the growth of Helicobacter pylori in vitro
              794. Human milk kappa-casein and inhibition of Helicobacter pylori adhesion to human gastric mucosa.
              795. Helicobacter pylori: The Mouth, Stomach, and Gut Axis
              796. Does Helicobacter pylori infection increase gastric sensitivity in functional dyspepsia?
              797. Eradication of Helicobacter pylori infection reverses E-cadherin promoter hypermethylation
              798. Asthma Is Inversely Associated with Helicobacter pylori Status in an Urban Population
              799. Helicobacter pylori Membrane Protein 1: A New Carcinogenic Factor of Helicobacter pylori
              800. Geographic Differences in Gastric Cancer Incidence Can be Explained by Differences between Helicobacter pylori Strains
              801. Vacuoles Induced by Helicobacter pylori Toxin Contain Both Late Endosomal and Lysosomal Markers
              802. Effect of Treatment of Helicobacter pylori Infection on Rosacea
              803. Helicobacter pylori and Socioeconomic Factors in Russia
              804. Smoking and peptic ulcer in the Helicobacter pylori era.
              805. Prevalence of Helicobacter pylori Infection Worldwide: A Systematic Review of Studies with National Coverage
              806. Epidemiology of Helicobacter pylori Infection
              807. The Relationship among Previous Antimicrobial Use, Antimicrobial Resistance, and Treatment Outcomes for Helicobacter pylori Infections
              808. Pro- and anti-inflammatory cytokines gene polymorphisms and Helicobacter pylori infection: interactions influence outcome
              809. Promoter methylation of E-cadherin gene in gastric mucosa associated with Helicobacter pylori infection and in gastric cancer
              810. Analysis of the genetic diversity of Helicobacter pylori: the tale of two genomes
              811. Localization of Helicobacter pylori urease and heat shock protein in human gastric biopsies.
              812. The Role of T Cell Subsets and Cytokines in the Pathogenesis of Helicobacter pylori Gastritis in Mice
              813. Helicobacter pylori infection in pernicious anemia: A prospective controlled study
              814. Eradication of Helicobacter pylori Infection
              815. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole
              816. Helicobacter pylori and peptic ulcer disease.
              817. Lewis antigens in Helicobacter pylori: biosynthesis and phase variation
              818. Helicobacter pylori infection among offspring of patients with stomach cancer
              819. Helicobacter pylori Factors Associated With Disease Development
              820. The Versatility of Helicobacter pylori CagA Effector Protein Functions: The Master Key Hypothesis
              821. A urease-negative mutant of Helicobacter pylori constructed by allelic exchange mutagenesis lacks the ability to colonize the nude mouse stomach.
              822. Role of Innate Immunity in Helicobacter pylori-Induced Gastric Malignancy
              823. Consequences of Helicobacter pylori infection in children
              824. Helicobacter pylori Infection Is Markedly Increased in Patients With Autoimmune Atrophic Thyroiditis
              825. Gastric autoimmunity: the role of Helicobacter pylori and molecular mimicry
              826. Hyperammonaemia and Helicobacter pylori
              827. The Association Between Helicobacter pylori Infection and Insulin Resistance: A Systematic Review
              828. Helicobacter pylori: a ROS-inducing bacterial species in the stomach
              829. Randomized Placebo‐Controlled Trial of Helicobacter pylori Eradication for Iron‐Deficiency Anemia in Preadolescent Children and Adolescents
              830. Hydrogen uptake hydrogenase in Helicobacter pylori
              831. Vacuolating Cytotoxin of Helicobacter pylori Plays a Role during Colonization in a Mouse Model of Infection
              832. The Mother as Source of Helicobacter pylori Infection
              833. Levofloxacin based regimens for the eradication of Helicobacter pylori
              834. Helicobacter pylori infection: relation with cardiovascular risk factors, ischaemic heart disease, and social class.
              835. In Vitro Activity of Olive Oil Polyphenols against Helicobacter pylori
              836. Use Caution with Serologic Testing for Helicobacter pylori Infection in Children
              837. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy
              838. Test device and kit for detecting Helicobacter pylori
              839. Crystal Structure of the Hexameric Traffic ATPase of the Helicobacter pylori Type IV Secretion System
              840. Long‐term follow‐up of gastric histology after Helicobacter pylori eradication
              841. Prevalence of Helicobacter pylori infection in children (south of Iran)
              842. One-week low-dose triple therapy for the eradication of Helicobacter pylori infection.
              843. Complete Remission of Primary High-Grade B-Cell Gastric Lymphoma After Cure of Helicobacter pylori Infection
              844. Association of symptoms with Helicobacter pylori infection in children
              845. Helicobacter pylori infection and food-cobalamin malabsorption
              846. Construction of a Helicobacter pylori genome map and demonstration of diversity at the genome level.
              847. Mechanism of clarithromycin resistance in clinical isolates of Helicobacter pylori
              848. Transmission of Helicobacter pylori infection.
              849. Features and trends in Helicobacter pylori antibiotic resistance in Lisbon area, Portugal (1990–1999)
              850. Diagnostic Tests for Helicobacter pylori: A Prospective Evaluation of Their Accuracy, without Selecting a Single Test as the Gold Standard.
              851. Helicobacter pylori and the gastric microbiota
              852. Genetic diversity of Helicobacter pylori
              853. Improved Efficacy of 10-Day Sequential Treatment for Helicobacter pylori Eradication in Children: A Randomized Trial
              854. Bactericidal and anti-adhesive properties of culinary and medicinal plants against Helicobacter pylori
              855. Helicobacter pylori in the oral cavity: A critical review of the literature
              856. Helicobacter pylori is killed by nitrite under acidic conditions
              857. Intracellular, Intercellular, and Stromal Invasion of Gastric Mucosa, Preneoplastic Lesions, and Cancer by Helicobacter pylori
              858. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection
              859. Helicobacter pylori CagA and Gastric Cancer: A Paradigm for Hit-and-Run Carcinogenesis
              860. In Vitro susceptibility of Helicobacter pylori to botanical extracts used traditionally for the treatment of gastrointestinal disorders
              861. Helicobacter pylori infection and cancer
              862. Detection of Helicobacter pylori in oral aphthous ulcers
              863. Helicobacter pylori infection and insulin-dependent diabetes mellitus
              864. Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori.
              865. Hyperemesis Gravidarum and Helicobacter pylori Infection: A Systematic Review
              866. Impact of Metronidazole Resistance on the Eradication of Helicobacter pylori
              867. Neutrophil Activation by Helicobacter pylori Lipopolysaccharides
              868. Helicobacter pylori sero-prevalence in asthma
              869. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial
              870. Virulent Strains of Helicobacter pylori Demonstrate Delayed Phagocytosis and Stimulate Homotypic Phagosome Fusion in Macrophages
              871. Is Helicobacter pylori associated with non-ulcer dyspepsia and will eradication improve symptoms? A meta-analysis
              872. Helicobacter pylori picB, a homologue of the Bordetella pertussis toxin secretion protein, is required for induction of IL‐8 in gastric epithelial cells
              873. Meta‐analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first‐line therapies for Helicobacter pylori
              874. Phosphorylation of Helicobacter pylori CagA by c-Abl leads to cell motility
              875. Helicobacter pylori culture and antimicrobial resistance in Iran
              876. Long-term colonization with single and multiple strains of Helicobacter pylori assessed by DNA fingerprinting.
              877. Helicobacter pylori seropositivity in patients with hyperemesis gravidarum
              878. A Century of Helicobacter pylori
              879. Relation of smoking and alcohol and coffee consumption to active Helicobacter pylori infection: cross sectional study
              880. Towards deciphering the Helicobacter pylori cytotoxin
              881. Seroepidemiology of Helicobacter pylori infection in a cohort of children monitored from 6 months to 11 years of age.
              882. Conservation, localization and expression of HopZ, a protein involved in adhesion of Helicobacter pylori
              883. Inhibition of T-Cell Proliferation by Helicobacter pylori γ-Glutamyl Transpeptidase
              884. Pathogenic Properties of Helicobacter pylori
              885. Helicobacter pylori in the pathogenesis of gastric cancer and gastric lymphoma
              886. “Rescue” regimens after Helicobacter pylori treatment failure
              887. Involvement of the CD95 (APO-1/Fas) receptor and ligand system in Helicobacter pylori-induced gastric epithelial apoptosis.
              888. Detection of Helicobacter pylori in gastric biopsy and resection specimens.
              889. Helicobacter pylori: seroprevalence and colorectal cancer.
              890. Relationship between the cagA 3′ repeat region of Helicobacter pylori, gastric histology, and susceptibility to low pH
              891. The Translation of Helicobacter pylori Basic Research to Patient Care
              892. Molecular epidemiology, population genetics, and pathogenic role of Helicobacter pylori
              893. Growth Phase-Dependent Response of Helicobacter pylori to Iron Starvation
              894. Stimulation of interleukin-8 production in epithelial cell lines by Helicobacter pylori.
              895. Accurate Diagnosis of Helicobacter pylori: Urease Tests
              896. Vacuolating cytotoxin A (VacA), a key toxin for Helicobacter pylori pathogenesis
              897. The Helicobacter pylori vacA s1, m1 genotype and cagA is associated with gastric carcinoma in Germany
              898. Capsaicin as an inhibitor of the growth of the gastric pathogen Helicobacter pylori
              899. Mutation as an origin of genetic variability in Helicobacter pylori
              900. The status of antimicrobial resistance of Helicobacter pylori in eastern Europe
              901. Healing of protein losing hypertrophic gastropathy by eradication of Helicobacter pylori–is Helicobacter pylori a pathogenic factor in Ménétrier’s disease?
              902. Results from the Pediatric European Register for Treatment of Helicobacter pylori (PERTH)
              903. Metronidazole resistance in Helicobacter pylori is due to null mutations in a gene (rdxA) that encodes an oxygen‐insensitive NADPH nitroreductase
              904. Pathogenesis of Helicobacter pylori Infection
              905. A study of the pathogenesis of Helicobacter pylori negative chronic duodenal ulceration.
              906. The effect of Helicobacter pylori eradication on gastro-oesophageal reflux.
              907. Urea breath tests in the management of Helicobacter pylori infection
              908. Human and Helicobacter pylori coevolution shapes the risk of gastric disease
              909. Treatment of Helicobacter pylori Infection 2011
              910. Production of a Cytotoxin by Helicobacter pylori
              911. Impaired Production of Gastric Ghrelin in Chronic Gastritis Associated with Helicobacter pylori
              912. Helicobacter pylori factors associated with disease
              913. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial
              914. Rifabutin‐based Helicobacter pylori eradication ‘rescue therapy’
              915. Helicobacter pylori Phenotypes Associated with Peptic Ulceration
              916. Immunomagnetic separation and PCR for detection of Helicobacter pylori in water and stool specimens.
              917. Central Serous Chorioretinopathy and Helicobacter pylori
              918. Chemotactic activity of Helicobacter pylori sonicate for human polymorphonuclear leucocytes and monocytes.
              919. The Relationship Between Consumption of Antimicrobial Agents and the Prevalence of Primary Helicobacter pylori Resistance
              920. Role of Helicobacter pylori CagA+ strains and risk of adenocarcinoma of the stomach and esophagus
              921. Helicobacter pylori and Chronic ITP
              922. Identification, characterization, and spatial localization of two flagellin species in Helicobacter pylori flagella.
              923. Iron deficiency anaemia and Helicobacter pylori infection
              924. Helicobacter pylori Reinfection Is Virtually Absent after Successful Eradication
              925. Survival of Helicobacter pylori in milk and tap water
              926. Identification of Helicobacter pylori Biofilms in Human Gastric Mucosa
              927. The effect of environmental pH on the proton motive force of Helicobacter pylori
              928. Treatment of Helicobacter pylori infection and factors influencing eradication
              929. Structural characterization of the lipid A component of Helicobacter pylori rough- and smooth-form lipopolysaccharides.
              930. Linking Helicobacter pylori to gastric cancer
              931. Helicobacter pylori infection rates in relation to age and social class in a population of Welsh men.
              932. Appendicectomy, childhood hygiene, Helicobacter pylori status, and risk of inflammatory bowel disease: a case control study
              933. Helicobacter pyloriThe Etiologic Agent for Peptic Ulcer
              934. Review article Is Helicobacter pylori transmitted by the gastro‐oral route?
              935. Bactericidal and morphological effects of amoxicillin on Helicobacter pylori.
              936. Omeprazole and Helicobacter pylori: temporary suppression rather than true eradication
              937. Abstract 4269: Regulation and functional roles of autophagy in Helicobacter pylori CagA-mediated gastric cancer
              938. Diagnosis and treatment of Helicobacter pylori in adults with an intellectual disability
              939. Prevalence of Helicobacter pylori infection and antibiotic resistance profile in Armenia
              940. Real-time PCR detection of a 16S rRNA single mutation of Helicobacter pylori isolates associated with reduced susceptibility and resistance to tetracycline in the gastroesophageal mucosa of individual hosts
              941. Pharmaceutical compositions for the treatment of Helicobacter pylori
              942. Maturation of atypical ribosomal RNA precursors in Helicobacter pylori
              943. Helicobacter pylori lipids can form ordered membrane domains (rafts)
              944. Classification of Helicobacter pylori Virulence Factors: Is CagA a Toxin or Not?
              945. A DNAzyme‐Based Colorimetric Paper Sensor for Helicobacter pylori
              946. Noninvasive Diagnostic Tests for Helicobacter pylori Infection
              947. Review: Helicobacter pylori and extragastric diseases
              948. Does Eradication of Helicobacter pylori Cause Inflammatory Bowel Disease?
              949. Helicobacter pylori senses bleach (HOCl) as a chemoattractant using a cytosolic chemoreceptor
              950. 45 – Helicobacter pylori Infection
              951. Iron status determination in individuals with Helicobacter pylori infection: conventional vs. new laboratory biomarkers
              952. Helicobacter pylori Vacuolating Cytotoxin A Causes Anorexia and Anxiety via Hypothalamic Urocortin 1 in Mice
              953. Review: Diagnosis of Helicobacter pylori infection
              954. Inhibition of polarity-regulating kinase PAR1b contributes to Helicobacter pylori inflicted DNA Double Strand Breaks in gastric cells
              955. The Helicobacter pylori HopQ outermembrane protein inhibits immune cell activities
              956. Helicobacter pylori infection promotes autophagy through Nrf2-mediated heme oxygenase upregulation in human gastric cancer cells
              957. PTU-067 Helicobacter pylori resistance: a complex socioeconomic problem?
              958. Helicobacter pylori infection and gastrointestinal tract cancer biology: considering a double-edged sword reflection
              959. The core genome m5C methyltransferase JHP1050 (M.Hpy99III) plays an important role in orchestrating gene expression in Helicobacter pylori
              960. Risk of gastric cancer in the second decade of follow-up after Helicobacter pylori eradication
              961. Helicobacter pylori Deregulates T and B Cell Signaling to Trigger Immune Evasion
              962. How many protein molecules are secreted by single Helicobacter pylori cells: Quantification of serine protease HtrA
              963. Pathogenic potential of Helicobacter pylori strains can explain differences in H. pylori associated diseases rates from Chile and Cuba
              964. Reconciliation of Recent Helicobacter pylori Treatment Guidelines in a Time of Increasing Resistance to Antibiotics
              965. Effect of environmental salt concentration on the Helicobacter pylori exoproteome
              966. Comparative proteomics of Helicobacter pylori strains reveals geographical features rather than genomic variations
              967. A Genome-Wide Helicobacter pylori Morphology Screen Uncovers a Membrane-Spanning Helical Cell Shape Complex
              968. Development of a loop-mediated isothermal amplification assay for rapid Helicobacter pylori detection
              969. Within-host evolution of Helicobacter pylori shaped by niche-specific adaptation, intragastric migrations and selective sweeps
              970. Mechanisms of Inflammasome Signaling, microRNA Induction and Resolution of Inflammation by Helicobacter pylori
              971. Helicobacter pylori Infection
              972. Utilization Rate of Helicobacter pylori Immunohistochemistry Is Not Associated With the Diagnostic Rate of Helicobacter pylori Infection
              973. Antimicrobial resistance of Helicobacter pylori in Germany, 2015 to 2018
              974. Impact of Helicobacter pylori and/or Helicobacter pylori–related metabolic syndrome on incidence of all-cause and Alzheimer’s dementia
              975. Helicobacter pylori eradication in dyspepsia: New evidence for symptomatic benefit
              976. Structural insights into the AapA1 toxin of Helicobacter pylori
              977. Review: Treatment of Helicobacter pylori Infection 2019
              978. α-Difluoromethylornithine reduces gastric carcinogenesis by causing mutations in Helicobacter pylori cagY
              979. Update of primary Helicobacter pylori resistance to antimicrobials in Brussels, Belgium
              980. Helicobacter pylori Induces IL-33 Production and Recruits ST-2 to Lipid Rafts to Exacerbate Inflammation
              981. Helicobacter pylori infection and risk of preeclampsia: a systematic review and meta-analysis
              982. Helicobacter pylori‐activated gastric fibroblasts induce epithelial‐mesenchymal transition of gastric epithelial cells in vitro in a TGF‐β‐dependent manner
              983. Halitosis: Helicobacter pylori or oral factors
              984. Efficacy of a tailored PCR-guided triple therapy in the treatment of Helicobacter pylori infectionEfficacité d’un traitement d’éradication guidé par PCR pour le traitement de l’infection par Helicobacter pylori
              985. High-resolution mapping reveals that microniches in the gastric glands control Helicobacter pylori colonization of the stomach
              986. Association between Helicobacter pylori infection and risk of nonalcoholic fatty liver disease: An updated meta-analysis.
              987. Structure of the Helicobacter pylori Cag type IV Secretion System
              988. Amoxicillin sensitization rate in patients with eruptions after Helicobacter pylori eradication therapy
              989. Systematic review with meta‐analysis: association between Helicobacter pylori CagA seropositivity and odds of inflammatory bowel disease
              990. Helicobacter pylori treatment in Turkey: Current status and rational treatment options
              991. Targeted mobilization of Lrig1+ gastric epithelial stem cell populations by a carcinogenic Helicobacter pylori type IV secretion system
              992. Treatment of Helicobacter pylori
              993. Helicobacter pylori infection, chronic atrophic gastritis and risk of stomach and esophagus cancer: Results from the prospective population‐based ESTHER cohort study
              994. Extract of Helicobacter pylori Ameliorates Parameters of Airway Inflammation and Goblet Cell Hyperplasia following Repeated Allergen Exposure
              995. Crystal structure of CagV, the Helicobacter pylori homologue of the T4SS protein VirB8
              996. Nod1 Imprints Inflammatory and Carcinogenic Responses toward the Gastric Pathogen Helicobacter pylori
              997. Recognition of Helicobacter pylori by protein‐targeting aptamers
              998. Nonhelical Helicobacter pylori Mutants Show Altered Gland Colonization and Elicit Less Gastric Pathology than Helical Bacteria during Chronic Infection
              999. The lipoprotein HP1454 of Helicobacter pylori regulates T‐cell response by shaping T‐cell receptor signalling
              1000. The Sweeping Role of Cholesterol Depletion in the Persistence of Helicobacter pylori Infections
              1001. Factors Associated With Adherence to Helicobacter pylori Testing During Hospitalization for Bleeding Peptic Ulcer Disease
              1002. CagA Effector Protein in Helicobacter pylori-Infected Human Gastric Epithelium in Vivo: From Bacterial Core and Adhesion/Injection Clusters to Host Cell Proteasome-Rich Cytosol
              1003. In Situ Molecular Architecture of the Helicobacter pylori Cag Type IV Secretion System
              1004. Synergistic effect of photodynamic therapy at 400 nm and doxycycline against Helicobacter pylori
              1005. Role of a Stem-Loop Structure in Helicobacter pylori cagA Transcript Stability
              1006. ADP heptose, a novel pathogen-associated molecular pattern identified in Helicobacter pylori
              1007. Establishment of serine protease htrA mutants in Helicobacter pylori is associated with secA mutations
              1008. Susceptibility-guided therapy for Helicobacter pylori infection treatment failure
              1009. Induction of CD44 Variant Isoforms is an Early Epithelial Response to Helicobacter pylori Infection
              1010. Selective Inhibitors of Helicobacter pylori Methylthioadenosine Nucleosidase and Human Methylthioadenosine Phosphorylase
              1011. Expression of CEACAM1 or CEACAM5 in AZ‐521 cells restores the type IV secretion deficiency for translocation of CagA by Helicobacter pylori
              1012. CHAC1 overexpression in human gastric parietal cells with Helicobacter pylori infection in the secretory canaliculi
              1013. Structural Analysis of Helicobacter pylori VacA Reveals Insights into Oligomerization
              1014. Hepatoma-derived growth factor participates in Helicobacter pylori-induced neutrophils recruitment, gastritis and gastric carcinogenesis
              1015. Gastric adenocarcinoma of fundic gland type after Helicobacter pylori eradication: A case report
              1016. Helicobacter pylori in relation to asthma and allergy modified by abdominal obesity: The HUNT study in Norway
              1017. Effects of Anti–Helicobacter pylori Therapy on Incidence of Autoimmune Diseases, Including Inflammatory Bowel Diseases
              1018. Varying pH influences the motility of Helicobacter pylori more strongly in porcine gastric mucin solutions than in broth.
              1019. Mutated Rnf43 Aggravates Helicobacter pylori-Induced Gastric Pathology
              1020. Epstein-Barr virus detection using gastric biopsy specimens after rapid urease test for Helicobacter pylori
              1021. Increased Programmed Death-Ligand 1 is an Early Epithelial Cell Response to Helicobacter pylori Infection
              1022. New Perspectives in Gastric Cancer: Helicobacter pylori-Uninfected Pure Signet Ring Cell Carcinoma
              1023. Intracellular Degradation of Helicobacter pylori VacA Toxin as a Determinant of Gastric Epithelial Cell Viability
              1024. Evaluation of Lineage Changes in the Gastric Mucosa Following Infection With Helicobacter pylori and Specified Intestinal Flora in INS-GAS Mice
              1025. Potential roles of Helicobacter pylori treatment, body mass index and waist circumference in the causation of erosive esophagitis: a randomized clinical trial (HEROES-GERD)
              1026. Helicobacter pylori
              1027. Association Between Helicobacter pylori Infection and Short-segment/Long-segment Barrett’s Esophagus in a Japanese Population: A Large Cross-Sectional Study.
              1028. Geometric localization of cell wall growth and shape determining proteins in Helicobacter pylori
              1029. Helicobacter pylori Pathophysiology
              1030. Malignant Helicobacter pylori-Associated Diseases: Gastric Cancer and MALT Lymphoma
              1031. Helicobacter pylori Infection
              1032. Review: Pathogenesis of Helicobacter pylori infection
              1033. Meta‐analysis of three‐in‐one single capsule bismuth‐containing quadruple therapy for the eradication of Helicobacter pylori
              1034. Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial
              1035. Helicobacter pylori infection and gastric cancer biology: tempering a double-edged sword
              1036. Helicobacter pylori and Related Virulence Factors for Gastrointestinal Diseases
              1037. Both diet and Helicobacter pylori infection contribute to atherosclerosis in pre- and postmenopausal cynomolgus monkeys
              1038. Cryo-EM Analysis Reveals Structural Basis of Helicobacter pylori VacA Toxin Oligomerization
              1039. Relative potency of proton‐pump inhibitors, Helicobacter pylori therapy cure rates, and meaning of double‐dose PPI
              1040. Helicobacter pylori Exploits the NLRC4 Inflammasome to Dampen Host Defenses
              1041. Helicobacter pylori infection and prevalence of stroke
              1042. Pathogenicity of Helicobacter pylori in cancer development and impacts of vaccination
              1043. CAPZA1 determines the risk of gastric carcinogenesis by inhibiting Helicobacter pylori CagA-degraded autophagy
              1044. Specific high affinity interaction of Helicobacter pylori CagL with integrin αVβ6 promotes type IV secretion of CagA into human cells
              1045. pH-dependent gating mechanism of the Helicobacter pylori urea channel revealed by cryo-EM
              1046. Low‐level primary clarithromycin resistance of Helicobacter pylori in Burkina Faso: A prospective molecular study
              1047. Helicobacter pylori infection and gastroduodenal lesions in patients with systemic lupus erythematosus
              1048. CDX1 Expression Induced by CagA-Expressing Helicobacter pylori Promotes Gastric Tumorigenesis
              1049. Association between parental history of Helicobacter pylori treatment failure and treatment failure in the offspring
              1050. Interleukin-21 (IL-21) Downregulates Dendritic Cell Cytokine Responses to Helicobacter pylori and Modulates T Lymphocyte IL-17A Expression in Peyer’s Patches during Infection
              1051. Cryo-EM structures of Helicobacter pylori vacuolating cytotoxin A oligomeric assemblies at near-atomic resolution
              1052. Effect of Helicobacter pylori chemotaxis on gastric epithelial repair
              1053. Gastric Mucosal Microarchitectures Associated with Irreversibility with Helicobacter pylori Eradication and Downregulation of Micro RNA (miR)
              1054. Abstract 173: Helicobacter pylori Infection Increases the Risk for Carotid Atherosclerosis
              1055. Biochemical characterization of the Helicobacter pylori bactofilin-homolog HP1542
              1056. Activity and Functional Importance of Helicobacter pylori Virulence Factors
              1057. A Novel View of Human Helicobacter pylori Infections: Interplay between Microbiota and Beta-Defensins
              1058. Potential impact of Helicobacter pylori-induced optic neurodegeneration on MS patients
              1059. A pH-sensitive excited state intramolecular proton transfer fluorescent probe for imaging mitochondria and Helicobacter pylori
              1060. Alternative eradication regimens for Helicobacter pylori infection in Indonesian regions with high metronidazole and levofloxacin resistance
              1061. Egyptian recommendations for management of Helicobacter pylori infection: 2018 report.
              1062. Probiotic Lactobacillus spp. Act Against Helicobacter pylori-induced Inflammation
              1063. Abstract 16244: Helicobacter pylori Infection Impairs Endothelial Function Through Exosome-Mediated Mechanism
              1064. Association Between Helicobacter pylori Exposure and Decreased Odds of Eosinophilic Esophagitis—A Systematic Review and Meta-analysis
              1065. The eradication of Helicobacter pylori to prevent gastric cancer: a critical appraisal
              1066. NOD1 mediates non-canonical inflammasome processing of interleukin-18 in epithelial cells to Helicobacter pylori infection
              1067. MEK Inhibitor Reverses Metaplasia and Allows Re-Emergence of Normal Lineages in Helicobacter pylori–Infected Gerbils
              1068. Helicobacter pylori resistance to current therapies
              1069. IN VITROANTI-Helicobacter pyloriAND ANTIMYCOBACTERIAL ACTIVITY EVALUATION OF PLANTS FROM TURKEY
              1070. MCOLN1/TRPML1 inhibition – a novel strategy used by Helicobacter pylori to escape autophagic killing and antibiotic eradication therapy in vivo
              1071. Helicobacter pylori VacA Targets Myeloid Cells in the Gastric Lamina Propria To Promote Peripherally Induced Regulatory T-Cell Differentiation and Persistent Infection
              1072. Helicobacter pylori virulence genes
              1073. Management of Antibiotic-Resistant Helicobacter pylori Infection: Perspectives from Vietnam
              1074. Helicobacter pylori eradication improves glycemic control in type 2 diabetes patients with asymptomatic active Helicobacter pylori infection
              1075. Molecular Basis of Unexpected Specificity of ABC Transporter-Associated Substrate-Binding Protein DppA from Helicobacter pylori
              1076. ASSOCIATION BETWEEN PROTEINURIA AND ACTIVE Helicobacter pylori INFECTION IN NON-DIABETIC PATIENTS
              1077. Increasing Testing for Helicobacter pylori Infection to Improve Quality of Patient Care
              1078. Methods for treating Helicobacter pylori infection
              1079. Retrospective Analysis Confirms Tetracycline Quadruple as Best Helicobacter pylori Regimen in the USA
              1080. Correlation between Helicobacter pylori Infection and Gastric Atrophy Examined in the Sera of Mongolian People
              1081. Recruitment of CCR6+ Foxp3+ regulatory gastric infiltrating lymphocytes in Helicobacter pylori gastritis
              1082. Preparation Method of Outer Core Octasaccharide of Helicobacter pylori Lipopolysaccharide
              1083. Tropism for Spasmolytic Polypeptide-Expressing Metaplasia Allows Helicobacter pylori to Expand Its Intragastric Niche
              1084. The frequency of circulating integrin α4β7+ cells correlates with protection against Helicobacter pylori infection in immunized mice
              1085. Th17 Cells in Helicobacter pylori Infection: a Dichotomy of Help and Harm
              1086. Helicobacter pylori Genetic Polymorphisms in Gastric Disease Development
              1087. Helicobacter pylori pathogenicity and primary antimicrobial resistance in Northern Spain
              1088. Prediction of Novel Host-Pathogen Interactions for Helicobacter pylori Through Interface Mimicry and their Implications to Gastric Cancer
              1089. Molecular detection of Helicobacter pylori and clarithromycin resistance in gastric biopsies: a prospective evaluation of RIDA®GENE Helicobacter pylori assay
              1090. Transmaternal Helicobacter pylori exposure reduces allergic airway inflammation in offspring through regulatory T cells
              1091. Review: Helicobacter pylori in pediatrics
              1092. Loss of a Cardiolipin Synthase in Helicobacter pylori G27 Blocks Flagellum Assembly
              1093. Risk factors for reflux esophagitis after eradication of Helicobacter pylori
              1094. HupA, the main undecaprenyl pyrophosphate and phosphatidylglycerol phosphate phosphatase in Helicobacter pylori is essential for colonization of the stomach
              1095. Interleukin‐27 is abrogated in gastric cancer, but highly expressed in other Helicobacter pylori‐associated gastroduodenal diseases
              1096. The Cyclopropane Fatty Acid Synthase Mediates Antibiotic Resistance and Gastric Colonization of Helicobacter pylori
              1097. Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90% of Patients
              1098. Helicobacter pylori Uses the TlpB Receptor To Sense Sites of Gastric Injury
              1099. Correction to: Mutations in the nucleotide binding and hydrolysis domains of Helicobacter pylori MutS2 lead to altered biochemical activities and inactivation of its in vivo function
              1100. Helicobacter pylori and low‐dose aspirin ulcer risk: A meta‐analysis
              1101. Serologic Response to Helicobacter pylori Proteins Associated With Risk of Colorectal Cancer Among Diverse Populations in the United States
              1102. Gastric Cancer Prevention Using Helicobacter pylori Eradication in Japan
              1103. Genetic Determinants and Prediction of Antibiotic Resistance Phenotypes in Helicobacter pylori
              1104. Anti-Helicobacter pylori activity of ethoxzolamide
              1105. Protocol of the European Registry on the management of Helicobacter pylori infection (Hp‐EuReg)
              1106. Potential Role of Biofilm Formation in the Development of Digestive Tract Cancer With Special Reference to Helicobacter pylori Infection
              1107. Acute and chronic gastritis due to Helicobacter pylori
              1108. Helicobacter pylori: Survival in cultivable and non-cultivable form in artificially contaminated Mytilus galloprovincialis
              1109. Vonoprazan and Helicobacter pylori Treatment: A Lesson From Japan or a Limited Geographic Phenomenon?
              1110. Gastric Helicobacter pylori infection perturbs human oral microbiota
              1111. Is there a difference concerning red cell distribution width in patient with or without Helicobacter pylori and gastric inflammation severity?
              1112. Molecular Links Between Alzheimer’s Disease and Gastrointestinal Microbiota: Emphasis on Helicobacter pylori Infection Involvement
              1113. Asymptomatic Helicobacter pylori Infection in Preschool Children and Young Women Does Not Predict Iron Bioavailability from Iron-Fortified Foods
              1114. Synergistic effect of anti-Helicobacter pylori urease immunoglobulin Y from egg yolk of immunized hens and Lactobacillus johnsonii No.1088 to inhibit the growth of Helicobacter pylori in vitro and in vivo
              1115. Pylera® plus ranitidine vs Pylera® plus esomeprazole in first‐line treatment of Helicobacter pylori infection: Two pilot studies
              1116. Interaction Between Ethnicity and Helicobacter pylori Infection in the Occurrence of Reflux Disease.
              1117. Characterization of spirugenic iron oxide nanoparticles and their antibacterial activity against multidrug-resistantHelicobacter pylori
              1118. Helicobacter pylori infection, atrophic gastritis, and risk of pancreatic cancer: A population-based cohort study in a large Japanese population: the JPHC Study
              1119. Helicobacter pylori Infection in Children and Adolescents
              1120. The Hippo Kinase LATS2 Controls Helicobacter pylori–Induced Epithelial–Mesenchymal Transition and Intestinal Metaplasia in Gastric Mucosa
              1121. Identification of regulatory genes through global gene expression analysis of a Helicobacter pylori co-culture system
              1122. Inflammation, Immunity, and Vaccine Development for the Gastric Pathogen Helicobacter pylori
              1123. The Effect of Trimebutine and/or Helicobacter pylori Eradication on the Gastroesophageal Reflux Disease, Irritable Bowel Syndrome, and Functional Dyspepsia Overlapping Disorders
              1124. Helicobacter pylori infection selectively increases the risk for carotid atherosclerosis in young males
              1125. IDDF2019-ABS-0213 Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication- a multicentre randomised trial
              1126. Smoking andHelicobacter pyloriinfection: an individualparticipant pooled analysis (Stomach Cancer Pooling- StoPProject)
              1127. The Epidemiology of Gastric Cancers in the Era of Helicobacter pylori Eradication: A Nationwide Cancer Registry-Based Study in Taiwan
              1128. Helicobacter pylori infection and demyelinating disease of the central nervous system
              1129. Carcinogenic Helicobacter pylori Strains Selectively Dysregulate the In Vivo Gastric Proteome, Which May Be Associated with Stomach Cancer Progression
              1130. Development of Helicobacter pylori treatment: How do we manage antimicrobial resistance?
              1131. Changes of Dyspeptic Symptom after Successful Eradication in Helicobacter pylori-Associated Dyspepsia
              1132. Increased risk of chronic myeloid leukaemia following gastric conditions indicating Helicobacter pylori infection: a case-control study
              1133. Chapter 33 – A Future for a Vaccine Against the Cancer-Inducing Bacterium Helicobacter pylori?
              1134. Comparison of concomitant therapy versus standard triple-drug therapy for eradication of Helicobacter pylori infection: A prospective open-label randomized controlled trial
              1135. Are Patients with Perforated Peptic Ulcers Who are Negative for Helicobacter pylori at a Greater Risk?
              1136. Helicobacter pylori infection and peptic ulcers
              1137. Intraluminal therapy for Helicobacter pylori infection
              1138. Enhanced infectivity of strains of Helicobacter pylori isolated from children compared with parental strains
              1139. Pistacia vera L. oleoresin and levofloxacin is a synergistic combination against resistant Helicobacter pylori strains
              1140. Role of Helicobacter pylori in Upper Gastrointestinal Bleeding Among Ischemic Stroke Hospitalizations: A Nationwide Study of Outcomes
              1141. Sex differences in the prevalence of Helicobacter pylori infection
              1142. Association between Helicobacter pylori infection and risk of nonalcoholic fatty liver disease: An updated meta-analysis
              1143. Gastric cancer and gastrin: on the interaction of Helicobacter pylori gastritis and acid inhibitory induced hypergastrinemia
              1144. Characterization of a novel Helicobacter pylori East Asian-type CagA ELISA for detecting patients infected with various cagA genotypes
              1145. Impact of Helicobacter pylori Virulence Factors on the Host Immune Response and Gastric Pathology
              1146. T Cell–Dependent Maturation of Pathogen-Specific Igs in the Antrum of Chronically Helicobacter pylori–Infected Patients
              1147. Gastric Microbiota in Helicobacter pylori-Negative and -Positive Gastritis Among High Incidence of Gastric Cancer Area
              1148. The relationship between previous antimicrobial use, antimicrobial resistance and treatment outcome among Alaskans treated for Helicobacter pylori infection
              1149. In vitro activity of neem (Azadirachta indica) oil extract against Helicobacter pylori
              1150. Antibacterial activity of ovatodiolide isolated from Anisomeles indica against Helicobacter pylori
              1151. Urine testing and Helicobacter pylori infection
              1152. Smoking and Drinking Did Not Increase the Failure of Therapeutic Helicobacter pylori Eradication by Vonoprazan, Clarithromycin, and Amoxicillin
              1153. Role of the protein CagA from Helicobacter pylori in the modifications of the human B lymphocyte cytoskeleton
              1154. Correction to: Mutations in the nucleotidebinding and hydrolysis domains ofHelicobacter pylori MutS2 lead to alteredbiochemical activities and inactivation of itsin vivo function
              1155. Tryptophan usage by Helicobacter pylori differs among strains
              1156. Carbohydrate-Dependent and Antimicrobial Peptide Defence Mechanisms Against Helicobacter pylori Infections
              1157. Detecting both current and prior Helicobacter pylori infection is important to assess its impact on dementia
              1158. Short‐term and long‐term impacts of Helicobacter pylori eradication with reverse hybrid therapy on the gut microbiota
              1159. Increase in antibiotic resistant Helicobacter pylori in a University Hospital in Japan
              1160. Reply to: Helicobacter pylori eradication treatment and the risk of gastric adenocarcinoma in a western population
              1161. Helicobacter pylori Infection, the Gastric Microbiome and Gastric Cancer
              1162. Helicobacter pylori, stomach cancer and its prevention in New Zealand
              1163. Metronidazole for Helicobacter pylori eradication therapy among children and adolescents in Japan: Overcoming controversies and concerns
              1164. Helicobacter pylori Detection in Shellfish: A Real-Time Quantitative Polymerase Chain Reaction Approach
              1165. The Interaction of Helicobacter pylori with TFF1 and Its Role in Mediating the Tropism of the Bacteria Within the Stomach
              1166. Infections with Helicobacter pylori and challenges encountered in Africa
              1167. Influence of Living Environment during Childhood on Helicobacter pylori Infection in Japanese Young Adults
              1168. Is Helicobacter pylori associated with Behçet’s syndrome? A meta‐analysis
              1169. Prevalence of Helicobacter pylori infection in Latin America and the Caribbean populations: A systematic review and meta-analysis
              1170. BetadefensinsandanalogsinHelicobacterpyloriinfections:mRNAexpressionlevels,DNAmethylation,andantibacterialactivity
              1171. Oral pH sensitive GNS@ab nanoprobes for targeted therapy of Helicobacter pylori without disturbance gut microbiome
              1172. The Possible Role of Helicobacter pylori in Gastric Cancer and Its Management
              1173. Clinical features of Helicobacter pylori antibody‐positive junior high school students in Nagano Prefecture, Japan
              1174. The frequency of Helicobacter pylori infection in patients with primary antibody deficiencies
              1175. Chronic Urticaria Associated withHelicobacter pylori
              1176. Immune Cell Signaling by Helicobacter pylori: Impact on Gastric Pathology
              1177. New insights into resistance of Helicobacter pylori against third‐ and fourth‐generation fluoroquinolones: A molecular docking study of prevalent GyrA mutations
              1178. Efficacy of Lactobacillus-supplemented triple therapy for Helicobacter pylori infection in children: a meta-analysis of randomized controlled trials
              1179. Risk Factors and Incidence of Gastric Cancer After Detection of Helicobacter pylori Infection: A Large Cohort Study
              1180. Daphnetin: A Novel Anti-Helicobacter pylori Agent
              1181. Sequential Therapy for First-Line Helicobacter pylori Eradication: 10- or 14-Day Regimen?
              1182. Vonoprazan-Based Third-Line Therapy Has a Higher Eradication Rate against Sitafloxacin-Resistant Helicobacter pylori
              1183. Temporin-SHa and Its Analogs as Potential Candidates for the Treatment of Helicobacter pylori
              1184. Review: Epidemiology of Helicobacter pylori infection
              1185. Changes of tight junction and interleukin‐8 expression using a human gastroid monolayer model of Helicobacter pylori infection
              1186. The fragility of randomized trial outcomes underlying management of dyspepsia and Helicobacter pylori infections
              1187. Helicobacter pylori Infection and the Risk of Mortality in Prostate Cancer Patients Receiving Androgen Deprivation Therapy: A Real-World Evidence Study
              1188. Evaluation of the epidemiological efficacy of eradicating Helicobacter pylori on development of gastric cancer
              1189. Association between atrial fibrillation and Helicobacter pylori
              1190. Efficacy of N-acetyl Cysteine in Patients with Dyspepsia with Negative Helicobacter pylori Infection
              1191. Cancer Stem-Cell Marker CD44v9-Positive Cells Arise From Helicobacter pylori–Infected CAPZA1-Overexpressing Cells
              1192. RIFABUTIN-BASED COMPOSITIONS AND METHODS FOR TREATING Helicobacter pylori INFECTION
              1193. Helicobacter pylori Antibody Titers in the High Normal Range Include Cases of H. pylori Infection in Patients with H. pylori-related Gastritis
              1194. Increasing antimicrobial resistance to clarithromycin and metronidazole in pediatric Helicobacter pylori infection in southern Taiwan: A comparison between two decades
              1195. Molecular characterization and prevalence of antibiotic resistance in Helicobacter pylori isolates in Kuala Lumpur, Malaysia
              1196. Potential involvement of Helicobacter pylori from oral specimens in overweight body-mass index
              1197. Association between Helicobacter pylori infection, eradication and diabetes mellitus
              1198. Rapidly decreasing prevalence of Helicobacter pylori among Japanese children and adolescents
              1199. Lipopolysaccharides From Non-Helicobacter pylori Gastric Bacteria Potently Stimulate Interleukin-8 Production in Gastric Epithelial Cells
              1200. An oral alpha-galactosylceramide adjuvanted Helicobacter pylori vaccine induces protective IL-1R- and IL-17R-dependent Th1 responses
              1201. Helicobacter pylori growth stimulation by adrenaline detected by two methods
              1202. Review: Helicobacter pylori and non‐malignant upper gastrointestinal diseases
              1203. Artemisinin and its derivatives prevent Helicobacter pylori-induced gastric carcinogenesis via inhibition of NF-κB signaling
              1204. Helicobacter pylori Virulent Genes in the Upregulation of CCL20 and β-actin Expression and Progression towards Gastric Disorders
              1205. Mucus penetration enhanced lipid polymer nanoparticles improve the eradication rate of Helicobacter pylori biofilm
              1206. Bone of Contention: Helicobacter pylori and Osteoporosis—Is There an Association?
              1207. Is there an association between Helicobacter pylori infection and irritable bowel syndrome? A meta-analysis
              1208. Abstract 1041: Casein kinase 2 modulates epithelial mesenchymal transition through Helicobacter pylori CagA dependent pathway in gastric cancer cells
              1209. Clostridiumdifficile‐associated disease and Helicobacter pylori seroprevalence: A case‐control study
              1210. Effect of Helicobacter pylori eradication on the incidence of gastric cancer: a systematic review and meta-analysis
              1211. Helicobacter pylori antimicrobial resistance and antibiotic consumption in the low‐resource Central America setting
              1212. Helicobacter pylori Seropositivity: Prevalence, Associations, and the Impact on Incident Metabolic Diseases/Risk Factors in the Population-Based KORA Study
              1213. Smoking, Helicobacter pylori Serology, and Gastric Cancer Risk in Prospective Studies from China, Japan, and Korea
              1214. Favorable outcomes of culture‐based Helicobacter pylori eradication therapy in a region with high antimicrobial resistance
              1215. Immunity and Vaccine Development Against Helicobacter pylori
              1216. Role of sortase A in Lactobacillus gasseri Kx110A1 adhesion to gastric epithelial cells and competitive exclusion of Helicobacter pylori
              1217. oipA “on” status of Helicobacter pylori is associated with gastric cancer in North-Eastern Brazil
              1218. Development and Assessment of a Helicobacter pylori Medication Adherence and Stomach Cancer Prevention Curriculum for a Chinese American Immigrant Population
              1219. Unveiling the potentials of biocompatible silver nanoparticles on human lung carcinoma A549 cells and Helicobacter pylori
              1220. Efficacy of Vonoprazan for Helicobacter pylori Eradication
              1221. Eradication Efficacy of Modified Dual Therapy Compared with Bismuth-Containing Quadruple Therapy as a First-Line Treatment of Helicobacter pylori
              1222. Role of abnormal microRNA expression in Helicobacter pylori associated gastric cancer
              1223. Role of Probiotics in Eradication Therapy for Helicobacter pylori Infection
              1224. Incidences, temporal trends and risks of hospitalisation for gastrointestinal bleeding in new or chronic low-dose aspirin users after treatment for Helicobacter pylori: a territory-wide cohort study
              1225. Efficacy of dexlansoprazole-based triple therapy for Helicobacter pylori infections
              1226. Correlating prophage presence in Helicobacter pylori with restriction-modification systems
              1227. Chronic Urticaria Associated with Helicobacter pylori
              1228. Serum Pepsinogen Values in Japanese Junior High School Students With Reference to Helicobacter pylori Infection
              1229. Novel Insights of Lymphomagenesis of Helicobacter pylori-Dependent Gastric Mucosa-Associated Lymphoid Tissue Lymphoma
              1230. Effect of Helicobacter pylori biofilm formation on susceptibility to amoxicillin, metronidazole and clarithromycin
              1231. A liposomal drug delivery system for improved eradication of Helicobacter pylori
              1232. Circulating microRNA signatures serve as potential diagnostic biomarkers for Helicobacter pylori infection
              1233. Effect of Previous Nitroimidazole Treatment on Helicobacter pylori Eradication Success.
              1234. Helicobacter pylori Eradication for Metachronous Gastric Cancer: An Unsuitable Methodology Impeding Broader Clinical Usage
              1235. Correlation among fecal indicator bacteria and physicochemical parameters with the presence of Helicobacter pylori DNA in raw and drinking water from Bogotá, Colombia
              1236. The unique trimeric assembly of the virulence factor HtrA from Helicobacter pylori occurs via N-terminal domain swapping
              1237. In Vitro and In Vivo Activities of Zinc Linolenate, a Selective Antibacterial Agent against Helicobacter pylori
              1238. Inactivation of NikR from Helicobacter pylori by a bismuth drug
              1239. Association of host immunity with Helicobacter pylori infection in recurrent gastric cancer
              1240. Review of current diagnostic methods and advances in Helicobacter pylori diagnostics in the era of next generation sequencing
              1241. Different phenotypes of gastric fundic gland polyposis and cancer in patients with familial adenomatous polyposis depending on Helicobacter pylori infection
              1242. Genome-wide mutation analysis of Helicobacter pylori after inoculation to Mongolian gerbils
              1243. Low-Molecular-Weight Dextran Sulfate Nanocapsules Inhibit the Adhesion of Helicobacter pylori to Gastric Cells
              1244. Application of convolutional neural networks for evaluating Helicobacter pylori infection status on the basis of endoscopic images
              1245. Recent trends in the prevalence of Helicobacter pylori in symptomatic children: A 12-year retrospective study in a tertiary centre
              1246. Helicobacter pylori infection is not associated with rheumatoid arthritis
              1247. Randomised controlled trial: susceptibility‐guided therapy versus empiric bismuth quadruple therapy for first‐line Helicobacter pylori treatment
              1248. High‐dose PPI‐amoxicillin dual therapy with or without bismuth for first‐line Helicobacter pylori therapy: A randomized trial
              1249. Structure and Activity of PPX/GppA Homologs from Escherichia coli and Helicobacter pylori
              1250. Influence of Helicobacter pylori infection on periodontitis
              1251. Helicobacter pylori Infection Does Not Impact on Lung Transplant Outcome
              1252. Eradication of Helicobacter pylori Induces Immediate Regressive Changes in Early Gastric Adenocarcinomas
              1253. N‐acetylcysteine as an adjuvant therapy for Helicobacter pylori eradication
              1254. Comparison of the Clinicopathological Characteristics and Genetic Alterations Between Patients with Gastric Cancer with or Without Helicobacter pylori Infection
              1255. Gastric cancer risk stratification and surveillance after Helicobacter pylori eradication: 202
              1256. Modification of the Gastric Mucosal Microbiota by a Strain-Specific Helicobacter pylori Oncoprotein and Carcinogenic Histologic Phenotype
              1257. Effect of patchouli alcohol on Helicobacter pylori-induced neutrophil recruitment and activation
              1258. Tyrosine Kinases in Helicobacter pylori Infections and Gastric Cancer
              1259. Helicobacter pylori infection and risk of salmonella infection
              1260. A time‐saving–modified Giemsa stain is a better diagnostic method of Helicobacter pylori infection compared with the rapid urease test
              1261. The Role of E-cadherin in Helicobacter pylori-Related Gastric Diseases
              1262. Exosomal CagA derived from Helicobacter pylori-infected gastric epithelial cells induces macrophage foam cell formation and promotes atherosclerosis
              1263. Efficacy of N-acetyl Cysteine in Patients with Dyspepsia with Negative Helicobacter pyloriInfection
              1264. Current and Future Treatment of Helicobacter pylori Infections
              1265. Bovine lactoferrin enhances the efficacy of levofloxacin-based triple therapy as first-line treatment of Helicobacter pylori infection: an in vitro and in vivo study
              1266. Synthesis and In Vitro Enzymatic Studies of New 3-Aryldiazenyl Indoles as Promising Helicobacter pylori IMPDH Inhibitors
              1267. Atractylodes lancea volatile oils attenuated Helicobacter pylori NCTC11637 growth and biofilm
              1268. Risks of hospitalization for upper gastrointestinal bleeding in users of selective serotonin reuptake inhibitors after Helicobacter pylori eradication therapy: a propensity score matching analysis
              1269. Vonoprazan and Helicobacter pylori Treatment: A Lesson From Japan or a Limited Geographic Phenomenon?
              1270. Helicobacter pylori pediatric infection changes FcεRI expression in dendritic cells and Treg profile in vivo and in vitro
              1271. Synthetic Lipopeptide Enhances Protective Immunity Against Helicobacter pylori Infection
              1272. Identification and characterization of the α-CA in the outer membrane vesicles produced by Helicobacter pylori
              1273. Impact of Previous Exposure to Macrolide Antibiotics on Helicobacter pylori Infection Treatment Outcomes
              1274. Clinical edge: The changing landscape of Helicobacter pylori – an update on diagnosis and treatment
              1275. Helicobacter pylori–induced matrix metallopeptidase-10 promotes gastric bacterial colonization and gastritis
              1276. β-carotene Inhibits Expression of c-Myc and Cyclin E in Helicobacter pylori-infected Gastric Epithelial Cells
              1277. Integration of virtual screening and susceptibility test to discover active-site subpocket-specific biogenic inhibitors of Helicobacter pylori shikimate dehydrogenase
              1278. Helicobacter pylori Infection and the Development of Advanced Colorectal Neoplasia.
              1279. A novel method for rapid detection of a Helicobacter pylori infection using a γ-glutamyltranspeptidase-activatable fluorescent probe
              1280. Helicobacter pylori infection and gastric cancer in the past, current and future in Europe.
              1281. Immune thrombocytopenia associated with Helicobacter pylori – unclear associative mechanisms
              1282. Deregulation of miRNA in Helicobacter pylori-Induced Gastric MALT Lymphoma: From Mice to Human
              1283. Distinct cytoskeletal proteins define zones of enhanced cell wall synthesis in Helicobacter pylori
              1284. Identifying potential novel drugs against Helicobacter pylori by targeting the essential response regulator HsrA
              1285. Prevalence of Helicobacter pylori Positive Non-cardia Gastric Adenocarcinoma Is Low and Decreasing in a US Population
              1286. Review of antimicrobial peptides with anti‐Helicobacter pylori activity
              1287. MEK Inhibitor Reverses Metaplasia and Allows Re-Emergence of Normal Lineages in Helicobacter pylori–Infected Gerbils
              1288. Helicobacter pylori PROTEOME: THE STATE OF THE ART
              1289. Infections with Helicobacter pylori and challenges encountered in Africa
              1290. Influence of Living Environment during Childhood on Helicobacter pylori Infection in Japanese Young Adults
              1291. Is Helicobacter pylori associated with Behçet’s syndrome? A meta‐analysis
              1292. Prevalence of Helicobacter pylori infection in Latin America and the Caribbean populations: A systematic review and meta-analysis
              1293. Beta-defensins and analogs in Helicobacter pylori infections: mRNA expression levels, DNA methylation, and antibacterial activity
              1294. Oral pH sensitive GNS@ ab nanoprobes for targeted therapy of Helicobacter pylori without disturbance gut microbiome
              1295. The Possible Role of Helicobacter pylori in Gastric Cancer and Its Management.
              1296. Clinical features of Helicobacter pylori antibody‐positive junior high school students in Nagano Prefecture, Japan
              1297. The frequency of Helicobacter pylori infection in patients with primary antibody deficiencies
              1298. Chronic Urticaria Associated with Helicobacter pylori
              1299. Immune Cell Signaling by Helicobacter pylori: Impact on Gastric Pathology
              1300. New insights into resistance of Helicobacter pylori against third‐ and fourth‐generation fluoroquinolones: A molecular docking study of prevalent GyrA mutations
              1301. Efficacy of Lactobacillus-supplemented triple therapy for Helicobacter pylori infection in children: a meta-analysis of randomized controlled trials
              1302. Risk Factors and Incidence of Gastric Cancer After Detection of Helicobacter pylori Infection: A Large Cohort Study
              1303. Daphnetin: A Novel Anti-Helicobacter pylori Agent
              1304. Sequential therapy for first-line Helicobacter pylori eradication: 10-or 14-day regimen?
              1305. Vonoprazan-based third-line therapy has a higher eradication rate against sitafloxacin-resistant Helicobacter pylori
              1306. Temporin-SHa and Its Analogs as Potential Candidates for the Treatment of Helicobacter pylori
              1307. Epidemiology of Helicobacter pylori infection
              1308. Changes of tight junction and interleukin‐8 expression using a human gastroid monolayer model of Helicobacter pylori infection
              1309. The fragility of randomized trial outcomes underlying management of dyspepsia and Helicobacter pylori infections
              1310. Helicobacter pylori Infection and the Risk of Mortality in Prostate Cancer Patients Receiving Androgen Deprivation Therapy: A Real-World Evidence Study
              1311. Evaluation of the epidemiological efficacy of eradicating Helicobacter pylori on development of gastric cancer
              1312. Association between atrial fibrillation and Helicobacter pylori
              1313. Efficacy of N-acetyl Cysteine in Patients with Dyspepsia with Negative Helicobacter pylori Infection
              1314. Cancer Stem-Cell Marker CD44v9-Positive Cells Arise From Helicobacter pylori–Infected CAPZA1-Overexpressing Cells
              1315. RIFABUTIN-BASED COMPOSITIONS AND METHODS FOR TREATING Helicobacter pylori INFECTION
              1316. Helicobacter pylori Antibody Titers in the High Normal Range Include Cases of H. pylori Infection in Patients with H. pylori-related Gastritis
              1317. Increasing antimicrobial resistance to clarithromycin and metronidazole in pediatric Helicobacter pylori infection in southern Taiwan: A comparison between two …
              1318. Molecular characterization and prevalence of antibiotic resistance in Helicobacter pylori isolates in Kuala Lumpur, Malaysia
              1319. Potential involvement of Helicobacter pylori from oral specimens in overweight body-mass index
              1320. Association between Helicobacter pylori infection, eradication and diabetes mellitus
              1321. Rapidly decreasing prevalence of Helicobacter pylori among Japanese children and adolescents
              1322. Lipopolysaccharides From Non-Helicobacter pylori Gastric Bacteria Potently Stimulate Interleukin-8 Production in Gastric Epithelial Cells
              1323. An oral alpha-galactosylceramide adjuvanted Helicobacter pylori vaccine induces protective IL-1R-and IL-17R-dependent Th1 responses
              1324. Helicobacter pylori growth stimulation by adrenaline detected by two methods
              1325. Helicobacter pylori and non‐malignant upper gastrointestinal diseases
              1326. Artemisinin and its derivatives prevent Helicobacter pylori-induced gastric carcinogenesis via inhibition of NF-κB signaling
              1327. Helicobacter pylori Virulent Genes in the Upregulation of CCL20 and β-actin Expression and Progression towards Gastric Disorders
              1328. Mucus penetration enhanced lipid polymer nanoparticles improve the eradication rate of Helicobacter pylori biofilm
              1329. Bone of Contention: Helicobacter pylori and Osteoporosis—Is There an Association?
              1330. Is there an association between Helicobacter pylori infection and irritable bowel syndrome? A meta-analysis
              1331. Casein kinase 2 modulates epithelial mesenchymal transition through Helicobacter pylori CagA dependent pathway in gastric cancer cells
              1332. Clostridium difficile‐associated disease and Helicobacter pylori seroprevalence: A case‐control study
              1333. Effect of Helicobacter pylori eradication on the incidence of gastric cancer: a systematic review and meta-analysis
              1334. Helicobacter pylori antimicrobial resistance and antibiotic consumption in the low‐resource Central America setting
              1335. Helicobacter pylori seropositivity: Prevalence, associations and the impact on incident metabolic diseases/risk factors in the population-based KORA study
              1336. Smoking, Helicobacter pylori serology, and gastric cancer risk in prospective studies from China, Japan, and Korea
              1337. Favorable outcomes of culture‐based Helicobacter pylori eradication therapy in a region with high antimicrobial resistance
              1338. Immunity and Vaccine Development Against Helicobacter pylori
              1339. Role of sortase A in Lactobacillus gasseri Kx110A1 adhesion to gastric epithelial cells and competitive exclusion of Helicobacter pylori
              1340. oip A “on” status of Helicobacter pylori is associated with gastric cancer in North-Eastern Brazil
              1341. Development and Assessment of a Helicobacter pylori Medication Adherence and Stomach Cancer Prevention Curriculum for a Chinese American Immigrant …
              1342. Unveiling the potentials of biocompatible silver nanoparticles on human lung carcinoma A549 cells and Helicobacter pylori
              1343. Efficacy of Vonoprazan for Helicobacter pylori Eradication
              1344. Eradication Efficacy of Modified Dual Therapy Compared with Bismuth-Containing Quadruple Therapy as a First-Line Treatment of Helicobacter pylori
              1345. Role of abnormal microRNA expression in Helicobacter pylori associated gastric cancer
              1346. Role of Probiotics in Eradication Therapy for Helicobacter pylori Infection
              1347. … temporal trends and risks of hospitalisation for gastrointestinal bleeding in new or chronic low-dose aspirin users after treatment for Helicobacter pylori: a territory-wide …
              1348. Efficacy of dexlansoprazole-based triple therapy for Helicobacter pylori infections
              1349. Correlating prophage presence in Helicobacter pylori with restriction-modification systems
              1350. Chronic Urticaria Associated with Helicobacter pylori
              1351. Serum Pepsinogen Values in Japanese Junior High School Students With Reference to Helicobacter pylori Infection
              1352. Novel insights of lymphomagenesis of Helicobacter pylori-dependent gastric mucosa-associated lymphoid tissue lymphoma
              1353. Effect of Helicobacter pylori biofilm formation on susceptibility to amoxicillin, metronidazole and clarithromycin
              1354. A liposomal drug delivery system for improved eradication of Helicobacter pylori
              1355. Circulating microRNA signatures serve as potential diagnostic biomarkers for Helicobacter pylori infection
              1356. Effect of Previous Nitroimidazole Treatment on Helicobacter pylori Eradication Success.
              1357. Helicobacter pylori eradication for metachronous gastric cancer: An unsuitable methodology impeding broader clinical usage
              1358. Correlation among fecal indicator bacteria and physicochemical parameters with the presence of Helicobacter pylori DNA in raw and drinking water from Bogotá …
              1359. The unique trimeric assembly of the virulence factor HtrA from Helicobacter pylori occurs via N-terminal domain swapping
              1360. In Vitro and In Vivo Activities of Zinc Linolenate, a Selective Antibacterial Agent against Helicobacter pylori
              1361. Inactivation of NikR from Helicobacter pylori by a bismuth drug
              1362. Association of host immunity with Helicobacter pylori infection in recurrent gastric cancer
              1363. Review of current diagnostic methods and advances in Helicobacter pylori diagnostics in the era of next generation sequencing
              1364. Different phenotypes of gastric fundic gland polyposis and cancer in patients with familial adenomatous polyposis depending on Helicobacter pylori infection
              1365. Genome-wide mutation analysis of Helicobacter pylori after inoculation to Mongolian gerbils
              1366. Low-molecular-weight dextran sulfate nanocapsules inhibit the adhesion of Helicobacter pylori to gastric cells
              1367. Application of convolutional neural networks for evaluating Helicobacter pylori infection status on the basis of endoscopic images
              1368. The complete genome and methylome of Helicobacter pylori hpNEAfrica strain HP14039
              1369. Recent trends in the prevalence of Helicobacter pylori in symptomatic children: A 12-year retrospective study in a tertiary centre
              1370. Helicobacter pylori infection is not associated with rheumatoid arthritis
              1371. Randomised controlled trial: susceptibility‐guided therapy versus empiric bismuth quadruple therapy for first‐line Helicobacter pylori treatment
              1372. High‐dose PPI‐amoxicillin dual therapy with or without bismuth for first‐line Helicobacter pylori therapy: A randomized trial
              1373. Structure and Activity of PPX/GppA Homologs from Escherichia coli and Helicobacter pylori
              1374. Influence of Helicobacter pylori infection on periodontitis
              1375. Helicobacter pylori Infection Does Not Impact on Lung Transplant Outcome
              1376. Eradication of Helicobacter pylori Induces Immediate Regressive Changes in Early Gastric Adenocarcinomas
              1377. N‐acetylcysteine as an adjuvant therapy for Helicobacter pylori eradication
              1378. Comparison of the Clinicopathological Characteristics and Genetic Alterations Between Patients with Gastric Cancer with or Without Helicobacter pylori Infection
              1379. Gastric cancer risk stratification and surveillance after Helicobacter pylori eradication: 2020
              1380. Modification of the Gastric Mucosal Microbiota by a Strain-Specific Helicobacter pylori Oncoprotein and Carcinogenic Histologic Phenotype
              1381. Effect of patchouli alcohol on Helicobacter pylori-induced neutrophil recruitment and activation
              1382. Tyrosine Kinases in Helicobacter pylori Infections and Gastric Cancer
              1383. Helicobacter pylori infection and risk of salmonella infection
              1384. A time‐saving–modified Giemsa stain is a better diagnostic method of Helicobacter pylori infection compared with the rapid urease test
              1385. The Role of E-cadherin in Helicobacter pylori-Related Gastric Diseases
              1386. Exosomal CagA derived from Helicobacter pylori-infected gastric epithelial cells induces macrophage foam cell formation and promotes atherosclerosis
              1387. Efficacy of N-acetyl cysteine in dyspeptic patients with negative Helicobacter pylori infection
              1388. Current and Future Treatment of Helicobacter pylori Infections
              1389. Bovine lactoferrin enhances the efficacy of levofloxacin-based triple therapy as first-line treatment of Helicobacter pylori infection: an in vitro and in vivo study
              1390. Synthesis and in vitro enzymatic studies of new 3-aryldiazenyl indoles as promising Helicobacter pylori IMPDH inhibitors
              1391. Atractylodes lancea volatile oils attenuated Helicobacter pylori NCTC11637 growth and biofilm
              1392. Risks of hospitalization for upper gastrointestinal bleeding in users of selective serotonin reuptake inhibitors after Helicobacter pylori eradication therapy: a propensity …
              1393. Vonoprazan and Helicobacter pylori Treatment: A Lesson From Japan or a Limited Geographic Phenomenon?
              1394. Helicobacter pylori pediatric infection changes FcεRI expression in dendritic cells and Treg profile in vivo and in vitro
              1395. Synthetic Lipopeptide Enhances Protective Immunity against Helicobacter pylori Infection
              1396. Identification and characterization of the α-CA in the outer membrane vesicles produced by Helicobacter pylori
              1397. Impact of Previous Exposure to Macrolide Antibiotics on Helicobacter pylori Infection Treatment Outcomes
              1398. Clinical edge: The changing landscape of Helicobacter pylori-an update on diagnosis and treatment
              1399. Helicobacter pylori–induced matrix metallopeptidase-10 promotes gastric bacterial colonization and gastritis
              1400. β-carotene Inhibits Expression of c-Myc and Cyclin E in Helicobacter pylori-infected Gastric Epithelial Cells
              1401. Integration of virtual screening and susceptibility test to discover active-site subpocket-specific biogenic inhibitors of Helicobacter pylori shikimate dehydrogenase
              1402. Helicobacter pylori Infection and the Development of Advanced Colorectal Neoplasia.
              1403. A novel method for rapid detection of a Helicobacter pylori infection using a γ-glutamyltranspeptidase-activatable fluorescent probe
              1404. Helicobacter pylori infection and gastric cancer in the past, current and future in Europe.
              1405. Immune thrombocytopenia associated with Helicobacter pylori-unclear associative mechanisms
              1406. Deregulation of miRNA in Helicobacter pylori-Induced Gastric MALT Lymphoma: From Mice to Human
              1407. Distinct cytoskeletal proteins define zones of enhanced cell wall synthesis in Helicobacter pylori
              1408. Identifying potential novel drugs against Helicobacter pylori by targeting the essential response regulator HsrA
              1409. Eradication rate of Helicobacter pylori reinfection in Korea: A retrospective study
              1410. Selection of a fully human single domain antibody specific to Helicobacter pylori urease
              1411. Exploring the impact of Helicobacter pylori on gut microbiome composition
              1412. A Comment on Anti–Helicobacter pylori Therapy and Autoimmune Diseases
              1413. Thiamin transport in Helicobacter pylori lacking the de novo synthesis of thiamin
              1414. Relationship between Helicobacter pylori infection and gastric dysplasia: Results from histology of gastric samples in the South of Iran
              1415. Helicobacter pylori urease induces pro‐inflammatory effects and differentiation of human endothelial cells: Cellular and molecular mechanism
              1416. Noninvasive diagnostic tests for Helicobacter pylori infection
              1417. Colon Cancer Risk and VacA Toxin of Helicobacter pylori
              1418. Rapidly declining trend of signet ring cell cancer of the stomach may parallel the infection rate of Helicobacter pylori
              1419. Helicobacter pylori Infection and Vitamin B12 Deficiency During Early Pregnancy in an Urban Slum in Bangladesh (P24-035-19)
              1420. In vitro and In vivo Inhibition of Helicobacter pylori by Ethanolic Extracts of Lions Mane Medicinal Mushroom Hericium erinaceus (Agaricomycetes)
              1421. Association of active Helicobacter pylori infection and anemia in elderly males
              1422. IDDF2019-ABS-0144 Efficacy of 7-day vonoprazan and amoxicillin dual therapy as first-line Helicobacter pylori treatment: protocol of multi-center, non-inferiority …
              1423. The cost effectiveness of Helicobacter pylori population screening—economic evaluation alongside a randomised controlled trial with 13‐year follow‐up
              1424. Identification of selective inhibitors of Helicobacter pylori IMPDH as a targeted therapy for the infection
              1425. Ethnic and racial difference in Helicobacter pylori infection in patients with immune thrombocytopenia treated at a major urban medical center
              1426. CYP2C19 Genotype, CagA Genotype and Antibiotic Resistant Strain of Helicobacter pylori Infection
              1427. Recurrence of Helicobacter pylori infection: incidence and influential factors
              1428. Helicobacter pylori biofilm cells are metabolically distinct, express flagella, and antibiotic tolerant
              1429. PTU-066 Management of Helicobacter pylori infection in patients with upper GI bleeding: compliance with guidelines
              1430. Lifestyle Factors Rather Than Helicobacter pylori Infection or Estradiol Level are Associated With Osteopenia in Japanese Men
              1431. Study of rdxA and frxA genes mutations in metronidazole-resistant and-susceptible Helicobacter pylori clinical isolates from the central region of Portugal
              1432. Synthesis, Molecular Modelling and antibacterial activity against Helicobacter pylori of novel diflunisal derivatives as urease enzyme inhibitors
              1433. Helicobacter pylori Growth Stage Determines the Size, Protein Composition, and Preferential Cargo Packaging of Outer Membrane Vesicles
              1434. Structural Aspects of Helicobacter pylori Antibiotic Resistance
              1435. Helicobacter pylori infection: association with dietary habits and socioeconomic conditions
              1436. Evolutionary mechanism leading to the multi-cagA genotype in Helicobacter pylori
              1437. Fragment-based screening identifies inhibitors of ATPase activity and of hexamer formation of Cagα from the Helicobacter pylori type IV secretion system
              1438. DNA methylation accumulation in gastric mucosa adjacent to cancer after Helicobacter pylori eradication
              1439. Empiric Versus Resistance-Guided Therapy in Obese Patients with Helicobacter pylori Infection
              1440. Virulence factor genotyping of Helicobacter pylori isolated from Costa Rican dyspeptic patients
              1441. Epitope peptides of Helicobacter pylori CagA antibodies from sera by whole-peptide mapping
              1442. Potential of automatic diagnosis system with linked color imaging for diagnosis of Helicobacter pylori infection
              1443. Evaluation of a Novel Stool Antigen Rapid Test Kit for Detection of Helicobacter pylori Infection
              1444. Astaxanthin from Shrimp Cephalothorax Stimulates the Immune Response by Enhancing IFN-γ, IL-10, and IL-2 Secretion in Splenocytes of Helicobacter pylori …
              1445. Prevalence of Helicobacter pylori infection and its associated diseases in low socio-economic workers in tertiary care hospital of Lahore, Pakistan
              1446. Helicobacter pylori Detected in Tap Water of Peruvian Patients with Gastric Cancer
              1447. Genomic landscape of epithelium with low-grade atypia on gastric cancer after Helicobacter pylori eradiation therapy
              1448. Accurate detection of Helicobacter pylori antigen in human stool specimens by two novel immunoassays
              1449. Tailor-Made Detection of Individual Phosphorylated and Non-Phosphorylated EPIYA-Motifs of Helicobacter pylori Oncoprotein CagA
              1450. Epidemiology, Diagnosis and Risk Factors of Helicobacter pylori Infection
              1451. Oral administration of recombinant Bacillus subtilis spores expressing Helicobacter pylori neutrophil‐activating protein suppresses peanut allergy via up‐regulation …
              1452. Helicobacter pylori: a perspective in low- and middle-income countries
              1453. Long-term proton pump inhibitor use after Helicobacter pylori eradication may create a gastric environment for N-nitrosamine formation and gastric cancer …
              1454. Helicobacter pylori eradication rates with concomitant and tailored therapy based on 23S rRNA point mutation: A multicenter randomized controlled trial
              1455. Is breath testing without 13C-labelled external urea able to detect Helicobacter pylori infection?
              1456. Sugar-Modified Analogs of Auranofin Are Potent Inhibitors of the Gastric Pathogen Helicobacter pylori
              1457. Application of Helicobacter pylori stool antigen test to survey the updated prevalence of H. pylori infection in Taiwan
              1458. Correction: Kinetic and catalytic properties of M. HpyAXVII, a phase-variable DNA methyltransferase from Helicobacter pylori.
              1459. Prevalence of Helicobacter pylori cagA and sabA Genotypes in Patients with Gastric Disease
              1460. Optimizing proton pump inhibitors in Helicobacter pylori treatment: Old and new tricks to improve effectiveness
              1461. An Updated Approach to Evaluation and Treatment of Helicobacter pylori Infection.
              1462. Helicobacter pylori: Infection and New Perspective for the Treatment
              1463. The Helicobacter pylori Urease Virulence Factor Is Required for the Induction of Hypoxia-Induced Factor-1α in Gastric Cells
              1464. ceRNA network construction and comparison of gastric cancer with or without Helicobacter pylori infection
              1465. Comparative study between Helicobacter pylori and host human genetics in the Dominican Republic
              1466. Anti-inflammatory effects of Kaempferol on Helicobacter pylori-induced inflammation
              1467. Reply to: Influence of Helicobacter pylori‐connected metabolic syndrome on non‐alcoholic fatty liver disease and its related colorectal neoplasm high risk
              1468. Back Cover: Helicobacter pylori Growth Stage Determines the Size, Protein Composition, and Preferential Cargo Packaging of Outer Membrane Vesicles
              1469. The validity of breath collection bags method in detecting Helicobacter pylori using the novel BreathID®Hp Lab System: a multicenter clinical study in 257 subjects
              1470. Association between Helicobacter pylori infection and arterial stiffness: Results from a large cross-sectional study
              1471. Randomized trial of vonoprazan‐based versus proton‐pump inhibitor‐based third‐line triple therapy with sitafloxacin for Helicobacter pylori
              1472. Primary and secondary antibiotic resistance of Helicobacter pylori in Korea from 2003 to 2018
              1473. Multidrug resistance in Helicobacter pylori: current state and future directions
              1474. Vitamin D3 activates the autolysosomal degradation function against Helicobacter pylori through the PDIA3 receptor in gastric epithelial cells
              1475. Molecular links between Alzheimer’s disease and Gastrointestinal microbiota with its-related metabolic syndrome: emphasis on Helicobacter pylori infection …
              1476. Search for potential Inducible Nitric Oxide Synthase inhibitors with favorable ADMET profiles for the therapy of Helicobacter pylori infections.
              1477. Kinetic and catalytic properties of M. HpyAXVII, a phase-variable DNA methyltransferase from Helicobacter pylori
              1478. Efficacy and safety of eradication therapy for elderly patients with Helicobacter pylori infection
              1479. GastroPanel® Biomarker Assay: The Most Comprehensive Test for Helicobacter pylori Infection and Its Clinical Sequelae. A Critical Review
              1480. VacA promotes CagA accumulation in gastric epithelial cells during Helicobacter pylori infection
              1481. Helicobacter pylori recrudescence and its influencing factors
              1482. Management of Helicobacter pylori in patients with immune thrombocytopenia
              1483. Potential of Helicobacter pylori‐uninfected signet ring cell carcinoma to invade the submucosal layer
              1484. Spanish primary care survey on the management of Helicobacter pylori infection and dyspepsia: Information, attitudes, and decisions
              1485. Diabetes Increases Risk of Gastric Cancer After Helicobacter pylori Eradication: A Territory-Wide Study With Propensity Score Analysis
              1486. Helicobacter pylori seroprevalence in Spain: influence of adult and childhood sociodemographic factors
              1487. Probiotic therapy in Helicobacter pylori infection: a potential strategy against a serious pathogen?
              1488. 1071PDTreatment outcome for Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma
              1489. Helicobacter pylori infection, serum pepsinogens as markers of atrophic gastritis, and leukocyte telomere length: a population-based study
              1490. Characterization and Antibacterial Activity Against Helicobacter pylori of Lactic Acid Bacteria Isolated from Thai Fermented Rice Noodle
              1491. Banxia Xiexin Decoction for patients with peptic ulcer or chronic gastritis infected with Helicobacter pylori
              1492. Mixed Borrelia burgdorferi and Helicobacter pylori Biofilms in Morgellons Disease Dermatological Specimens
              1493. … PPI, tetracycline, metronidazole quadruple therapy with Pylera® or Lactobacillus reuteri for treatment naïve or for retreatment of Helicobacter pylori. Two randomized …
              1494. Helicobacter pylori Infection Prevalence and Histopathologic Findings in Laparoscopic Sleeve Gastrectomy
              1495. Molecular evolution of the VacA p55 binding domain of Helicobacter pylori in mestizos from a high gastric cancer region of Colombia
              1496. Correction: Eradication Efficacy of Modified Dual Therapy Compared with Bismuth-Containing Quadruple Therapy as a First-Line Treatment of: Helicobacter pylori
              1497. Helicobacter pylori eradication increases the serum high density lipoprotein cholesterol level in the infected patients with chronic gastritis: A single-center …
              1498. Downregulation of miR‐146a promotes cell migration in Helicobacter pylori–negative gastric cancer
              1499. Gastric Parietal Cell Physiology and Helicobacter pylori-Induced Disease
              1500. Antimicrobial effects of black rice extract on Helicobacter pylori infection in Mongolian gerbil
              1501. Association of Clinicopathological features of Cholecystitis with Helicobacter pylori Infection in Gall bladders
              1502. Helicobacter pylori-induced DNA methylation as an epigenetic modulator of gastric cancer: recent outcomes and future direction
              1503. Is Human Papillomavirus and Helicobacter pylori Related in Gastric Lesions?
              1504. Anti-urease immunoglobulin (IgY) from egg yolk prevents Helicobacter pylori infection in a mouse model
              1505. … -0126 Levofloxacin sequential therapy versus bismuth quadruple therapy in the second-line and third-line treatment of Helicobacter pylori-a multicenter randomized …
              1506. Relationship between Helicobacter pylori infection and obesity in Chinese adults: A systematic review with meta-analysis
              1507. Helicobacter pylori VacA, a distinct toxin exerts diverse functionalities in numerous cells: An overview
              1508. 10-Year Trends in Helicobacter pylori Eradication Rates by Sitafloxacin-Based Third-Line Rescue Therapy
              1509. Exploring the synthetic application of Helicobacter pylori α1, 3/4-fucosyltransferase FucTIII toward the syntheses of fucosylated human milk glycans and Lewis …
              1510. Western-Type Helicobacter pylori CagA are the Most Frequent Type in Mongolian Patients
              1511. Biopolymers-based gastroretentive buoyant systems for therapeutic management of Helicobacter pylori infection
              1512. Helicobacter pylori status and risks of metachronous recurrence after endoscopic resection of early gastric cancer: a systematic review and meta-analysis
              1513. Gastric Tumorigenesis: Role of Inflammation and Helicobacter pylori
              1514. Influence of serum vitamin D level on Helicobacter pylori eradication: a multi‐center, observational, prospective and cohort study
              1515. Chemoprevention of gastric cancer by Helicobacter pylori eradication and its underlying mechanism
              1516. Neutralizing antibodies for Helicobacter pylori urease inhibit bacterial colonization in the murine stomach in vivo
              1517. Five alternative Helicobacter pylori antibiotics to counter high levofloxacin and metronidazole resistance in the Dominican Republic
              1518. Analysis of core protein clusters identifies candidate variable sites conferring metronidazole resistance in Helicobacter pylori
              1519. Risk factors of rescue bismuth quadruple therapy failure for Helicobacter pylori eradication
              1520. Correlation between macrophage migration inhibitory factor and autophagy in Helicobacter pylori-associated gastric carcinogenesis
              1521. Association of TLR4 Polymorphisms, Expression, and Vitamin D with Helicobacter pylori Infection
              1522. Downregulation of tumor suppressor RACK1 by Helicobacter pylori infection promotes gastric carcinogenesis through the integrin β-1/NF-κB signaling pathway
              1523. Are probiotics useful for therapy of Helicobacter pylori diseases?
              1524. Helicobacter pylori infection and the risk of colorectal cancer: a nationwide population-based cohort study
              1525. Association between Helicobacter pylori infection and non-alcoholic fatty liver disease in North Chinese: a cross-sectional study
              1526. Lower Risk of Gastric Atrophy and Intestinal Metaplasia in Patients with MALT Lymphoma despite Helicobacter pylori Infection
              1527. A Helicobacter pylori screening and treatment program to eliminate gastric cancer among junior high school students in Saga Prefecture: a preliminary report
              1528. IDDF2019-ABS-0317 Incidence of Helicobacter pylori antibiotic resistance a single center cross-sectional study
              1529. Guidelines for the management of Helicobacter pylori infection in Japan: 2016 Revised Edition
              1530. Neutrophil-activating Protein Polymorphism of Helicobacter pylori Determines the Host Risk of Dyspepsia
              1531. Planning Mass Eradication of Helicobacter pylori Infection for Indigenous Taiwanese Peoples to Reduce Gastric Cancer
              1532. Frontline antibiotic therapy for early-stage Helicobacter pylori-negative gastric MALT lymphoma.
              1533. Prevalence of Helicobacter pylori infection in Sari Northern Iran; a population based study
              1534. Gastric juice‐based PCR assay: An alternative testing method to aid in the management of previously treated Helicobacter pylori infection
              1535. Helicobacter pylori Colonisation in Heterotopic Gastric Mucosa in Meckel Diverticulum: Case Report and Review of the Literature
              1536. Reply To: A Comment on Helicobacter pylori and Lung Transplant Outcome: Is Serology the Ideal Diagnostic Approach?
              1537. Investigating effect of Helicobacter pylori treatment on improvement of non-alcoholic fatty liver parameters: a randomized trial
              1538. Complete genome sequence of Helicobacter pylori B128 7.13 and a single‐step method for the generation of unmarked mutations
              1539. Antimicrobial susceptibility and mutations in the 23S rRNA gen of Helicobacter pylori in dyspeptic patients
              1540. Influence of Helicobacter pylori Infection and Atrophic Gastritis on the Gut Microbiota in a Japanese Population
              1541. Gastric subserous vaccination with Helicobacter pylori vaccine: an attempt to establish tissue-resident CD4+ memory T cells and induce prolonged protection
              1542. The effect of Helicobacter pylori infection and different H. pylori components on the proliferation and apoptosis of gastric epithelial cells and fibroblasts
              1543. Eradication of Helicobacter pylori in Patients with Inflammatory Bowel Disease for Prevention of Recurrences-Impact on the Natural History of the Disease
              1544. Management of Helicobacter pylori infection by clinicians: A nationwide survey in a developing country
              1545. Impaired gastric mucosal integrity identified by confocal endomicroscopy in Helicobacter pylori‐negative functional dyspepsia
              1546. Prognostic significance of Helicobacter pylori-infection in gastric diffuse large B-cell lymphoma
              1547. Noninvasive Helicobacter pylori Diagnostic Methods in Indonesia.
              1548. Propolis polyphenolic compounds affect the viability and structure of Helicobacter pylori in vitro
              1549. Role of Probiotics in Helicobacter pylori Eradication: Lessons from a Study of Lactobacillus reuteri Strains DSM 17938 and ATCC PTA 6475 (Gastrus®) and a Proton …
              1550. Helicobacter pylori and diabetes mellitus: a controversial relationship.
              1551. Association between atrial fibrillation and Helicobacter pylori
              1552. Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial
              1553. Helicobacter pylori infection is an infectious disease and the empiric therapy paradigm should be changed
              1554. … -loaded nanoemulsion delivery system with ability of extending antigen release elicits potent Th1 response for intranasal vaccine against Helicobacter pylori
              1555. Influence of Helicobacter pylori‐connected metabolic syndrome on non‐alcoholic fatty liver disease and its related colorectal neoplasm high risk
              1556. … testing of nitroethylene-and 7-nitrobenzoxadiazol-based flavodoxin inhibitors against Helicobacter pylori drug-resistant clinical strains and in Helicobacter pylori …
              1557. Autoantibodies to a specific peptide epitope of human Hsp60 (ATVLA) with homology to Helicobacter pylori HspB in H. pylori‐infected patients
              1558. 2165. Helicobacter pylori Infections in the Bronx, New York: Whole-Genome Sequencing for Rapid Genotypic Susceptibility Testing.
              1559. Helicobacter pylori infection alters gastric and tongue coating microbial communities
              1560. Role of Th22 cells in Helicobacter pylori-related gastritis and peptic ulcer diseases
              1561. Role of NOD1 and ALPK1/TIFA Signalling in Innate Immunity Against Helicobacter pylori Infection
              1562. Helicobacter pylori prevalence and risk factors among children with celiac disease.
              1563. Helicobacter pylori antimicrobial resistance during a 5‐year period (2013‐2017) in northern Spain and its relationship with the eradication therapies
              1564. Impact factors that modulate gastric cancer risk in Helicobacter pylori‐infected rodent models
              1565. Screening and characterization of nucleic acid aptamers specifically binding to adhesin HpaA from Helicobacter pylori
              1566. Association of Helicobacter pylori infection with metabolic syndrome in aged Chinese females
              1567. PTU-071 Helicobacter pylori brexit: NICE vs maastricht A comparison of eradication guidelines and resistance in London
              1568. Cost‐effectiveness analysis of screen‐and‐treat strategy in asymptomatic Chinese for preventing Helicobacter pylori‐associated diseases
              1569. Treatment for Helicobacter pylori appears to reduce the incidence of gastric cancer: eradication effect or screening effect?
              1570. Relationship between primary eradication of Helicobacter pylori and drinking habits in women: collaborative research between a pharmacy and a clinic
              1571. Prevalence of human papillomavirus and Helicobacter pylori in esophageal and gastroesophageal junction cancer biopsies from a case–control study in …
              1572. Depressed gastric-type adenoma in nonatrophic gastric mucosa without Helicobacter pylori infection
              1573. Helicobacter pylori‐downregulated tumor necrosis factor receptor‐associated protein 1 mediates apoptosis of human gastric epithelial cells
              1574. SIRT1-targeted miR-543 autophagy inhibition and epithelial–mesenchymal transition promotion in Helicobacter pylori CagA-associated gastric cancer
              1575. A perspective on risk factors for esophageal adenocarcinoma: emphasis on Helicobacter pylori infection
              1576. A167 ANTIMICROBIAL SUSCEPTIBILITY OF Helicobacter pylori IN THE SASKATOON HEALTH REGION
              1577. The relationship between Helicobacter pylori–related microbiota dysbiosis and gastrointestinal tract pathologies
              1578. Cost-Effectiveness Analysis of Helicobacter pylori Eradication Therapy for Prevention of Gastric Cancer: A Markov Model
              1579. Effects of Ankaferd Hemostat on Helicobacter pylori strains and antibiotic resistance
              1580. A Novel Role for Helicobacter pylori Gamma-Glutamyltranspeptidase in Regulating Autophagy and Bacterial Internalization in Human Gastric Cells
              1581. Burden of disease from Helicobacter pylori infection in western Canadian Arctic communities
              1582. Helicobacter pylori Mutations Conferring Resistance to Fluoroquinolones and Clarithromycin among Dyspeptic Patients Attending a Tertiary Hospital, Tanzania
              1583. Long‐term effect of Helicobacter pylori eradication on prevalence of reflux esophagitis
              1584. The Reduction in Gastric Atrophy after Helicobacter pylori Eradication Is Reduced by Treatment with Inhibitors of Gastric Acid Secretion
              1585. One piece biopsy for both rapid urease test and cultivation of Helicobacter pylori
              1586. Immunoinformatics approaches to explore Helicobacter pylori proteome (Virulence Factors) to design B and T cell multi-epitope subunit vaccine
              1587. Systematic review and network meta‐analysis: Comparative effectiveness of therapies for second‐line Helicobacter pylori eradication
              1588. Hierarchical-Clustering, Scaffold-Mining Exercises and Dynamics Simulations for Effectual Inhibitors Against Lipid-A Biosynthesis of Helicobacter pylori
              1589. Inhibitory Effects of Menadione on Helicobacter pylori Growth and Helicobacter pylori-Induced Inflammation via NF-κB Inhibition
              1590. Evolution of Helicobacter pylori associated with gastroduodenal ulcers or erosions in children over the past 23 years: Decline or steady state?
              1591. Comparison of Helicobacter pylori stool antigen, salivary IgG, serum IgG, and serum IgM as diagnostic markers of H. pylori infection in children
              1592. Teprenone for the prevention of low-dose aspirin-induced gastric mucosal injury in Helicobacter pylori-negative patients
              1593. Helicobacter pylori and its hematological effect
              1594. The mucosal adjuvant effect of plant polysaccharides for induction of protective immunity against Helicobacter pylori infection
              1595. Diagnostic methods for Helicobacter pylori infection: ideals, options, and limitations
              1596. Differences in Helicobacter pylori and CagA antibody changes after eradication between subjects developing and not developing gastric cancer
              1597. Helicobacter pylori inhibits GKN1 expression via the CagA/p‐ERK/AUF1 pathway
              1598. Relationship between African Biogeographical Ancestry and Helicobacter pylori infection in children of a large Latin American urban center
              1599. Prevalence of clarithromycin-resistant Helicobacter pylori in children living in South of Sweden: a 12-year follow-up
              1600. Altered Mucin Expression in the Gastric Epithelium After Injury and Regeneration May Result in Increased Helicobacter pylori-Induced Gastric Ulcers in the Elderly
              1601. Effect of Helicobacter pylori Treatment on Unexplained Iron Deficiency Anemia
              1602. First-line Helicobacter pylori eradication rates are significantly lower in patients with than those without type 2 diabetes mellitus
              1603. Incidence of metachronous gastric cancer in patients whose primary gastric neoplasms were discovered after Helicobacter pylori eradication
              1604. Mutant selection window of clarithromycin for clinical isolates of Helicobacter pylori
              1605. In silico probing exercises, bioactive-conformational and dynamic simulations strategies for designing and promoting selective therapeutics against Helicobacter pylori …
              1606. Helicobacter pylori eradication regimens in an antibiotic high‐resistance European area: A cost‐effectiveness analysis
              1607. The eradication of Helicobacter pylori restores rather than disturbs the gastrointestinal microbiota in asymptomatic young adults
              1608. Benefit of Helicobacter pylori eradication therapy in all systemic sclerosis patients regardless of clinical symptoms.
              1609. A Next-Generation Sequencing-Based Approach to Identify Genetic Determinants of Antibiotic Resistance in Cambodian Helicobacter pylori Clinical Isolates
              1610. Identification of Anti-Helicobacter pylori Compounds From Usnea undulata
              1611. Helicobacter pylori and Related Diseases
              1612. Impact of nitric oxide’s bidirectional role on glaucoma: focus on Helicobacter pylori–related nitrosative stress
              1613. ENDOSCOPIC BIOPSY PROVEN CO-INFECTION OF Helicobacter pylori AND GIARDIA LAMBLIA IN ADULT POPULATION OF KARACHI CITY
              1614. Activation of CD3+ T cells by Helicobacter pylori DNA vaccines in potential immunotherapy of gastric carcinoma
              1615. Potential transmission sources of Helicobacter pylori infection: detection of H. pylori in various environmental samples
              1616. Helicobacter pylori upregulates TRPC6 via Wnt/β-catenin signaling to promote gastric cancer migration and invasion
              1617. Prevalence of Helicobacter pylori and Its Associated Factors among Healthy Asymptomatic Residents in the United Arab Emirates
              1618. Previous Helicobacter pylori infection–induced atrophic gastritis: A distinct disease entity in an understudied population without a history of eradication
              1619. Helicobacter pylori infections in Ethiopia; prevalence and associated factors: a systematic review and meta-analysis
              1620. Inverse association of Helicobacter pylori cagPAI genotypes with risk of cardia and non‐cardia gastric adenocarcinoma
              1621. Correlates of infection with Helicobacter pylori positive and negative cytotoxin-associated gene A phenotypes among Arab and Jewish residents of Jerusalem
              1622. Systematic review: Would susceptibility‐guided treatment achieve acceptable cure rates for second‐line Helicobacter pylori therapy as currently practiced?
              1623. Properties of the HtrA protease from bacterium Helicobacter pylori whose activity is indispensable for growth under stress conditions
              1624. Helicobacter pylori in allergic and non-allergic rhinitis does play a protective or causative role?
              1625. Influence of Helicobacter pylori Infection on Endoscopic Findings of Gastric Adenocarcinoma of the Fundic Gland Type
              1626. The Accuracy of the Serum Antibody Test for Helicobacter pylori Infection among Junior High School Students
              1627. In Silico and In Vitro Anti-Helicobacter pylori Effects of Combinations of Phytochemicals and Antibiotics
              1628. Mechanistic Insight into the Interaction between Helicobacter pylori Urease Subunit α and Its Molecular Chaperone Hsp60
              1629. Eradication therapy for Helicobacter pylori infection improves nutrition status in Japanese hemodialysis patients: a pilot study
              1630. Ulcer disease and Helicobacter pylori infection: current treatment
              1631. Helicobacter pylori infection may increase the severity of nonalcoholic fatty liver disease via promoting liver function damage, glycometabolism, lipid metabolism …
              1632. Molecular diagnosis of Helicobacter pylori infection in gastric biopsies: Evaluation of the Amplidiag® H. pylori + ClariR assay
              1633. Spasmolytic polypeptide‐expressing metaplasia associated with higher expressions of miR‐21, 155, and 223 can be regressed by Helicobacter pylori eradication in …
              1634. Effective therapeutic regimens in two South Asian countries with high resistance to major Helicobacter pylori antibiotics
              1635. In vitro and in vivo anti-Helicobacter pylori activity of Casearia sylvestris leaf derivatives
              1636. Characterisation of point mutations in domain V of the 23S rRNA gene of clinical Helicobacter pylori strains and clarithromycin-resistant phenotype in central Vietnam
              1637. Molecular Diagnosis of Helicobacter pylori Antibiotic Resistance in Taif Region, Saudi Arabia
              1638. Structural analysis of the flagellar capping protein FliD from Helicobacter pylori
              1639. up-regulation of Mir-1915 Inhibits Proliferation, Invasion, and Migration of Helicobacter pylori-Infected Gastric cancer cells via targeting rAGE
              1640. Interactions between Helicobacter pylori and gastroesophageal reflux disease
              1641. Histological Features of Gastric Mucosa Serologically Diagnosed as Gastric Atrophy without Helicobacter pylori Infection
              1642. Post Helicobacter pylori Gastric Diseases
              1643. Polysorbate 80 add-on therapy in the treatment of Helicobacter pylori infection: Polysorbate 80 and HP antibiotic resistance
              1644. Antimicrobial activities of peptide Cbf-K16 against drug-resistant Helicobacter pylori infection in vitro and in vivo
              1645. A lucid review of Helicobacter pylori‐induced DNA damage in gastric cancer
              1646. Characterization of vacuolating cytotoxin A of Helicobacter pylori in cell binding and cellular activity
              1647. Effect of Drug Combination on Omeprazole Metabolism by Cytochrome P450 2C19 in Helicobacter pylori Eradication Therapy
              1648. Association between IL-1B gene polymorphisms and Helicobacter pylori infection: A meta-analysis
              1649. Rate and predictive factors of Helicobacter pylori recurrence: Analysis of a screening cohort
              1650. Combined Effect Of Helicobacter pylori Infection And Elevated C-Reactive Protein On 3-Month Prognosis Of Ischemic Stroke
              1651. Crystal structure of the flagellin protein FlaG from Helicobacter pylori
              1652. Polymorphism in Toll-Like Receptors and Helicobacter pylori Motility in Autoimmune Atrophic Gastritis and Gastric Cancer
              1653. Characteristics and Predictive Factor of Helicobacter pylori-Associated Functional Dyspepsia in Japanese Patients
              1654. Nationwide antibiotic resistance mapping of Helicobacter pylori in Korea: A prospective multicenter study
              1655. Evaluation of Clarithromycin and Metronidazole Resistance of Helicobacter pylori Infection in Symptomatic Iranian Children
              1656. The ‘missing’gastric microbe; the impact of gastric cancer-associated microbiota on Helicobacter pylori growth in vitro and its implications in gastric carcinogenesis
              1657. Insights into the Suppression of Multidrug-Resistant Helicobacter pylori by Probiotics Supernatant
              1658. Extraction of molecular features for the drug discovery targeting protein‐protein interaction of Helicobacter pylori CagA and tumor suppressor protein ASSP2
              1659. Evaluation of Four Different DNA Targets in Polymerase Chain Reaction for Detection and Genotyping of Helicobacter pylori
              1660. Association Between Seropositivity of Helicobacter pylori Infection and Anaemia Amongst Children Aged 5-15 Years in Western Highlands of Kenya
              1661. Helicobacter pylori: molecular basis for colonization and survival in gastric environment and resistance to antibiotics. A short review
              1662. Relationship of Helicobacter pylori Infection with Gastric Black Spots Shown by Endoscopy
              1663. A combination of serum anti-Helicobacter pylori antibody titer and Kyoto classification score could provide a more accurate diagnosis of H pylori
              1664. Antibacterial activity of Na-clinoptilolite against Helicobacter pylori: in-vitro tests, synergistic effect with amoxicillin and stability of the antibiotic formulated with the …
              1665. STRUCTURAL AND FUNCTIONAL STUDIES ON THE Helicobacter pylori PROTEOME
              1666. A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in …
              1667. 1081P Efficacy of salvage therapy in the treatment of Helicobacter pylori-positive gastric low-grade mucosa-associated lymphoid tissue lymphoma
              1668. Development of a Berberine Loaded Multifunctional Design for the Treatment of Helicobacter pylori Induced Gastric Ulcer
              1669. Preventing Metachronous Gastric Cancer after the Endoscopic Resection of Gastric Epithelial Neoplasia: Roles of Helicobacter pylori Eradication and Aspirin
              1670. Epigenetic changes in gastric cancer induction by Helicobacter pylori
              1671. Demographics and Clinical and Endoscopic Characteristics of Patients with Helicobacter pylori Infection and Gastroesophageal Reflux Disease: A Case-Control Study
              1672. Pathogenesis and clinical management of Helicobacter pylori gastric infection
              1673. Assessment of prevalence and risk factors of Helicobacter pylori infection in an oilfield Community in Hebei, China
              1674. Current status of first- and second-line Helicobacter pylori eradication therapy in the metropolitan area: a multicenter study with a large number of patients
              1675. Helicobacter pylori antibiotic sensitivity pattern in dyspeptic patients in Kano, Nigeria
              1676. Molecular interaction between human SUMO-I and histone like DNA binding protein of Helicobacter pylori (Hup) investigated by NMR and other biophysical tools
              1677. Helicobacter pylori inhibited cell proliferation in human periodontal ligament fibroblasts through the Cdc25C/CDK1/cyclinB1 signaling cascade
              1678. Online registry for nationwide database of Helicobacter pylori eradication in Korea: Correlation of antibiotic use density with eradication success
              1679. Prevalence and associated factors of Helicobacter pylori Infection among HIV positive adults onAnti-retroviral Therapy
              1680. Helicobacter pylori infection promotes epithelial-to-mesenchymal transition of gastric cells by upregulating LAPTM4B
              1681. Molecular association of FtsZ with the intrabacterial nanotransportation system for urease in Helicobacter pylori
              1682. Helicobacter pylori infection increases risk of incident metabolic syndrome and diabetes: A cohort study
              1683. Study of the Coexistence of Helicobacter pylori and Candida in the Saliva of Patients with Dyspepsia
              1684. Verrucous antral gastritis in relation to Helicobacter pylori infection, nutrition, and gastric atrophy
              1685. Genetic analysis of a case of Helicobacter pylori-uninfected intramucosal gastric cancer in a family with hereditary diffuse gastric cancer
              1686. Single-nucleotide polymorphisms in Toll-like receptor genes are associated with the prognosis of gastric cancer and are not associated with Helicobacter pylori …
              1687. Bismuth‐containing quadruple therapy versus concomitant quadruple therapy as first‐line treatment for Helicobacter pylori infection in an area of high resistance to …
              1688. Helicobacter pylori and nutrition: a bidirectional communication.
              1689. … IL-17RB expression impairs CD11b+ CD11c− myeloid cell accumulation in gastric mucosa and host defense during the early-phase of Helicobacter pylori …
              1690. Effect of patchouli alcohol on macrophage mediated Helicobacter pylori digestion based on intracellular urease inhibition
              1691. 1500. Gastric Carcinoma Survival Related with Helicobacter pylori Infection in Cali, Colombia: A Hospital-Based Cancer Study.
              1692. Systematic review and meta‐analysis: Effect of Helicobacter pylori eradication on chronic spontaneous urticaria
              1693. Helicobacter pylori (HP) infection alone, but not HP-induced atrophic gastritis, increases the risk of gastric lymphoma: a case-control study in Japan
              1694. Positive Association Between Helicobacter pylori Infection and Metabolic Syndrome in a Korean Population: A Multicenter Nationwide Study
              1695. Helicobacter pylori infection associated with an increased risk of colorectal adenomatous polyps in the Chinese population
              1696. Broad spectrum resistance in Helicobacter pylori isolated from gastric biopsies of patients with dyspepsia in Cameroon and efflux-mediated multiresistance …
              1697. Prevalence of Helicobacter pylori Infection in Patients with Chronic Kidney Disease
              1698. Helicobacter pylori is associated with poor prognosis of laryngeal precancerous lesion
              1699. Helicobacter pylori infection aggravates dysbiosis of gut microbiome in children with gastritis
              1700. Immunization with a Synthetic Helicobacter pylori Peptide Induces Secretory IgA Antibodies and Protects Mice against Infection
              1701. How does Helicobacter pylori cause gastric cancer through connexins: An opinion review
              1702. Does Helicobacter pylori Eradication Reduce the Incidence of Metachronous Gastric Cancer After Curative Endoscopic Resection of Early Gastric Cancer: A …
              1703. Comparison of the detection of Helicobacter pylori infection by commercially available serological testing kits and the 13C-urea breath test
              1704. Impact of Helicobacter pylori Eradication in Children with Acute Immune Thrombocytopenia: A Randomized Controlled Study
              1705. A new anti-Helicobacter pylori juglone from Reynoutria japonica
              1706. Estimating the Force of Infection with Helicobacter pylori in Japan
              1707. Discovery and validation of methylated-differentially expressed genes in Helicobacter pylori-induced gastric cancer
              1708. Low-Molecular-Weight Dextran Sulfate Nanocapsules Inhibit the Adhesion of Helicobacter pylori to Gastric Cells
              1709. Is there any relationship between Helicobacter pylori infection and human epidermal growth factor receptor 2 expression in gastric cancer?
              1710. VacA generates a protective intracellular reservoir for Helicobacter pylori that is eliminated by activation of the lysosomal calcium channel TRPML1
              1711. Gastric Mucosa Plasma Cells is Unspecific for Diagnosing Helicobacter pylori Infection
              1712. A Longitudinal, Population-Level, Big-Data Study of Helicobacter pylori-Related Disease across Western Australia
              1713. Cost‐effectiveness of a tailored Helicobacter pylori eradication strategy based on the presence of a 23S ribosomal RNA point mutation that causes clarithromycin …
              1714. Helicobacter pylori infection as a risk factor for serum bilirubin change and less favourable lipid profiles: a hospital-based health examination survey
              1715. High Helicobacter pylori Bacterial Load and Low Cytokine Expression Levels Are Associated with Nodular Gastropathy
              1716. Amoxicillin-Clarithromycin-Containing Bismuth Quadruple Therapy for Primary Eradication of Helicobacter pylori
              1717. Empirical Helicobacter pylori rescue therapy: an 18‐year single‐centre study of 1,200 patients
              1718. Helicobacter pylori and its antibiotic heteroresistance: A neglected issue in published guidelines
              1719. Evaluation of Helicobacter pylori Infection and Its Relation with Coated Tongue in Patients Referring to UBT
              1720. Effect of vitamin D on Helicobacter pylori infection and eradication: A meta‐analysis
              1721. The effect of synbiotics in improving Helicobacter pylori eradication: A systematic review and meta-analysis
              1722. Inhibitory Effects of β-caryophyllene on Helicobacter pylori Infection: A Randomized Double-blind, Placebo-controlled Study
              1723. Helicobacter pylori Ribosomal Protein-A2 Peptide/Silk Fibroin Nanofibrous Composites as Potential Wound Dressing
              1724. An association of Helicobacter pylori infection with endoscopic and histological findings in the Nepalese population
              1725. Changes in Helicobacter pylori Immunoglobulin G Levels and Gastric Mucosal Atrophy after Successful Eradication of Helicobacter pylori
              1726. Differential Helicobacter pylori Plasticity in the Gastric Niche of Subjects at Increased Gastric Cancer Risk
              1727. Prevention of gastric cancer by Helicobacter pylori eradication: A review from Japan
              1728. Clarithromycin resistance and female gender affect Helicobacter pylori eradication failure in chronic gastritis
              1729. Population-level macrolide consumption is associated with clarithromycin resistance in Helicobacter pylori: an ecological analysis
              1730. Successful Eradication of Helicobacter pylori Could Prevent Metachronous Gastric Cancer: A Propensity Matching Analysis
              1731. Protective effect of curcumin decreases incidence of gastric cancer induced by Helicobacter pylori and N-methyl-N-nitrosourea in rats
              1732. An overview of nanotechnology-based treatment approaches against Helicobacter pylori
              1733. Helicobacter pylori Infection following Endoscopic Resection of Early Gastric Cancer
              1734. Helicobacter pylori Infection and Psoriasis: A Systematic Review and Meta-Analysis
              1735. Synergistic effect of 2D material coated Pt nanoparticles with PEDOT polymer on electrode surface interface for a sensitive label free Helicobacter pylori CagA (Ag-Ab) …
              1736. Allicin as add-on therapy for Helicobacter pylori infection: A systematic review and meta-analysis
              1737. High primary resistance to metronidazole and levofloxacin, and a moderate resistance to clarithromycin in Helicobacter pylori isolated from Karnataka patients
              1738. A food-grade engineered Lactococcus lactis strain delivering Helicobacter pylori Lpp20 alleviates bacterial infection in H. pylori-challenged mice
              1739. α-Lipoic Acid Inhibits IL-8 Expression by Activating Nrf2 Signaling in Helicobacter pylori-infected Gastric Epithelial Cells
              1740. The role of Helicobacter pylori DnaA domain I in orisome assembly on a bipartite origin of chromosome replication
              1741. Association between Helicobacter pylori infection and nonalcoholic fatty liver disease: a systemic review and meta-analysis
              1742. Formulation and evaluation of bilayer tablets of clarithromycin and omeprazole against Helicobacter pylori infection
              1743. IDDF2019-ABS-0146 Efficacies of tailored therapy versus guideline-recommended empiricaltherapies for eradication of Helicobacter pylori–a trend survey over 20 …
              1744. DIAGNOSTIC OF Helicobacter pylori VIA ENDOSCOPY: THE CLINICAL ISSUE OF SUPPRESSIVE CONDITIONS
              1745. The Diagnosis and Therapy of Helicobacter pylori Infection in Hungary: Comparison of Strategies Applied by Family Physicians and Internists
              1746. Inflammatory responses induced by Helicobacter pylori on the carcinogenesis of gastric epithelial GES‑1 cells
              1747. T-bet+ Cells Polarization in Patients Infected with Helicobacter pylori Increase the Risk of Peptic Ulcer Development
              1748. Faster Detection of Helicobacter pylori Infection by 13 C-Urea Breath Test. Comparing Short versus Standard Sampling Time.
              1749. Relationship between Helicobacter pylori Infection and Plasmacytoid and Myeloid Dendritic Cells in Peripheral Blood and Gastric Mucosa of Children
              1750. Increased serum gastrin in patients with different clinical forms of Chagas disease coinfected with Helicobacter pylori
              1751. The Role of Host Genetic Polymorphisms in Helicobacter pylori Mediated Disease Outcome
              1752. Associations of a NLRP3 rs10754558 Polymorphism with Helicobacter pylori-Infected Patients with Gastritis and Peptic Ulcer Disease
              1753. Prediction of progression of chronic atrophic gastritis with Helicobacter pylori and poor prognosis of gastric cancer by CYP3A4
              1754. Helicobacter pylori vacA, cagA and iceA genotypes in dyspeptic patients from southwestern region, Saudi Arabia: distribution and association with clinical …
              1755. Development of a novel gene signature in patients without Helicobacter pylori infection gastric cancer
              1756. A novel taxon selection method, aimed at minimizing recombination, clarifies the discovery of a new sub‐population of Helicobacter pylori from Australia
              1757. Eradicating Helicobacter pylori Infections to Treat Ulcers: Case Histories of Significant Medical Advances
              1758. Upregulation of MUC5AC production and deposition of LEWIS determinants by Helicobacter pylori facilitate gastric tissue colonization and the …
              1759. Accuracies of Endoscopic Diagnosis of Helicobacter pylori-Gastritis: Multicenter Prospective Study Using White Light Imaging and Linked Color Imaging
              1760. Circulating CD14+ CD163+ CD209+ M2-like monocytes are associated with the severity of infection in Helicobacter pylori-positive patients
              1761. Expression of Circadian Clock Components PER2 and BMAL1 are Altered During Infection of Helicobacter pylori
              1762. Helicobacter pylori heteroresistance to clarithromycin in adults—New data by in situ detection and improved concept
              1763. Astaxanthin Prevents Decreases in Superoxide Dismutase 2 Level and Superoxide Dismutase Activity in Helicobacter pylori-infected Gastric Epithelial Cells
              1764. Accuracy of invasive and noninvasive methods of Helicobacter pylori infection diagnosis in Saudi children
              1765. The Role of C5-cytosine Methyltransferase, hpyAVIBM in Helicobacter pylori Associated Virulence in Mice
              1766. Helicobacter pylori eradication rate of standard triple therapy and factors affecting eradication rate at Bahir Dar city administration, Northwest Ethiopia: A …
              1767. Vaccine‐induced gastric CD4+ tissue‐resident memory T cells proliferate in situ to amplify immune response against Helicobacter pylori insult
              1768. Role of Helicobacter pylori-induced Antralization in Gastric Carcinogenesis and its Implications in Clinical Practice
              1769. Periodontal treatment is more effective in gastric Helicobacter pylori eradication in those patients who maintain good oral hygiene
              1770. Syk: a new target for attenuation of Helicobacter pylori-induced gastric mucosal inflammatory responses
              1771. Lack of Association between Past Helicobacter pylori Infection and Diabetes: A Two-Cohort Study
              1772. Lactobacillus gasseri suppresses the production of the proinflammatory cytokines in Helicobacter pylori-infected macrophages by inhibiting the expression of ADAM17
              1773. Effectiveness and safety of furazolidone‐containing quadruple regimens in patients with Helicobacter pylori infection in real‐world practice
              1774. Differential diagnosis of Helicobacter pylori-associated gastritis with the linked-color imaging score
              1775. Ultrastructure Characteristics of Different Chinese Medicine Syndromes of Helicobacter pylori-Correlated Gastric Diseases
              1776. Potential antigen candidates for subunit vaccine development against Helicobacter pylori infection
              1777. Treating Helicobacter pylori infection in the face of growing antibiotic resistance.
              1778. Asymmetric dimethylation and citrullination of proteinic arginine and homoarginine synthesis in human Helicobacter pylori infection
              1779. The analysis of virulence factors and antibiotic resistance between Helicobacter pylori strains isolated from gastric antrum and body
              1780. Association of p53 Gene Mutation With Helicobacter pylori Infection in Gastric Cancer Patients and Its Correlation With Clinicopathological and Environmental …
              1781. Helicobacter pylori Infection and Glaucoma
              1782. Risks of substance uses, alcohol flush response, Helicobacter pylori infection and upper digestive tract diseases—An endoscopy cross‐sectional study
              1783. Eradication of Helicobacter pylori in a Living Donor Liver Transplant Recipient With Immunosuppressive Therapy of Cyclosporine A: A Case Report
              1784. Comparison of oral flora before and after triple therapy for Helicobacter pylori eradication in patient with gastric disease
              1785. 3D Confinement Effects on\textit {Helicobacter pylori} Swimming
              1786. sncRNAs packaged by Helicobacter pylori outer membrane vesicles attenuate IL-8 secretion in human cells
              1787. The protective effect of Helicobacter pylori infection on the susceptibility of multiple sclerosis
              1788. Eradication of Helicobacter pylori through the inhibition of urease and peptide deformylase: Computational and biological studies
              1789. Association between Helicobacter pylori infection and nonalcoholic fatty liver disease: A systematic review and meta‐analysis of observational studies
              1790. Helicobacter pylori infection is associated with diabetes among Chinese adults
              1791. Dukku and Baekam springwater inhibit the urease activity of Helicobacter pylori
              1792. Interpretation of the principles and strategies for the treatment of Helicobacter pylori infection from the perspective of integrated medicine
              1793. Inhibitory effect of medicinal plants from Cameroon on the growth and adhesion of Helicobacter pylori
              1794. Current information on the association of Helicobacter pylori with autophagy and gastric cancer
              1795. Importance of the Cys124− Cys128 intermolecular disulfide bonding for oligomeric assembly and hemolytic activity of the Helicobacter pylori TlyA hemolysin
              1796. Hydrotalcite Can Prevent the Damaging Effects of Helicobacter pylori on Gastric Epithelial Cells—CORRIGENDUM
              1797. The relationship between Helicobacter pylori infection and depressive symptoms in the general population in China: The TCLSIH cohort study
              1798. Bismuth supplements as the first‐line regimen for Helicobacter pylori eradication therapy: Systemic review and meta‐analysis
              1799. Helicobacter pylori-Induced DNA Damage Is a Potential Driver for Human Gastric Cancer AGS Cells
              1800. Antacids may increase the appearance of white opaque substance in Helicobacter pylori-eradicated gastric epithelial neoplasia
              1801. Endoscopic and Histological Findings among Israeli Populations Infected with Helicobacter pylori: Does Ethnicity Matter?
              1802. How Causal are Microbiomes? A Comparison with the Helicobacter pylori Explanation of Ulcers
              1803. Relationship between Helicobacter pylori infection and osteoporosis: a systematic review and meta-analysis
              1804. Current Status of Helicobacter pylori Diagnosis and Eradication Therapy in Japan Using a Nationwide Database
              1805. A Potassium-Competitive Acid Blocker-Based Regimen as Second-Line Therapy Improves Helicobacter pylori Eradication
              1806. Case Histories of Significant Medical Advances: Eradicating Helicobacter pylori Infections to Treat Ulcers
              1807. Helicobacter pylori infection in rehabilitation staff younger than 35 years: Infection surveillance for three years
              1808. CagW, a VirB6 homologue interacts with Cag-type IV secretion system substrate CagA in Helicobacter pylori
              1809. Atorvastatin in combination with conventional antimicrobial treatment of Helicobacter pylori eradication: A randomized controlled clinical trial
              1810. … modified release–based and lansoprazole-based nonbismuth quadruple (concomitant) therapy for first-line Helicobacter pylori eradication: a prospective …
              1811. Association between Helicobacter pylori gastritis and dental diseases: A cross‐sectional, hospital‐based study in Eastern Saudi Arabia
              1812. Effect of Helicobacter pylori eradication and high-density lipoprotein on the risk of de novo gastric cancer development
              1813. The risk of Helicobacter pylori infection for adverse pregnancy outcomes: A systematic review and meta‐analysis
              1814. Chronic CagA‐positive Helicobacter pylori infection with MNNG stimulation synergistically induces mesenchymal and cancer stem cell‐like properties in gastric …
              1815. Helicobacter pylori Antral Density More Valuable than Corporal Density in Chronic Gastritis Patients
              1816. FC022 Helicobacter pylori COLONISATION INCREASES PHOSPHATE BINDER PILL BURDEN IN DIALYSIS PATIENTS
              1817. Non-malignant Helicobacter pylori-Associated Diseases
              1818. Panning using a phage-displayed random peptide library to identify peptides that antagonize the Helicobacter pylori ArsS acid-sensing domain
              1819. Prevalence of Helicobacter pylori infection among dyspeptic patients with and without type 2 diabetes mellitus in Nigeria.
              1820. HISTOLOGICAL PROFILE OF Helicobacter pylori-INDUCED CHRONIC GASTRITIS: ABOUT 227 CASES
              1821. Genetic polymorphisms in TLR1, TLR2, TLR4, and TLR10 of Helicobacter pylori-associated gastritis in Thai population
              1822. Biochemical characterization of Helicobacter pylori α1–3-fucosyltransferase and its application in the synthesis of fucosylated human milk oligosaccharides
              1823. Correlation Analysis of Mental Health Status and Sleep Quality in Helicobacter pylori Positive Patients
              1824. Endoscopic Mucosal Phenotypes in the Helicobacter pylori Infection
              1825. In vitro anti-Helicobacter pylori activity of aqueous extract from Persian Oak testa
              1826. Helicobacter pylori Eradication Therapy for Functional Dyspepsia: A Meta-Analysis by Region and H. pylori Prevalence
              1827. Gastric Cancer with Submucosal Invasion after Successful Helicobacter pylori Eradication: A Propensity Score-Matched Analysis of Patients with Annual Patient …
              1828. Insights Into Pediatric Autoimmune Gastritis: Is There a Role for: Helicobacter pylori: Infection?
              1829. Association between Gastric Pathology and Hepatitis B Virus Infection in Patients with or without Helicobacter pylori
              1830. Mo1348 Helicobacter pylori INFECTION STATUS IN HUMAN IMMUNODEFICIENCY VIRUS-POSITIVE PATIENTS
              1831. Detection of Helicobacter pylori with clarithromycin resistance‐associated mutations using peptide nucleic acid probe‐based melting point analysis
              1832. Increased Serum Interleukin-10 Could lead to Allergic Disease Development in Helicobacter pylori Infected Adult
              1833. The Association between Helicobacter pylori Infection and Glycated Hemoglobin A in Diabetes: A Meta-Analysis
              1834. Complete Genome Sequence of Helicobacter pylori Strain GD63, Isolated from a Vietnamese Patient with a Gastric Ulcer
              1835. Immunoinformatics Approach to Design a Novel Epitope-Based Oral Vaccine Against Helicobacter pylori
              1836. Prevalence of Helicobacter pylori in Turkish children with celiac disease and its effect on clinical, histopathological, and laboratory parameters
              1837. Management of Helicobacter pylori infection at the primary care level. The implementation of specific counseling improves eradication rates
              1838. Validity of endoscopic features for the diagnosis of Helicobacter pylori infection status based on the Kyoto classification of gastritis
              1839. What Would the Screen-and-Treat Strategy for Helicobacter pylori Mean in Terms of Antibiotic Consumption?
              1840. Importance of Toll-like Receptors in Pro-inflammatory and Anti-inflammatory Responses by Helicobacter pylori Infection
              1841. Seroprevalence and determinants of Helicobacter pylori infection among asymptomatic under-five children at a Tertiary Hospital in the South-Western region of …
              1842. A Triple-Drug Blister-Packaged Drug with Vonoprazan Improves First-Line Eradication of Helicobacter pylori in Elderly Patients: A Retrospective Propensity Score …
              1843. Combined effect between WT1 methylation and Helicobacter pylori infection, smoking, and alcohol consumption on the risk of gastric cancer
              1844. Clarithromycin versus levofloxacin-based regimens for Helicobacter pylori eradication in the Kurdistan Region of Iraq: A randomized clinical trial
              1845. The most influential articles in Helicobacter pylori research: A bibliometric analysis
              1846. Helicobacter pylori‐induced YAP1 nuclear translocation promotes gastric carcinogenesis by enhancing IL‐1β expression
              1847. … modified carboxymethyl chitosan-graft-stearic acid polymeric nano-micelles as a targeted delivering carrier of clarithromycin for Helicobacter pylori: Preparation and in …
              1848. Shifts in the human gut microbiota structure caused by quadruple Helicobacter pylori eradication therapy
              1849. Clarithromycin-Susceptible But Virulent Helicobacter pylori Strains Infecting Iranian Patients’ Stomachs
              1850. Association between infection with Helicobacter pylori and platelet indices among school-aged children in central Ethiopia: a cross-sectional study
              1851. Linked color imaging identifies important risk factors associated with gastric cancer after successful eradication of Helicobacter pylori
              1852. Association between Helicobacter pylori infection and nonalcoholic fatty liver: A meta-analysis
              1853. Prevalence of and Helicobacter pylori infection rate in heterotopic gastric mucosa on histological analysis of duodenal specimens from patients with duodenal …
              1854. Characterization of gastric cells infection by diverse Helicobacter pylori strains through Fourier-transform infrared spectroscopy
              1855. VacA Genotype in Helicobacter pylori
              1856. Prevalence of Helicobacter pylori Infection among Internally Displaced Persons from Bakassi Peninsular and Etim Ekpo in South Southern, Nigeria
              1857. Diagnostic Techniques and Antimicrobial Susceptibility Test of Helicobacter pylori Infection in Gashua Town.
              1858. The role of high sensitive C-reactive protein and histopathological evaluation in chronic gastritis patients with or without Helicobacter pylori infection
              1859. … nanospheres as signal tags and target-triggered strand displacement reaction as signal amplification for highly sensitive detection of Helicobacter pylori DNA
              1860. Gastric Xanthoma Is a Predictive Marker for Early Gastric Cancer Detected after Helicobacter pylori Eradication
              1861. Relationship between Helicobacter pylori and expression of programmed death-1 and its ligand in gastric intraepithelial neoplasia and early-stage gastric …
              1862. Ranitidine, A Potential Option for Helicobacter pylori Eradication
              1863. Half‐dose clarithromycin‐containing bismuth quadruple therapy is effective and economical in treating Helicobacter pylori infection: A single‐center, open‐label …
              1864. Helicobacter pylori INFECTION IS AN AVOIDABLE RISK FACTOR FOR PARKINSON’S DISEASE.
              1865. … microRNA Gene Methylater in the Precancerous Background Mucosa with and without Gastric Cancer: Analysis of Effects of Helicobacter pylori Eradication and Long …
              1866. Once‐daily rabeprazole, levofloxacin, clarithromycin‐MR, and bismuth for Helicobacter pylori eradication: A randomized study of 7 or 14 days (ONCE study)
              1867. Relationship between Helicobacter pylori cytotoxin-associated gene A protein with clinical outcomes in patients with rheumatoid arthritis
              1868. Roles of Adhesion to Epithelial Cells in Gastric Colonization by Helicobacter pylori
              1869. … the Bifunctional 2‐C‐Methyl‐d‐erythritol 4‐Phosphate Cytidylyl Transferase/2‐C‐Methyl‐d‐erythritol‐2, 4‐cyclopyrophosphate Synthase (IspDF) of Helicobacter pylori
              1870. Bismuth, rabeprazole, amoxicillin, and doxycycline as first‐line Helicobacter pylori therapy in clinical practice: A pilot study
              1871. Twice daily short‐message‐based re‐education could improve Helicobacter pylori eradication rate in young population: A prospective randomized controlled study
              1872. The Story of Helicobacter pylori: Depicting Human Migrations from the Phylogeography
              1873. Saccharomyces boulardii as an adjuvant therapy for Helicobacter pylori eradication: A systematic review and meta‐analysis with trial sequential analysis
              1874. Development of an animal model of Helicobacter pylori (Indian strain) infection
              1875. The impact of Helicobacter pylori on the presence of Barrett’s esophagus in Azerbaijan, a high-prevalence area of infection
              1876. Does anti-Helicobacter pylori immunohistochemical staining has a confirmative role in the definitive diagnosis of negative gastric biopsy samples stained with …
              1877. Preliminary X-ray crystallographic studies on the Helicobacter pylori ABC transporter glutamine-binding protein GlnH
              1878. Interleukin-6 Expression in Serum, Gastric Juice and Gastric Mucosa of Helicobacter pylori Positive Gastric Cancer Patients
              1879. Correlations between gastric Helicobacter pylori infection and colorectal polyps or cancer
              1880. Detection of the clarithromycin resistance of Helicobacter pylori in gastric mucosa by the amplification refractory mutation system combined with quantitative real‐time …
              1881. Novel metabolites from Trichoderma atroviride against human prostate cancer cells and their inhibitory effect on Helicobacter pylori and Shigella toxin producing …
              1882. Decreased circulating interleukin-33 concentration in Helicobacter pylori-infected patients with peptic ulcer: Evaluation of its association with a cytokine gene …
              1883. The Effect of Red Rose Extract on Helicobacter pylori Eradication: A Randomized Controlled Clinical Trial
              1884. Protein changes in gastric epithelial cells RGM‐1 in response to Helicobacter pylori infection
              1885. Diagnosis of Helicobacter pylori in cholelithiasis and cholecystitis: by histology and serological association
              1886. Minor allele of rs1057317 polymorphism in TLR4 is associated with increased risk of Helicobacter pylori ‐induced gastric cancer
              1887. Effect of Helicobacter pylori Treatment on Long-Term Mortality in Patients with Hypertension
              1888. Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan, Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori
              1889. Association between Helicobacter pylori Infection and Iron Deficiency Anemia in School-aged Iranian Children
              1890. Initial Reverse Transcription is Essential for Reliable Helicobacter pylori 23S rDNA Real-Time PCR Diagnostics from Fecal Samples.
              1891. Phenotypic and genotypic characterization of Helicobacter pylori isolated from Egyptian endoscopic units
              1892. Tailored therapy in treatment of Helicobacter pylori infectionbasedon clarithromycinsensitivity
              1893. Application of PCR and Microscopy to Detect Helicobacter pylori in Gastric Biopsy Specimen among Acid Peptic Disorders at Tertiary Care Centre in Eastern Nepal
              1894. Prevalence of Helicobacter pylori Infection in Patients with Dyspeptic Symptoms in Damaturu Metropolitan
              1895. Optimization of HPMC K100M and Sodium Alginate Ratio in Metronidazole Floating Tablets for the Effective Eradication of Helicobacter pylori
              1896. Evaluating the Accuracy of the Endoscopic ABC Classification System in Diagnosing Helicobacter pylori-Infected Gastritis
              1897. The prognostic role of Helicobacter pylori in gastric cancer patients: a meta-analysis
              1898. Erratum to “Epidemiological and Clinical-Pathological Aspects of Helicobacter pylori Infection in Brazilian Children and Adults”
              1899. Frequency of Helicobacter pylori in patients with functional dyspepsia.
              1900. Prevalence of Infection and Antibiotic Susceptibility of Helicobacter pylori: An Evaluation in Public and Private Health Systems of Southern Chile
              1901. High Efficacy of Rapid Urine Test for Diagnosis of Helicobacter pylori Infection in Thai People
              1902. Evaluation of the Relationship Between Childhood Asthma and Helicobacter pylori Sero-Prevalence
              1903. Correlation Analysis of Pathways and Operons of Helicobacter pylori Resistance Genes Using Bibliometrics.
              1904. Detection of Helicobacter pylori and its virulence genes (cag A, dup A, and vac A) among patients with gastroduodenal diseases in Chris Hani Baragwanath …
              1905. Helicobacter pylori Induces GATA3-Dependent Chitinase 3 Like 1 (CHI3L1) Upregulation and Contributes to Vascular Endothelial Injuries
              1906. The antibiotic resistance of Helicobacter pylori to five antibiotics and influencing factors in an area of China with a high risk of gastric cancer
              1907. Testing of Helicobacter pylori by Endoscopic Biopsy: The Clinical Dilemma of Suppressive Conditions
              1908. Selected commensal bacteria change profiles of Helicobacter pylori‐induced T cells via dendritic cell modulation
              1909. The Gastro-protective Effect of Ginger (Zingiber officinale Roscoe) in Helicobacter pylori Positive Functional Dyspepsia
              1910. Relationship between type II diabetes mellitus and Helicobacter pylori infection in Erbil city
              1911. Dynamics of Helicobacter pylori infection in infants during the first six months of life
              1912. Cost‐effectiveness analysis and effectiveness of pharmacist‐managed outpatient clinics in Helicobacter pylori eradication therapy
              1913. Correlation of registered drug packs with Maastricht V/Florence Consensus Report and national treatment guidelines for management of Helicobacter pylori infection
              1914. Sequestration inside the yeast vacuole may enhance Helicobacter pylori survival against stressful condition
              1915. Identification and characterisation of Helicobacter pylori O‐acetylserine‐dependent cystathionine β‐synthase, a distinct member of the PLP‐II family
              1916. Optimization of 13C‐urea breath test threshold levels for the detection of Helicobacter pylori infection in a national referral laboratory
              1917. Association between a regular arrangement of collecting venules and absence of Helicobacter pylori infection in a European population
              1918. Helicobacter pylori DNA promotes cellular proliferation, migration, and invasion of gastric cancer by activating toll-like receptor 9
              1919. Effects of Pathogenesis Outcomes on Adherence Rate and Gene Toxicity in Helicobacter pylori
              1920. Penicillin‑binding protein 1A mutation‑positive Helicobacter pylori promotes epithelial‑mesenchymal transition in gastric cancer via the suppression of microRNA‑134
              1921. Rapid Characterization of Virulence Determinants in Helicobacter pylori Isolated from Non-Atrophic Gastritis Patients by Next-Generation Sequencing
              1922. Evaluation of the Usefulness and Convenience of the Kyoto Classification of Gastritis in the Endoscopic Diagnosis of the Helicobacter pylori Infection Status
              1923. The negative association between inflammatory bowel disease and Helicobacter pylori seropositivity
              1924. Helicobacter pylori: A Mini Primer
              1925. Association of Helicobacter pylori with oral potentially malignant disorders and oral squamous cell carcinoma—a systematic review and meta-analysis
              1926. 642. Higher Diagnostic Accuracy with Ultrasensitive Detection of Helicobacter pylori Stool Antigen Using Single-Molecule Counting Technology
              1927. Development of a Novel Antibacterial Medicine that Targets a Characteristic Lipid of the Cell Membranes of Helicobacter pylori
              1928. Investigation on the role of gene hp0788 in Helicobacter pylori in infecting gastric epithelial cells
              1929. Adapted first-line treatment of Helicobacter pylori infection in Algerian children
              1930. Molecular Detection of Helicobacter pylori UreC and 16sRNA genes in Saliva from Stool Antigen Positive Patients in Saad Rashwan Medical Center in Khartoum …
              1931. Helicobacter pylori CagA promotes the malignant transformation of gastric mucosal epithelial cells through the dysregulation of the miR‐155/KLF4 signaling pathway
              1932. Effects of eradicating Helicobacter pylori on metachronous gastric cancer prevention: A systematic review and meta‐analysis
              1933. Helicobacter pylori evasion strategies of the host innate and adaptive immune responses to survive and develop gastrointestinal diseases
              1934. Comparative study of magnifying narrow-band imaging and conventional white light endoscopy in the diagnosis of Helicobacter pylori status after eradication …
              1935. A Study of Helicobacter pylori Infection in Patients with Non-Alcoholic Fatty Liver Disease
              1936. Rifabutin-Based Rescue Therapy for Helicobacter pylori Eradication: A Long-Term Prospective Study in a Large Cohort of Difficult-to-Treat Patients
              1937. The regulatory role of C1q on Helicobacter pylori-induced inflammatory cytokines secretion in THP-1 cells
              1938. Colonization of Dental Unit Waterlines by Helicobacter pylori: Risk of Exposure in Dental Practices
              1939. Helicobacter pylori Mutations Detected by Next-Generation Sequencing in Formalin-Fixed, Paraffin-Embedded Gastric Biopsy Specimens Are Associated with …
              1940. Effect of 25-hydroxyvitamin D on Helicobacter pylori eradication in patients with type 2 diabetes
              1941. Comparison of new and classical point mutations associated with clarithromycin resistance in Helicobacter pylori strains isolated from dyspeptic patients and their …
              1942. Improvement in the implementation of Helicobacter pylori management guidelines among primary care physicians following a targeted educational …
              1943. Migraine, dyspepsia, and Helicobacter pylori: Zeroing in on the culprit
              1944. Surveillance of the Antimicrobial Resistance Rates of Helicobacter pylori Ten Years Later in the Western Central Region, Colombia
              1945. Helicobacter pylori infection in children: an overview of diagnostic methods
              1946. Efficacy and safety of probiotics in eradicating Helicobacter pylori: A network meta-analysis
              1947. The safety and effectiveness of vonoprazan-based Helicobacter pylori eradication therapy; a prospective post-marketing surveillance
              1948. Pathogenic interactions between Helicobacter pylori adhesion protein HopQ and human cell surface adhesion molecules CEACAMs in gastric epithelial cells
              1949. Epidemiological characterization, genetic alterations of Helicobacter pylori infection in chronic gastric disorder and prognostic values of heterozygosity loss in …
              1950. Production of 3‐Fucosyllactose in Engineered Escherichia coli with α‐1,3‐Fucosyltransferase from Helicobacter pylori
              1951. A Correlative Study between Chronic Tonsillitis and Helicobacter pylori
              1952. Phyto anti-biofilm elicitors as potential inhibitors of Helicobacter pylori
              1953. Pilot Study Indicates Helicobacter pylori Infection May Induce Small Intestinal Mucosal Injury
              1954. Genetic Diversity of the cagA gene of Helicobacter pylori strains from Sudanese Patients with Different Gastroduodenal Diseases
              1955. Antimicrobial resistance and genotyping of vacA, cagA, and iceA alleles of the Helicobacter pylori strains isolated from traditional dairy products
              1956. Blue light emitting diodes cripple Helicobacter pylori by targeting its virulence factors.
              1957. Contribution of interaction between genetic variants of interleukin-11 and Helicobacter pylori infection to the susceptibility of gastric cancer
              1958. Simvastatin improves the eradication rate of Helicobacter pylori: upper Egypt experience
              1959. The important role played by chemokines influence the clinical outcome of Helicobacter pylori infection
              1960. Frequency of Helicobacter pylori stool antigen in individuals with dyspeptic symptom
              1961. Rapid and accurate detection of Helicobacter pylori from biopsy specimens using loop‐mediated isothermal amplification
              1962. Prevalence of Pathogenic Genes cagA and vacA of Helicobacter pylori Isolated in Patients with Digestive Disorders
              1963. Dietary patterns and Helicobacter pylori infection in a group of Chinese adults ages between 45 and 59 years old: An observational study
              1964. Effects of Proton Pump Inhibitor on the Distribution of Helicobacter pylori and Associated Gastritis in Patients with Gastric Atrophy
              1965. CD177 Expression and Inflammation Grade in Helicobacter pylori-Infected Wild-Type and CD177-/-C57BL/6 Mice
              1966. area of Helicobacter pylori endemicity [version 1; peer review
              1967. Efficacy of tailored therapy for Helicobacter pylori eradication based on clarithromycin resistance and survey of previous antibiotic exposure: A single‐center …
              1968. Research Article Antimicrobial and Anti-Biofilm Effect of an Electrolyzed Superoxidized Solution at Neutral-pH against Helicobacter pylori
              1969. Protective activity of geraniol against acetic acid and Helicobacter pylori-induced gastric ulcers in rats
              1970. Eradication Rates of 10-day Sequential Therapy for Helicobacter pylori: Results of an 8-year Prospective Study Conducted at a Tertiary Korean Hospital
              1971. Inverse relationship between cagG-positive Helicobacter pylori status and risk of gastric ulcer
              1972. EVALUATION OF THE RELATIONSHIP BETWEEN Helicobacter pylori AND THE SMALL WHITE SPOT LESIONS OF THE DUODENUM
              1973. Prevalence and genotyping of Helicobacter pylori in endoscopic biopsy samples from a Chinese population
              1974. Design, synthesis, and biological evaluation of Helicobacter pylori inosine 5′‐monophosphate dehydrogenase (HpIMPDH) inhibitors
              1975. Sex difference in patients with Helicobacter pylori infection
              1976. Analysis of babA, cagE and cagA genes in Helicobacter pylori from upper gastric patients in the north of Iran
              1977. Role of Outer Inflammatory Protein A/Cystine-Glutamate Transporter Pathway in Gastric Mucosa Injury Induced by Helicobacter pylori
              1978. In Vitro Anti-Helicobacter pylori Activity of Berberine and Barberry Extracts: A Preliminary Report
              1979. Effect of Age on Effectiveness of Vonoprazan in Triple Therapy for Helicobacter pylori Eradication
              1980. Modulation of host metabolism by the human gastric pathogen Helicobacter pylori
              1981. Utility of Rapid urease test in diagnosis of Helicobacter pylori infection
              1982. Cefuroxime, levofloxacin, esomeprazole, and bismuth as first-line therapy for eradicating Helicobacter pylori in patients allergic to penicillin
              1983. Helicobacter pylori and hematological disorders.
              1984. Molecular Characteristics and Clinical Relevance of Cytotoxin‑Associated Genes A and E of Helicobacter pylori from Patients with Gastric Diseases
              1985. Association between body mass index and gastric cancer risk according to effect modification by Helicobacter pylori infection
              1986. FAM60A, increased by Helicobacter pylori, promotes proliferation and suppresses apoptosis of gastric cancer cells by targeting the PI3K/AKT pathway
              1987. A Comment on Helicobacter pylori and Lung Transplant Outcome: Is Serology the Ideal Diagnostic Approach?
              1988. Exploring the influence of conserved lysine69 on the catalytic activity of the Helicobacter pylori shikimate dehydrogenase: A combined QM/MM and MD simulations
              1989. Clinical significance and influencing factors of linked color imaging technique in real-time diagnosis of active Helicobacter pylori infection
              1990. MicroRNA‑146a inhibits the inflammatory responses induced by interleukin‑17A during the infection of Helicobacter pylori
              1991. Increased anti-Helicobacter pylori effect of the probiotic Lactobacillus fermentum UCO-979C strain encapsulated in carrageenan evaluated in gastric simulations …
              1992. Association of Helicobacter pylori with Peptic Ulcer Perforation
              1993. Association between Helicobacter pylori infection and primary open-angle glaucoma
              1994. Cloning, expression, and purification of HpaA-CagA fusion recombinant protein of Helicobacter pylori in E. coli BL 21 strain
              1995. High-resolution magnified endoscopy combined with flexible spectral imagining colour enhancement techniques in the diagnosis of Helicobacter pylori …
              1996. Genotypic determination of resistance and heteroresistance to clarithromycin in Helicobacter pylori isolates from antrum and corpus of Colombian …
              1997. Association Between Horizontal Gene Transfer and Adaptation of Gastric Human Pathogen Helicobacter pylori to the Host
              1998. … AND MAGNIFYING ENDOSCOPY WITH NARROW BAND IMAGING IN THE UNDIAGNOSED GASTRIC LESIONS AFTER Helicobacter pylori ERADICATION
              1999. Association of different genotypes of Helicobacter pylori with CDX2 expression in intestinal metaplasia and gastric cancer
              2000. Global estimate of gastric cancer in Helicobacter pylori–infected population: A systematic review and meta‐analysis
              2001. Clinical efficacy of radiotherapy in Helicobacter pylori negative or unresponsive to eradication therapy primary gastric mucosa-associated lymphoid tissue …
              2002. Association of current Helicobacter pylori infection and metabolic factors with gastric cancer in 35,519 subjects: A cross-sectional study
              2003. Prevalence of Helicobacter pylori in diabetes patients and health workers at a tertiary hospital in south west Nigeria
              2004. Role of Probiotics in Prophylaxis of Helicobacter pylori Infection
              2005. Optimal duration of concomitant nonbismuth quadruple therapy as first-line therapy for Helicobacter pylori: a prospective, open-label, comparative study
              2006. What is the most effective management for Helicobacter pylori non-ulcer dyspepsia?
              2007. Impact of Helicobacter pylori Infection on Gastric Variceal Bleeding among Patients with Liver Cirrhosis
              2008. A comparative study of subsequent liver cirrhosis risk in non‐Helicobacter pylori‐infected peptic ulcer patients with and without vagotomy: An Asian population cohort …
              2009. Introduction of a C-terminal hexa-lysine tag increases thermal stability of the LacDiNac binding adhesin (LabA) exodomain from Helicobacter pylori
              2010. Levofloxacin-containing triple therapy versus bismuth-based quadruple therapy as regimens for second line anti-Helicobacter pylori
              2011. Helicobacter pylori infection
              2012. Caracterización clínico-epidemiológica, endoscópica y microbiológica de pacientes con síntomas digestivos según su status de Helicobacter pylori
              2013. Use of probiotics in the Helicobacter pylori eradication in Italy: data from the Italian Registry on Helicobacter pylori treatment
              2014. Stability studies of selected Helicobacter pylori proteins required for survival
              2015. The heat-shock response of Helicobacter pylori: genomic and molecular characterization of the master repressor HspR
              2016. Nuevos retos en el tratamiento de la infección por Helicobacter pylori
              2017. TRATAMENTO DA BACTÉRIA Helicobacter pylori A PARTIR DA ESPÉCIE VEGETAL CYMBOPOGON CITRATUS: REVISÃO DE LITERATURA
              2018. Epidemiological survey of Helicobacter pylori infection in Tibetan population in Gangcha of Qinghai, 2017–2018
              2019. GASTRITE A Helicobacter pylori CHEZ L’ENFANT
              2020. In vivo expression of Helicobacter pylori virulence genes in patients with gastritis, ulcer, and gastric cancer
              2021. Caracterización de los pacientes con urticaria crónica asociada a infección por Helicobacter pylori
              2022. Endoskopische Diagnostik von Helicobacter pylori: Die klinische Herausforderung von suppressiven Bedingungen
              2023. Hemorrhagic Colitis Induced by Second-line Helicobacter pylori Eradication
              2024. Prevención del cáncer gástrico y erradicación de Helicobacter pylori
              2025. Avaliação do risco de câncer gástrico em pacientes com gastrite crônica por Helicobacter pylori
              2026. Utilidad del antígeno de Helicobacter pylori en heces como método diagnóstico no invasivo
              2027. Terapia periodontal como adjuvante para o tratamento de gastrite provocada por Helicobacter pylori
              2028. Ulcère à Helicobacter pylori: efficacité du traitement et facteurs qui influencent la guérison
              2029. Susceptibilidad antimicrobiana y mutaciones en el gen ARNr 23S de Helicobacter pylori en pacientes dispépticos
              2030. Helicobacter pylori infection and associated factors
              2031. Helicobacter pylori Infection and the Kyoto Classification of Gastritis
              2032. Tratamiento del Helicobacter pylori
              2033. Study on the Effect of Berberine on the Proliferation of Helicobacter pylori
              2034. Presence of cagA Gene in Patients with Gastric Cancer and Gastritis with Helicobacter pylori Infection
              2035. The prevalence of antibiotic resistant Helicobacter pylori: a literature review.

               


              “Helico works right away in killing Helicobater Pylori! I’ve been trying to get rid of this for years. The first side effects were not pleasant as the bacteria put up a fight. BUT after about 3 days I started getting better. I used to feel exhausted every time I ate. This no longer happens. I expect to see better and better health results now that the bacteria is gone. Thank you Gavin for your endless supply of info and support. You are much appreciated!”
              ⭐️⭐️⭐️⭐️⭐️
              —Shelley McKone

              Introducing

              INTERSTELLAR PARASLAYER ANTIHELMINTIC!

              200:1 Concentration

              Anthelmintics are a group of antiparasitic agents that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host.


              KILL THE WORMS!

              Featuring: Acacia Catechu • Acacia Nilotica • Acalypha Rhomboidea • Achyranthes Aspera • Acorus Calamus • Ajania Nubigena • Akanda (Calotropis Gigantea L.) • Albendazole • Albizia Anthelmintica Maerua Edulis • Albizia Gummifera • Allophylus Serratus • Alocasia Indica • Alpinia Galanga • Alstonia Boonei De Wild • Amaranthus Caudatus • Amaranthus Spinosus • Amorphophallus Paeoniifolius Tuber • Anaphalis Lawii • Annona Reticulata • Anthocleista Djalonensis . • Argemone Mexicana • Arisaema Lobatum • Aristolochia Indica • Artemisia Maritima • Artemisia Parviflora • Artemisia Vestita Wall Ex Dc • Artocarpus Lakoocha • Asparagus Racemosus • Asuro (Justicia Adhatoda) • Asystasia Gangeticum • Averrhoea Carambola • Azadirachta Indica • Baccaurea Ramiflora • Bacillus Cereus • Balanites Aegyptiaca • Baliospermum Montanum Muell • Barleria Gibsoni Dalz • Bauhinia Purpurea • Berlina Grandiflora • Biophytum Petersianum • Bougainvillea Glabra • Bridelia Ferruginae • Bryophyllum Pinnatum • Bryophyte Pottia Lanceolata • Caesalpinia Crista • Caesalpinia Pulcherrima • Caesalpinia Sappan • Cajanus Cajan • Camellia Sinensis • Canarium Schweinfurthii • Cansjera Rheedii Root Extract • Capparis Spinosa • Cardanthera Difformis Druce • Carica Papaya • Carissa Carandas • Carum Copticum • Cassia Fistula • Cassia Siamea Lamk • Cassia Tora • Castor Oil And Mustard Oil • Chenopodium Album • Chlorophytum Borivilianum Santapau • Chromolaena Odorata • Cissampelos Pareira • Cissus Quadrangularis L. • Citrus Medica • Clerodendrum Viscosum • Cloris Barbata • Coleus Aromaticus Benth • Coriandrum Sativum • Curcuma Longa Cyperus Rotundus • Dioscorea Bulbifera • Diplazium Esculentum • Drosera Regia • Drynaria Quercifolia • Eclipta Prostrate • Eichhornia Crassipes Roots • Elytraria Acaulis • Emblliaribes • Enicostemma Littorale Blume • Equisetum Arvense • Eucalyptus Globulus • Eugenia Jambolana • Eupatorium Triplinerve • Euphorbia Helioscopia • Euphorbia Ligularia Roxb • Evolvulus Alsinoides L • Ficus Vasta • Garcinia Cambogia • Goniothalamus Sesquipedalis • Gossypium Herbaceum • Grape Pomace Extract • Guava • Hedychium Spichatum • Helicteres Isora • Hugonia Mystax • Indigofera Oblongifolia • Iris Hookeriana • Ixora Coccinea • Jasminum Sessiliflorum • Juglans Regia • Justicia Beddomei • Kyllinga Nemoralis • Lagenaria Siceraria • Lanata Camara • Lasia Spinosa • Macrotyloma Uniflorum • Majoon Sarakhs • Malabathricum Linn Leaves And Nigella Sativa • Mallow (Malva Sylvestris L.) • Marine Sponge Extracts • Melia Azedarach • Melothria Heterophylla Lour • Memecyclon Malabaricum • Mentha Longifolia • Microphyllus Leaves • Millettia Pachycarpa • Mitragyna Parvifolia • Molineria Recurvata • Momordica Charantia • Momordica Dioica • Morinda Citrifolia • Myristica Fragrans • Nauclea Diderrichii • Neolamarckia Cadamba • Nepeta Cataria Suhaib • Nerium Oleander • Nigella Sativa • Nymphaea Rubra • Ocimum Basilicum • Ocimum Sanctum • Olea Europaea • Oleandra Musifolia • Pajanelia Longifolia • Paris Polyphylla • Pavetta Indica • Pelletíerine And Isopelletierine • Pineapple Leaf • Piper Betle • Piper Longum L • Plumbago Zeylanica • Pongamia Glabra • Prosopis Cineraria • Raphanus Sativus • Rhizophora Apiculata • Ridge Gourd • Rotula Aquatica Lour Bark • Rumex Hastatus • Saba Florida • Saraca Indica • Sesamum Indicum • Shea (Vitellaria Paradoxa) • Solanum Nigrum • Solanum Surattense • Soymida Febrifuga • Sterculia Villosa • Syzygium Aromaticum • Tectona Grandis • Tephrosea Purpurea • Terminalia Citrina Leaves • Trapa Natans • Trianthema Portulacastrum And Musa Paradisiaca • Tridax Procumbens • Trigonella Foenum-Graecum • Trikatu Churna • Tulsi Leaves [Ocimum Sanctum] • Vepris Louisii Gilbert • Vidangadi Churna • Viscum Congolensis • Vitex Trifolia • Xanthium Indicum Leaves • Ximenia Americana • Zanthoxylum Armatum • Zizyphus Jujuba Mill •

              INGREDIENTS & Science:


              Acacia Catechu


              Investigation of anthelmintic, anti-inflammatory activity of leaves extract of Acacia catechu Willd


              From ancient time Acacia catechu Willd. (AC) is used as a potent medicinal. Preliminary phytochemical tests were conducted with the crude extract obtained from the leaves of AC reveals the presence of carbohydrates, steroids, alkaloids, glycosides, tannins, saponins, flavones, and phenolic. anthelmintic activity of petroleum ether, ethanolic and ethanol:water (1:1) extracts of leaves of AC was evaluated by adult Indian earthworm, (Pheretima posthuma). The anthelmintic activity of extract was compared with standard albendazole.

              Ethanol:water (1:1) extract was found to possess potent anthelmintic activity and petroleum ether extract was found to be least active, while ethanol:water (1:1) extract playing an intermediate role. The anti-inflammatory activity of leaves extracts at the doses of 300mg/kg body weight was investigated in albino rats of wiester strain using carrageenan induced rat paw oedema. The ethanol extract of leaves showed significant anti-inflammatory activity (45%) when compared with the standard (54%). Further studies are suggested to isolate the active principles which are responsible for the anthelmintic and anti-inflammatory activity.



              Acacia Nilotica


              IN VITRO PHYTOCHEMICAL ANALYSIS AND anthelmintic ACTIVITY OF ACACIA NILOTICA WHOLE PLANT METHANOLIC AND AQUEOUS EXTRACT ON INDIAN ADULT earthworm


              anthelmintic activity, Acacia nilotica, Pheretimaposthuma, methanol extract, aqueous extract, phytochemical analysis There are various beneficial effects of Acacia nilotica since the ancient time is being reported. But in the project work anthelmintic activity against Pheretimaposthuma (an Indian earthworms is being studied by applying two different concentrations of plant methanolic extract. The result is then compared with standard drug Albendazole and control group. The pharmaceutical constituent of Acacia nilotica is being also studied here.



              Achyranthes Aspera


              In-vitro anthelmintic Activity of Methanolic and Aqueous Extracts of Achyranthes aspera linn. (Amaranthaceae) Stems


              The anthelmintic activities of methanolic and aqueous extracts of stems of Achyranthes aspera linn. were evaluated separately on Indian adult earthworms Pheretima posthuma (Annelida). For this work the stems were extracted separately with methanol and distilled water by following maceration method. Various concentrations (2.5, 5, 10, 20 mg/ml) of each extract were tested for anthelmintic activity which involved the determination of time of paralysis and time of death of the worms. The phytochemical screening of the crude extract showed the presence of saponins A and B, terpenoids, volatile oils. All extracts were able to show anthelmintic activity at all concentrations.

              The activities are well comparable with the standard drug, Albendazole as positive control. All the methanolic extracts showed better anthelmintic activity than the standard drug as well as the aqueous extract. Tween 20 (1%) with saline was used as negative control, did not showed any anthelmintic activity.



              Acorus Calamus


              anthelmintic activity of a standardized extract from the rhizomes of Acorus calamus Linn. (Acoraceae) against experimentally induced cestodiasis in rats


              The study revealed that b-asarone is the active principle of plant. The HPLC analysis of local variety of A. calamus revealed that active fraction contains 83.54% (w/w) of b-asarone. The in vivo study revealed that treatment of H. diminuta infected rats by a single 800 mg/kg dose of rhizome extract for 5 days results into 62.30% reduction in eggs per gram of feces counts and 83.25% reduction in Worm counts of animals. These findings compared well with the efficacy of a reference drug, praziquantel. The active principle b-asarone showed slightly better anthelmintic effects than crude extract. In acute toxicity assay, a single oral 2000 mg/kg dose of extract did not reveal any signs of toxicity or mortality in mice, and the LD50 of the extract was noted to be >2000 mg/kg.

              Taken together, the results of this study indicate that rhizomes of A. calamus bear significant dose-dependent effects against intestinal helminths. Further, the Indian variety of A. calamus contains high b-asarone content. Therefore, there exists a great potential to develop some suitable anthelmintic herbal products from this plant.



              Ajania Nubigena


              Compounds Derived from the Bhutanese Daisy, Ajania nubigena, Demonstrate Dual anthelmintic Activity against Schistosoma mansoni and Trichuris muris


              Background: whipworms and blood flukes combined infect almost one billion people in developing countries. Only a handful of anthelmintic drugs are currently available to treat these infections effectively; there is therefore an urgent need for new generations of anthelmintic compounds. Medicinal plants have presented as a viable source of new parasiticides Ajania nubigena, the Bhutanese daisy, has been used in Bhutanese traditional medicine for treating various diseases and our previous studies revealed that small molecules from this plant have antimalarial properties. Encouraged by these findings, we screened four major compounds isolated from A. nubigena for their anthelmintic properties.



              Akanda (Calotropis Gigantea L.)


              In-vitro anthelmintic activity of Akanda (Calotropis gigantea L.) whole plant methanolic extract in Indian adult earthworm


              After done all observation it may conclude that of Calotropis gigantean did produce very anthelmintic activity against India earthworms. During study this plant showed very significant anthelmintic activity at 100 mg/dl Conc. measured by time taken for paralyse / death of the earth worms. The result of different conc. of methanolic extracts of plants can compared with the rules of standard drug, Albendazole and Carboxy Methyl Cellulose (CMC) acts as a control. Future details research work on this plant will open a new avenue of drug industries.


              Albendazole


              Albendazole: a review of anthelmintic efficacy and safety in humans


              This comprehensive review briefly describes the history and pharmacology of albendazole as an anthelminthic drug and presents detailed summaries of the efficacy and safety of albendazole’s use as an anthelminthic in humans. Cure rates and 0% egg reduction rates are presented from studies published through March 1998 both for the recommended single dose of 400 mg for hookworm (separately for Necator americanus and Ancylostoma duodenale when possible), Ascaris lumbricoides, Trichuris trichiura, and Enterobius vermicularis and, in separate tables, for doses other than a single dose of 400 mg. Overall cure rates are also presented separately for studies involving only children 2-15 years. Similar tables are also provided for the recommended dose of 400 mg per day for 3 days in Strongyloides stercoralis, Taenia spp. and Hymenolepis nana infections and separately for other dose regimens. The remarkable safety record involving more than several hundred million patient exposures over a 20 year period is also documented, both with data on adverse experiences occurring in clinical trials and with those in the published literature and/or spontaneously reported to the company.

              The incidence of side effects reported in the published literature is very low, with only gastrointestinal side effects occurring with an overall frequency of just >1% . Albendazole’s unique broad-spectrum activity is exemplified in the overall cure rates calculated from studies employing the recommended doses for hookworm (78% in 68 studies: 92%, for A. duodenale in 23 studies and 75% for N. americanus in 30 studies), A. lumbricoides (95% in 64 studies), T. trichiura (48% in 57 studies), E. vermicularis (98% in 27 studies), S. stercoralis (62% in 19 studies), H. nana (68% in 11 studies), and Taenia spp. (85% in 7 studies).

              The facts that albendazole is safe and easy to administer, both in treatment of individuals and in treatment of whole communities where it has been given by paramedical and nonmedical personnel, have enabled its use to improve general community health, including the improved nutrition and development of children.



              Albizia anthelmintica Maerua Edulis


              Pharmacological and clinical evaluation anthelmintic activity of albizia anthelmintica maerua edulis de wolf and maerua subcordata plant extracts in sheep and mice


              The use of medicinal plants for the control of helminthoses has been in practice for centuries and there are many plants claimed to have anthelmintic activity. However, it is only a few of these plants that have their anthelmintic activity scientifically evaluated. These studies were done to evaluate the anthelmintic activity of Albizia anthelmintica Brogn, Maerua edulis De Wolf and Maerua subcordata De Wolf in sheep and mice and to determine the bioactivity of these plants using brine shrimp lethality test. An attempt was also made to separate the pharmacological active ingredient in Albizia anthelmintica water extract. A questionnaire was used to obtain medicinal plants used by farmers and herbalists in Kibwezi Division of Makueni district and Tunyo division of Marakwet district as anthelmintic. Out of 51 useful plants identified in Kibwezi, Albizia anthelmintica (Kyoa in Kikamba) and Maerua edulis (Munatha in Kikamba) were singled out by herbalists as very potent anthelmintics. In Tunyo division Albizia anthelmintica (Kitwongwo in Marakwet) and Maerua subcordata (Liswa in Marakwet) were identified as potent anthelmintics.

              For this reason, they were collected and botanically identified for further testing and analysis. The anthelmintic activity of the three plants was evaluated in the present study. Crude extraction of the plant samples was done as described by the herbalists. An aqueous extract from both unground and ground material of each plant material was prepared using boiling water. Twenty one clinically healthy sheep of mixed breeds and sexes were randomly allocated to four treatment groups of four animals each. The control group had three sheep. Faecal egg counts were done for all the sheep on day O. A single oral dose of 1.2 ml/kg body weight (Albizia anthelmintica ) and 0.8 ml/kg body weight (Maerua edulis) was administered to the sheep in the 4 treatment groups. The control was left untreated. Albizia anthelmintica extract was the only one which reduced faecal egg count. At double the dose, the percentage faecal egg count reduction was 55, 49, 38, 16 and 14 for powdered Albizia anthelmintica, powdered Maerua edulis, fresh Maerua subcordata, fresh Maerua edulis and fresh Albizia anthelmintica respectively.

              Therefore, the crude product could control helminthoses to a reasonable extent and maintain the animal at clinically healthy state. Brine shrimp assay was used to detect bioactivity (LC50) in the vanous extracts of Albizia anthelminitica, Maerua subcordata and Maerua edulis. The various extracts were made using water, methanol and chloroform and immediately freeze dried. Brine shrimp eggs obtained from pet shops were hatched using marine salt solution as media and yielded a large number of larvae. Serial dilution of the plant extracts were put into tubes with 10 brine shrimps each. The number of live larvae was determined after 24 hours. Probit method of the Finney computer programme was used to determine the lethal concentration fifty (LC50) and 95% confidence intervals. It was evident that the chloroform extract of the three plant extracts was the most toxic to the brine shrimps compared to water and methanol extracts. Albizia anthelmintica extracts of all the solvents was the most potent compared with the two Maerua species. The anthelmintic efficacy of the three plants was studied in mice experimentally infected with Heligmosomoides polygyrus.

              The results indicated a percentage faecal xv Heligmosomoides polygyrus egg count reduction of 72%, 69%, 50%, 42% using water extracts of Albizia anthelmintica at 10gm/kg bodyweight, Maerua edulis at 20gm/kg bodyweight, Albizia anthelmintica at 20gm/kg bodyweight and Albizia anthelmintica at 5gmlkg bodyweight respectively. Seven days after treatment there was a reduction in Worm counts at postmortem of 68%, 36%, 20%, 19%,16% and 14% for water extracts of Albizia anthelmintica at 5gmlkg bodyweight, Maerua edulis at 10gmlkg bodyweight, Albizia anthelmintica at 10gmlkg bodyweight, Albizia anthelmintica at 20gm/kg bodyweight, Maerua edulis at 20gm/kg bodyweight and Maerua edulis at 5gm/kg bodyweight respectively. Mice treated with Albizia anthelmintica at 5gm/kg bodyweight had a significantly lower mean Worm counts than the rest of the treatment groups and the control (p<0.05).There was insignificant reduction in Worm counts for other treatment groups compared with the control (p<0.05). The column and thin layer chromatography done on the aqueous extract of Albizia anthelmintica yielded only one fraction which was active and had a relative fraction (Rf) of 0.75.

              The results therefore indicate that the plant have some anthelmintic activity though low with Albizia anthelmintica being most efficacious. The bioactive fraction in Albizia anthelmintica obtained through chromatographic techniques indicate that there is a rationale in the use of this plant as an anthelmintic by the pastoralists. There is therefore a need to identify the active ingredient in Albizia anthelmintica for future commercial use.



              Albizia Gummifera


              In vitro anthelmintic activity of Albizia gummifera, Crotalaria axillaris, Manilkara discolor, Teclea trichocarpa and Zanthoxylum usambarense using sheep nematodes


              Albizia gummifera, Crotalaria axillaris, Manilkara discolor, Teclea trichocarpa and Zanthoxylum usambarense are used to treat different ailments in many parts of the world. For instance, A. gummifera is used to treat stomach pains, malaria, diarrhoea and sleeping sickness while C. axillaris treats ophthalmic disorders and kidney problems. Manilkara discolor stem bark infusion is used to treat stomach disorders and as an astringent while T. trichocarpa has been used to treat malaria, helminth infections and fever. Zanthoxylum usambarense is used to treat rheumatism, backache, painful joints, fever, sore throat, tonsillitis, chest pains, malaria, abscesses and wounds.

              Objective : The aim was to determine whether the crude plant extracts have in vitro anthelmintic activity.

              Materials and methods : Different parts of the plants were acquired from Ngong Hills forest, Kajiado County, Kenya in May 2012, dried and macerated to exhaustion with dichloromethane: methanol (1:1, v/v) solution. nematode eggs ( Haemonchus Spp, Trichostrongylus Spp and Oesophagostomum Spp) were obtained from infected sheep rectums at Department of Vet Farm, University of Nairobi based at Kabete. Varying concentrations of water solutions of the dry crude extracts were prepared. Egg hatch (EHA) and larvae development assays (LDA) were used to test the extracts’ effects on nematode egg hatching and larvae development, respectively Results : Albizia gummifera (root bark) and Zanthoxylum usambarense (stem bark) showed high activity (IC 50 below 300 μg / mL) in both tests. Albizia gummifera (root, stem bark and pods), Zanthoxylum usambarense root bark, Crotalaria axillaris twigs and Teclea trichocarpa root and stem bark showed high activity in LDAbut moderate activity (300 μg / mL 500 μg / mL) activity in EHA. Manilkara discolor extracts showed low activity in both tests.

              Conclusion: Different extracts of the plants tested may inhibit nematode growth and development and hence warrant in vivo tests would support their ethnomedicinal application. Key words: anthelmintic activity, egg hatch, larval development, Haemonchus, Trichostrongylus, Oesophagostomum



              Allophylus Serratus


              SCREENING OF IN-VITRO anthelmintic ACTIVITY OF ALLOPHYLUS SERRATUS (ROXB.) KURTZ ON INDIAN earthworms


              Aim: The study was aimedto evaluate the In-Vitro anthelmintic activity of Allophylus serratus on Indian earthworms.

              Materials &Methods: Differentconcentrations like 100mg/ml, 200mg/ml and 400mg/ml of Allophylus serratus leaf extract with ethanol were taken and were tested for time of paralysis and time of death in the worms according to the method Ajaiyeoba et al.

              Results: Itshowed that all the concentrations of Allophylus serratus had anthelmintic activity according to the dose dependant manner. Efficacy of the test samples were found to be decreased the time for paralysis & death of the worms with increased dose. The test samples were compared with the standard drug Albendazole (20mg/ml) showed that the test concentration of 400mg/ml had equalled potent with standard drug.

              Conclusion: The extract of 400mg/ml dose had potent anthelmintic activity than other extracts like 100mg/ml, 200mg/ml. On phytochemical screening of Allophylus serratus extract with ethanol was found to be phenolic compounds, flavonoids, tri-terpenoids, steroids and Glycosides. The study concluded that Allophylus serratus used as an anthelmentic drug in future.



              Alocasia Indica


              anthelmintic activity of leaves of Alocasia indica Linn.


              The study was designed to evaluate the anthelmintic activity of hydroalcoholic extract of leaves of Alocasia indica Linn. (Araceae) and its two different fractions namely petroleum ether and ethyl acetate using Pheretima posthuma as test Worms. Different concentrations (10, 25 and 50 mg/ml) of hydroalcoholic extract and its various fractions were tested in the bioassay, from which time of paralysis (P) and time of death (D) of the worms were determined. Piperazine citrate was used as standard reference and distilled water as control. All the extracts were found not only to paralyze (Vermifuge) but also to kill the earthworms (Vermicidal).

              The hydroalcoholic extract was found to be more effective to execute the earthworm at higher concentration of 50 mg/ml, as compared to standard reference Piperazine citrate. Further, systematic scientific studies are essential for screening different activities.



              Alpinia Galanga


              Phytochemical and anthelmintic activity of Alpinia galanga Linn


              Plants have been one of the important sources of medicines even since the damn of human civilization. Alpinia galanga L. (Family-Zingiberaceae). It is well known official drug thought the country as a holistic gift of nature for medicinal, culinary and cosmetic use. It has been found to possess various therapeutic activities, viz. anti-inflammatory, analgesic ant allergic, antifungal, ant diabetic, antibacterial, antiulcer, immunostimulating, anti-cancer, anti -oxidant, anti-amoebic, anti-dermatophytic and many more. For different concentrations (100, 60, 40, 20mg/ml) of each extract(aqueous extract) were studied in activity which involved the determination time of paralysis (vermifuge) and time death ( vermicidal) of the worms Piperazine adipate in the same concentration as the extract was included as standard reference and normal saline (0.9%NaCl) water with 1% CMC as control.

              The extract exhibited significant anthelmintic activity at a concentration of 100mg/ml in this case it was found that aqueous extract gives better activity compared to the standard. Results showed that Alpinia galanga rhizome extract gives better anthelmintic activity at all the tested doses.



              Alstonia Boonei De Wild


              In vitroanthelmintic activity of stem and root barks of Alstonia boonei De Wild


              Alstonia booneiDe Wild ethanol extracts of the stem bark (ABSB) and root bark (ABRB)were evaluated for possible anthelmintic activity. Three different concentrations of each extract (50, 100 and 150mg/ml) were evaluated for in vitroanthelmintic activity by determining the effects of the extracts on the paralysis and death times of Pheretima posthuma.Mebendazole(MBZ) 15 mg/mg was used as reference anthelmintic. ABSB and ABRBdemonstrated a concentration dependent anthelmintic activity with a reduction in paralytic anddeath times upon increase in theconcentrationof the extracts.

              ABSB revealedbetteranthelmintic activity than ABRBat all concentrations tested. ABSB also revealeda significant paralytic time (p<0.01) at 150mg/mlwith reference to MBZ. Phytochemical screening revealed the presence ofalkaloids, tannins, flavonoids saponins and glycosides in ABSBand ABRB.



              Amaranthus Caudatus


              anthelmintic activity of methanol extract of Amaranthus caudatus Linn


              Amaranthus caudatus Linn, traditionally used as vermifuge, so methanol extract of whole plant of A. caudatus was investigated for anthelmintic activity using earthworms (Pheretima posthuma). Various concentrations (10-100 mg/ml) of methanol extract were tested in the bioassay. Piperazine citrate (10 mg/ml) was used as reference standard drug whereas distilled water as control. Determination of paralysis time and death time of the Worms were recorded. Extract exhibited
              significant dose dependent anthelmintic activity at 60, 80, 100 mg/ml. The result provides scientific validation for traditional use.


              Amaranthus Spinosus


              Evaluation of anthelmintic and anti-inflammatory activity of Amaranthus spinosus Linn


              Water extracts of whole plant of Amaranthus spinosus Linn was evaluated for anthelmintic on adult Indian earthworms (Pheritima posthuma) and Tubifex tubifex ,using piperazine citrate as reference standard. Aqueous extract showed anthelmintic activity in dose‐dependent manner giving shortest time of paralysis(P) and death(D) with 50 mg/ml concentration, for both the worms. Extract shows more potent activity (15 mg/ml) against Tubifex tubifex. Extract shows more potent activity (15 mg/ml) against Tubifex tubifex.

              The petroleum ether and ethanolic extracts of whole plant of Amaranthus spinosus Linn. were tested for anti‐inflammatory activity at the dosed of 250,500 and 750 mg/kg body weight.The extract produced dose dependent and significant inhibition of carrageenan induced paw oedema. The exhibited anti‐inflammatory activity of this plant was comparable with the standard drug Ibuprofen.The presence of steroids, alkaloids & flavonoids in the extracts may be contributory to its antiinflammatory activity.



              Amorphophallus Paeoniifolius Tuber


              Evaluation of anthemintic activity of the methanolic extract of Amorphophallus paeoniifolius tuber


              Methanolic extracts of the tuber of Amorphophallus paeoniifolius were investigated for its antihelmintic activity against Pheretima posthuma and Tubifex tubifex. The extract with the concentrations of 25, 50 and 100 mg/ml were tested in the bioassay, which involved determination of time of paralysis and time of death of the worms. The extract exhibited significant antihelmintic activity at highest concentration of 100 mg/ml. Piperazine citrate (10 mg/ml) was included as standard reference and distilled water as control. The extracts were found not only to paralyze (Vermifuge) but also to kill the earthworms (Vermicidal).



              Anaphalis Lawii


              Elemental analysis, anticariogenic, insecticidal and anthelmintic activity of Anaphalis lawii (Hook.f.) Gamble


              The present study aimed at determining elemental composition, anticariogenic, insecticidal and anthelmintic efficacy of Anaphalis lawii (Hook.f) Gamble (Asteraceae). Elemental composition of powdered leaf material was estimated by ICP-OES technique after microwave digestion. Anticariogenic activity of methanol extract was tested against 13 clinical isolates of Streptococcus mutans by Agar well diffusion method. insecticidal activity of methanol extract in terms of larvicidal efficacy was tested against second instar larvae of Aedes aegypti. anthelmintic activity of methanol extract was determined using adult Indian earthworm Pheretima posthuma. The contents of potassium and iron were high among macro and microelements respectively. The leaf extract showed dose dependent inhibition of all S. mutans. The larvicidal effect of the extract was found to be dose dependent and the mortality of larvae of A. aegypti was recorded as 100% at 1.5mg/ml and higher concentrations of extract. The leaf extract resulted in paralysis and death of worms in a dose dependent manner.

              The A. lawii leaf can be used as a source of various elements which play key role in the normal physiology of an individual. The plant can be used to treat dental caries and Worm infections and to control insect vectors. The bioactivities of extract observed in this study might be related to the presence of phytochemicals. Further studies concerning fractionation of leaf extract and bioactivities of fractions are to be carried out.



              Annona Reticulata


              anthelmintic activity of Annona reticulata leaves


              Leaves of Annona reticulata L. (Annonaceae) were dried, powdered and extracted using ethanol and further fractionated using petroleum ether, chloroform, ethyl acetate, and ethanol. anthelmintic activity of these various fractions was evaluated on adult Indian earthworms Pherentima posthuma. Results showed that ethanol extract took less time to cause paralysis of the earthworms. In order to pinpoint the active constituent the ethanol fraction was further fractionated using column chromatography to yield fraction 1, 2, and 3 and again screened for activity.

              Results showed that the fraction 2 is most potent followed by fraction 3 and then fraction 1. It can be concluded that anthelmintic activity of the leaves of A. reticulata is due to compound present in fraction 2 of ethanol fraction of total ethanol extract.



              Argemone Mexicana


              Argemone mexicana: Chemical and pharmacological aspects


              The Papaveraceae, informally known as the poppy family, are an ethnopharmacologically important family of 44 genera and approximately 760 species of flowering plants. The present work offers a review addressing the detailed chemistry and pharmacology of Argemone mexicana L. regarded as one of the most significant plant species in traditional system of medicine. The plant is used in different parts of the world for the treatment of several ailments including tumors, warts, skin diseases, inflammations, rheumatism, jaundice, leprosy, microbial infections, and malaria. Interestingly, the plant is the source of a diverse kind of chemical constituents although alkaloids are mostly abundant.

              Beyond pharmaceutical efficacies, certain plant parts also show toxic effects as well. Hence, an up-to-date information on the chemical and pharmacological knowledge on this plant may be helpful to guide researchers anticipating to undertake further investigations in these directions. The present review covers literature up to 2012 and enlists 111 references.



              Arisaema Lobatum


              anthelmintic activity of Arisaema franchetianum and Arisaema lobatum essential oils against Haemonchus contortus


              Arisaema franchetianum and Arisaema lobatum are two perennial plants native to China. Arisaema franchetianum is universally used to promote the subsidence of induration and swelling, quicken blood and relieve pains, and kill intestinal parasites in humans and animals. Arisaema lobatum is used to treat malaria, intestinal parasites, and snake and insect bites in humans and animals. The aim of this study was to determine the composition of the essential oils from Arisaema franchetianum and Arisaema lobatum and evaluate the anthelmintic effect against Haemonchus contortus.



              Aristolochia Indica


              In Vitro Study on anthelmintic Activity of Aristolochia indica and A. tagala Roots


              The present study has been undertaken to screen the anthelmintic potential of aqueous root extracts of Aristolochia indica Linn. and A. tagala Cham. against adult Indian earthworm Pheritima posthuma and round worms Ascaridia galli. Different concentrations of the extracts ranging from 2-8 mg/mL were screened. Piperazine citrate was used as reference standard. Extract of A. tagala was found to be more potent and effective at the dose level of 2 mg/mL compared to the extract of A. indica. Extracts showed dose dependant activity. The study reports that the plants A. indica and A. tagala roots possess potent anthelmintic properties.



              Artocarpus Lakoocha


              IN VITRO anthelmintic ACTIVITY OF SEED EXTRACT OF ARTOCARPUS LAKOOCHA ROXB


              The ethanol extract of seeds of Artocarpus lakoocha Roxb. (ESAL) was investigated for anthelmintic activity using earthworms (Pheretima posthuma), tapeworms (Raillietina spiralis) and roundworms (Ascaridia galli). Various concentrations (10-50 mg/ml) of seed extract was tested in the bioassay. Piperazine citrate (10 mg/ml) was used as reference standard drug whereas DMF (Di-methyl formamide) as control. Determination of paralysis time and death time of the worms were recorded. Extract exhibited significant anthelmintic activity at highest concentration of 50 mg/ml. The result shows that seed extract possesses vermicidal activity and found to be effective as an anthelmintic. The anthelmintic activity of ethanol extract of the seeds of Artocarpus lakoocha has therefore been demonstrated for the first time.



              Asparagus Racemosus


              Phytochemical Screening and In Vitro Comparative Study ofanthelmintic Activity of Asparagus racemosus and Cucurbita maxima


              This study involves phytochemical screening and comparision of theIn-Vitro anthelmintic Activity of Asparagus racemosus and Cucurbitamaxima using adult Indian earthworm model.Methods : phytochemical investigation was done and anthelminthic assay was evaluated for both ethanolicand aqueous extracts of 100 and 200 mg /ml of both Asparagus racemosus and Cucurbita maxima by comparing parameters of time taken for paralysis andtime taken for death.Key findings : anthelminthic assay revealed that extracts of both plants showed significant anthelminthic activity .Dose dependentactivity was observed in Ethanolic and Aqueous extracts of both plants but Ethanolic root extract of Asparagus racemosus shows activity comparable withthat of standard Albendazole ( 20 mg / ml ) and better activity in comparision with cucurbita maxima.Conclusions : The results revealed that anthelminticactivity of Asparagus racemosus Ethanolic root extract was closely related to the Albendazole.



              Asuro (Justicia Adhatoda)


              anthelmintic ACTIVITY OF ASURO (Justicia adhatoda) AGAINST GASTROintestinal nematodes OF GOATS


              The anthelmintic activity of Justicia adhatoda leaves was evaluated against the gastrointestinal nematodes (GINs) of goats through fecal egg count reduction test in vivo & egg hatch inhibition test in vitro from July 2013 to October 2013. For in vivo experiment, goats were randomly divided into five treatment groups. Among five treatment groups, positive and negative control group received Albendazole (ABZ) and No Treatment (NT) respectively; remaining three groups received different doses of methanol extract of J. adhatoda as T1 : 100 mg/kg body weight, T2 : 150 mg/kg body weight and T3 : 200 mg/kg body weight. Fecal egg count reduction (FECR) was calculated on day 0, 7, 14 & 21. Data were analyzed by using SPSS software, Least significant Difference (LSD), least square procedure using Harvey (1990) and DMRT. The in vivo result indicated that T2 and T3 reduced EPG significantly (p<0.01) compared to NT on day 14 and day 21 post treatment. The highest reduction rate on FEC of treated group was 58.6% on 21 day post treatment at dose rate 200mg/kg body weight. For in vitro test different doses of methanol extract (50 mg/ml, 25 mg/ml, 12 mg/ml and 6 mg/ml) was used. In vitro test result indicated that egg hatch inhibition at 50 mg/ml was highest among the different treatment of methanol extract of J. adhatoda. Methanol extract showed dose dependent inhibition in in vitro egg hatch assay.

              The findings suggested that J. adhatoda leaf could be a promising alternative to commercially available synthetic anthelmintics. However further investigations to identify the biologically active compound to establish the dose rate and to understand the pharmacokinetics and level of toxicity are required to establish this plant as herbal anthelmintics.



              Averrhoea Carambola


              antimicrobial activity of Averrhoa carambola L. leaf extract and its Phytochemical Analysis


              Growing drug resistance of microorganisms and adverse result of antibiotic usage have led to the search for alternative medicines from nature. Many plants have been exploited to cure infectious diseases from time immemorial. The current investigation deals with the evaluation of the antimicrobial activity, preliminary phytochemical screening and Thin Layer Chromatography (TLC) analysis of Averrhoa carambola L. leaf extracts. The antimicrobial activity was done by agar well diffusion method. Preliminary phytochemical screening was done by standard method. Plant extracts were found active against all the bacteria. Aqueous extract of A. carambola leaves showed higher antibacterial activity as compared with methanol and petroleum ether extract at the concentration of 25 mg/ml. Highest antibacterial activity was exhibited by the aqueous extract against Salmonella typhi (29.23±0.02 mm). The highest antifungal potential was exhibited by the methanol extract against Candida krusei (21.09±0.08 mm). Plant extracts were observed to be active against all the fungal pathogens except Aspergillus niger.

              Minimum inhibitory concentration (MIC) was determined using serial dilution method. The preliminary phytochemical analysis revealed the presence of alkaloids, tannins and polyphenolic compounds, flavonoids, phytosterol, proteins and amino acids, carbohydrates, glycosides etc. while saponins was absent in both the extract. The petroleum ether and methanolic extracts were subjected to TLC study and the Rf value of different spots was observed in various solvent systems. The outcomes of the present study indicate that A. carambola leaf is endowed with potential antimicrobial activity and hold promise for development of pharmaceuticals and antimicrobial agents in future.



              Baccaurea Ramiflora


              STUDY OF anthelmintic AND insecticidal ACTIVITY OF BACCAUREARAMIFLORAPLANT IN DIFFERENT EXTRACTS


              Baccaurea ramiflora Lour., syn. Baccaurea sapida (Roxb.) Muell. Arg. known as Burmese grapes belongs to the family Euphorbiaceae and is native to Southeast Asia. The observance on Baccaurea ramiflora leads that this plant is utilized as an antichloristic and anodyne against rheumatoid arthritis, abscesses, cellulitis and treat injuries. This plant also has anti-diarrheal, analgesic, anti-inflammatory, neuro-pharmacological, antioxidant and cytotoxic activities. Therefore, the present study was conducted to evaluate anthelmintic and insecticidal activities of different extract of Baccaurea ramiflora. For anthelmintic activity, Pheretima posthuma was selected as test animal while 25, 50, 100 mg/ml concentrations of samples weretested in the bioassay, from which time of paralysis and time of death of worms were estimated.

              Evaluation of insecticidal activity was performed against Sitophilus oryzae to calculate the mortality rate. Extracts of MEE, EE, ACE, CHE, PEE, and NHE were for the activity determination. In the anthelmintic study, extract exhibited its activity in a dose-dependent manner showing higher the concentration, faster the effect. Extract of EE, PEE, CHE and MEE in case of 100 mg/ml concentration exhibited its paralytic effect followed by death within a short period among which ACE extract gave the best result which only took approx. 22.33 min to show paralytic effect and 33 min for death occurrence. In the insecticidal activity, all extracts showed potent activity with 100% mortality of rice insects Sitophilus oryzae at 80 mg/ml concentration in 24 h, proving the activity also followed a dose-dependent pattern. 80% mortality rate observed in case of 80 mg/ml concentration of ACE extract in 12 h whereas MEE, CHE, and NHE extracts showed 60% and PEE showed 70% mortality rate in treated rice insects.

              The present study shows that all the extracts of Baccaurea ramiflora are found to possess anthelmintic and insecticidal activities.



              Baliospermum Montanum Muell


              In Vitro anthelmintic Activity of Baliospermum montanum Muell. Arg roots


              Alcohol and aqueous extracts from the roots of Baliospermum montanum Muell. Arg were investigated for their anthelmintic activity against Pheretima posthuma and Ascardia galli. Various concentrations (10-100 mg/ml) of each extract were tested in the bioassay, which involved determination of time of paralysis and time of death of the worms. Both the extracts exhibited significant anthelmintic activity at highest concentration of 100 mg/ml. Piperazine citrate (10 mg/ml) was included as standard reference and distilled water as control.



              Biophytum Petersianum


              In vitro potential anthelmintic activity of Biophytum petersianum on Haemonchus contortus


              Haemonchus contortus is a major problem in small ruminants in Indonesia. The frequent use of the anthelmintic drugs has given rise to drug-resistant populations which increase the need for new anthelminthic compounds, particularly from endemic plants. This study evaluated the in vitro effects of Biophytum petersianum crude aqueous extract (BAE) as an anthelmintic compound against H. contortus adult Worm isolated from goats.



              Bougainvillea Glabra


              Evaluation of anthelmintic Activity of bougainvillea glabra Leaves


              The present study was designed to explore the anthelmintic activity of different extracts of leaves of Bougainvillea glabra using petroleum ether, ethyl acetate methanol and water as solvents. Various concentrations (25 and 50mg/ml) of all the extracts were tested, which involved determination of time of paralysis and time of death of the worms. It was compared with Albendazole as standard reference and normal saline as control. The study indicated the potential usefulness of Manihot esculenta against earthworm infections.



              Bridelia Ferruginae


              Evaluation of anthelmintic activity of the stem bark extract and chemical constituents of Bridelia ferruginae (Benth) Euphorbiaceae


              anthelmintic properties of the stem bark extract and compounds isolated from Bridelia ferruginae were investigated. In relation to the traditional use of B. ferruginae against gastro-intestinal infections, bioactivity-guided fractionations of the CHCl3- and CH2Cl2- soluble fractions of the 80% MeOH extract from the stem barks of B. ferruginae yielded two known triterpenoids: betuline (1), glucoside of betulinic acid (2) and other two known flavonoids: quercetin (3) and kaempferol (4). Structures of compounds 1 to 4 were elucidated by spectroscopic studies and comparison with related compounds in literature. The time of paralysis and death of the parasitic worms: Fasciola gigantical (liver fluke), Taenia solium (tape Worm) and Pheritima posthuma (earthworm, Annelid) were determined at 25, 50, 80 and 100 mg/ml. The stem barks extract of B. ferruginae and isolated compounds demonstrated concentration-dependent anthelmintic potencies against parasitic worms assayed. Structural-activity relationship is explained.



              Caesalpinia Pulcherrima


              INVESTIGATION OFIN VITROanthelmintic ACTIVITY OFCAESALPINIA PULCHERRIMALEAVES


              The crude Pet. Ether, dichloromethane, ethyl acetate and ethanol extracts ofCaesalpinia pulcherrima (Caesalpiniaceae) leafwere investigated for in-vitro anthelmintic activity on the Indian adult earthworms Eisenia foetida. The various concentrations(20, 40, 60mg/ml) of extracts were tested in-vitro for anthelmintic potency by determination of time of paralysis and time ofdeath of Worm. The leaf extracts of Caesalpinia pulcherrima exhibited a dose dependant inhibition of spontaneous motility(Paralysis) of earthworms. Piperazine citrate (10mg/ml) was used as standard drug and distilled water containing 2% tween 80was as control. All the extracts were found to be exhibited dose dependent anthelmintic activity.The decreasing order ofactivity of extracts was ethyl acetate, ethanol, dichloromethane and petroleum ether extracts. Thus the present studydemonstrates that the leaf of Caesalpinia pulcherrima could be categorized under anthelmintic herbal drugs and could beused as a potent key ingredient of herbal formulation.



              Cajanus Cajan


              anthelmintic activity of leaves of Cajanus cajan Linn. on Indian earthworm


              Modern synthetic medicines are very effective in curing diseases but also cause a number of side effects. parasites are of concern to the medical field for centuries and the helminthes considered causing considerable problems for human beings and animals. To investigate the anthelmintic activity of Cajanus cajan. Dried powder was taken and subjected to successive extraction with petroleum ether, ethyl acetate, ethanol and water in soxhlet apparatus. The anthelmintic activity was evaluated on adult Indian earthworm pheritima posthuma due to its anatomical and physiological resemblance with the intestinal roundWorm parasites of human beings. The earthworms were divided in nine groups, each group consisting of six earthworms of approximately equal size were released into 50 ml of the extract. Albendazole using as a standard drug, both alcoholic and aqueous extracts has shown significant anthelmintic activity compared to standard drug albendazole.

              The data reveals that the aqueous extract shown anthelmintic activity for paralyzing as well as death of Indian earthworm pheritima posthuma at 5mg concentration is of long duration of time, whereas the ethanolic extract showed paralysis and death at similar concentration in short time duration. The leaves of Cajanus Cajan Linn. Ethanolic extract has given potent anthelmintic activity as compared to standard drug, thus it is evident that leaves of this plant of daily use is useful for anthelmintic activity and it is concluded that further research is possible for finding active compound responsible for this activity.



              Camellia Sinensis


              In vitro anthelmintic Activity of Ethanolic Extracts of Camellia sinensis L. and Albizia lebbeck L. against Haemonchus contortus


              helminths are familiar as a major problem to livestock production. helminths cause multiple infections in animals of significant economic importance. Haemonchus contortus, (helminths Worm), is highly infectious parasite of small ruminants, and is a major cause of diseases and significant mortality in various cattle, sheep, deer, buffalo and goat, etc. Various synthetic anthelmintics have been used, on wide scale, to control the helminths infections.But the parasite worms have developed multiple resistances against the synthetic anthelmintics. Hence, various biological controls, vaccines and local medicinal plants are being explored to control the parasitic worms.
              The aim of this study was to evaluate the anthelmintic potential of two local plants, Albizia lebbeck L. and Camellia sinensis L against H. contortus using Adult Motility Assay (AMA). Crude Ethanolic Extracts (CEE)of dried leaves of A. lebbeck L. and whole plant of C. sinensis L. were prepared by cold maceration method. The anthelmintic activity was analyzed by adult motility assay (AMA). Levamisole was used as positive control to compare the efficacy of CEE of both plants. Adult worms were treated with different concentrations i.e., 2, 4, 6 and 8 mg/ml of ethanolic extract and motility of the worms was examined after every two to eight hours. Both A. lebbeck and C. sinensis exhibited 88% and 95% mortality at 6 & 8 mg/ml after 8 hrs of treatment. In conclusion, the ethanolic extracts of A. lebbeck L. and C. sinensis L. showed in vitro anthelmintic activity against H. contortus at concentrations tested.


              Canarium Schweinfurthii


              In Vitro anthelmintic Activity of Mucuna pruriens (DC) and Canarium schweinfurthii (Engl) on Ascaris suum


              The in vitro anthelmintic evaluation of the crude extracts and solvent partitions on Pheretima post-huma and Ascarissuum (eggs and L2 stage) respectively showed significant results at the same concentration (10, 20, 40 and 80 mg/ml). This study provides a clear evidence for usage of Mucuna pruriens and Canarium schweinfurthii as an anthelmintic.

              The most potent ovicidal partition of C. schweinfurthii (Engl) leaves and bark and leaves of M. pruriens (DC) is hexane (100.00 ± 0.33), chloroform (98.20 ± 0.12) and chloroform (98.70 ± 0.88) partitioned crude respectively at 80 mg/ml while the most potent larvicidal partition is hexane (0.06%), chloroform (0.1%) and chloroform (0.2%). The active compounds are predominantly in the non-polar solvent which supports the te-gumental diffusing activity of the compounds.



              Capparis Spinosa


              potential anthelmintic effect of Capparis spinosa (Capparidaceae) as related to its polyphenolic content and antioxidant activity


              Capparis spinosa is cultivated for several proprieties and the different parts of the plant (flower buds, fruits, leaf and seeds) have been employed in drugs, foods and cosmetics. This study aimed to explore the antioxidant potential effect and to assess the anthelmintic efficacy of an aqueous extract of Capparis spinosa. In vitro antioxidant activity of aqueous extracts from the fresh leaves and flower buds of C. spinosa was measured by determining free radical-scavenging activity against DPPH and ABTS radical cations. In vitro anthelmintic activities against eggs and adult worms of Haemonchus contortus from sheep were investigated in comparison to albendazole. DPPH and ABTS activities of both aqueous extracts increased in a dose dependent manner. The IC50 values of aqueous extracts from fresh leaves, flowers buds and ascorbic acid in the DPPH radical scavenging assay were 101.40; 70.40 and 57.56 μg/ml, respectively.

              The IC50 values of aqueous extracts fresh leaves, flowers buds and ascorbic acid in the ABTS radical scavenging assay were 110; 87.89 and 58.17 μg/ml, respectively. Both plant extracts showed ovicidal activity at all tested concentrations. The aqueous extract from flower buds (IC50 = 2.76 mg/ml) showed higher inhibitory effects (P < 0.05) than aqueous extract from leaves (IC50 = 8.54 mg/ml) in the egg hatching assay. The aqueous extract from flower buds inhibited more worms than the aqueous extract from leaves at all tested concentrations. After 6 h of exposure, the highest tested concentrations of aqueous extracts from flower buds and leaves induced 100 and 41.66% inhibition of motility, respectively.

              These results show for the first time that C. spinosa possesses in vitro anthelmintic properties which may be related to its high content of phenolic compounds such as flavonoids and tannins.



              Carica Papaya


              Evaluation of anthelmintic activity of ethanolic extracts of Carica papaya leaves using Paramphistomum cervi and Haemonchus contortus


              The aim of this present study is to evaluate the anthelmintic activity of leaves extracts of Carica papaya using Paramphistomum cervi and Haemonchus contortus as the test worms. A range of concentrations (100, 50 and 25%) of ethanolic extracts of C. papaya were tested to assay the procedure. This is mainly applied for the determination of time of death (D) and time of paralysis (P) of the tested worms. After the analysis, it was shown that for the H. contortus at 100% concentration, the paralysis occurred within the shortest time (P=24.5 min) and death came at the lowest possible time (D=56 min). The time of death and paralysis increased at 50% (D=64 min and P=28 min) and 25% concentration (D=74 min and P=34 min), respectively compared to the Piperazine citrate (P= 24 min and D= 54) at concentration of 10 mg/ml. Here, distilled water is as a control solution.

              The results of this study revealed that the ethanolic extracts of the leaves of the C. papaya expressed a demonstrated paralysis significantly, and also responsible for the death of P. cervi and H. contortus especially at the higher concentration (100%) compared to the standard reference of Piperazine citrate. Therefore, from the results it is declared that the ethanolic extracts of the leaves of C. papaya showed a great anthelmintic activity against P. cervi and H. contortus worms. Hence, the present research work signifies that the leaf of C. papaya has a major anthelmintic activity and also can be used as a potent drug for its low cost and availability.



              Carum Copticum


              anthelmintic activity of Carum copticum seeds against gastro-intestinal nematodes of sheep. J Animal Plant Sci 16(1-2):34-37


              This paper describes in-vivo anthelmintic activity of Carum copticum in comparison with levamisole. For in-vivo studies, the seeds of Carum copticum was administered as crude poweder (CP), Crude equeous extract (CAE) and crude methanol extract (CME) at graded doses (1,2 and 3 g kg -1 body weight (b.w.) to sheep naturally infected with mixed species of gastrointestinal nematodes. Maximum reduction (79.1%) in eggs per gram (EPG) of faeces was recorded on day 14 post treatment in sheep treated with Carum copticum CP at 3g kg -1 b.w.

              It was found that although, carum copticum seeds possesses anthelmintic activity against nematodes, it is not comparable with levamisole (99.2% reduction in EPG) at any of the doses tried in this study. However, increase in EPG reduction was noted with an increase in the dose of Carum copticum administered as CP, CAE and CME. The graded dose response suggested further studies on a larger number of animals on higher doses than those used in the current study.



              Cassia Fistula


              Assessment of anthelmintic Activity of Cassia fistula L


              There is increasing demand of herbal medicine worldwide, a great majority of medicinal plant were assessing for their efficacy. World health organization estimated that two billion of people harbor parasitic Worm infection. In view of this, attempts have been mad to study anthelmintic activity of Cassia fistula L fruit pulp and seeds. Both extracts were found not only paralyzed also killed the Pheritoma posthuma. The concentration of 100 mg/ml of extracts caused more significant paralysis as well as death of worms as compared to reference drug Piperazine citrate at dose of 10 mg/ml



              Cassia Siamea Lamk


              Exploration of anthelmintic activity of Cassia spp. extracts on gastrointestinal nematodes of sheep


              This study aimed to explore the phytochemical constituents and anthelmintic activities of four Cassia spp. leaves against Haemonchus contortus. Materials and methods: The extracts were prepared from four species of Cassia spp. (C. siamea, C. fistula, C. surattensis, and C. spectabilis). Phytochemical screening of the extract was done based on the Harborne method. Evaluation of the anthelmintic activities against H. contortus was done in vitro using infective larvae (L3) migration inhibition assay (LMIA). Measurement of larvae migrating was conducted through a nylon filter with a pore size of 20 μm. The doses of Cassia spp. extract implemented were 25, 50, 100, and 200 mg/ml. Results: tannins, alkaloids, phenol hydroquinone, flavonoids, steroids, triterpenoids, and saponins were present in all the extracts, whereas alkaloids were absent in C. fistula.  

              Size

              100g, 200g, 800g

              Concentration

              200:1, 20:1

              14 reviews for STOMACH RESET COMBO (Fix Virtually All Gastrointestinal Problems) Featuring: PURGE/ PARASLAYER/ HELICO

              1. Rated 5 out of 5

                Joyce Modie (verified owner) – May 16, 2021

                I have been Gavin’s silent Facebook follower for sometime. I was not really following his blends reviews much much until recently when our family health started declining. Over 2 months ago my husband started having really bad smell from his mouth. He couldn’t smell it first but those around him could. Eventually it got worse and he had to put on a mask all the time. He tried brushing and cleansing often. Taking mint, flossing and mouth washes were his close friends but still no improvement. This took his confidence and affected his everyday life. My good morning kiss stopped. When purge was released I spoke to Gavin about my husband’s condition and he lovingly advised us to get Stomach Reset Combo. We ordered same night and 6 days later we received our beautiful packaged life changing combo. Mind you we are all the way in Southern Africa, Botswana and to receive within 6 days as Gavin promised was a miracle. Less than 2 weeks ago my husband took the combo on a day he was not working. The purge was intense for him. He was in so much pain throughout. He was purging one end for hours then later he started vomiting. Mind you he is one man who never tries anything to cleanse his system. I was shocked he jumped in and paid for the combo immediately. The stomach cramps would intensify and get better after each vomit. A lot of mucus was coming out through his mouth. He stayed up all night still at it until early morning when he got a chance to rest. Pains had vanished completely by then. Smell was gone immediately, just like that. We were shocked and decided to keep checking daily for a couple more days and the smell is completely gone with just one cleanse. Just one, nothing more. I now get my morning kiss without any “morning breath” challenge. We are forever grateful to Gavin and the team. Thank you for saving us the shame and worry. We’re new to blends and still trying many more. Currently on Vital Force and we are looking forward to the results because we are already feeling it. We recommend Stomach Reset Combo for any gastrointestinal issue for healing and normal life. Once again thank you Gavin for saving lives and loving people selflessly.

              2. Rated 5 out of 5

                lewis (verified owner) – May 19, 2021

                this combo set completely fixed my IBS. without even having any purge I started taking helico and paraslayer in kefir morning and night within a week all of my IBS symptoms had disappeared. sorry to be graphic but I hadn’t had a solid stool in over a year and doctors would just fod me off with IBS medication. these herbs along side the kefir have really sorted all of my symptoms and within a week!!

                I then felt I was ready to purge… I took 1/4 teaspoon in grapefruit juice and quickly found out I wasn’t ready. that stuff is so powerful I was on the toilet for over and hour.

                I have purchased other combo sets before and can hanoestly say they are life changing. trinity, nebula and thermo completely eradicated my anxiety last year (alongside fasting and excercise). I am I the best shape I have been in my life!

              3. Rated 5 out of 5

                Ndiri – July 17, 2021

                Omg , big shoutout to the amazing Gavin who took his time out answering questions ,hes a kind man.i lost 15 pounds on purge less than 3 days.I love that i embrace this journey, and this purge taught me how to eat right,no more midnight snacks ,no more fatigue in the middle of day.

                This the Benefit of Purge for me
                help to boost my immune system,
                – Keeps me focused
                – Improves my mood
                – Gives me better overall energy
                – supports me weight loss etc
                Purge is my life.

              4. Rated 5 out of 5

                mkendell (verified owner) – July 20, 2021

                I have using Interstellar Blends for two years now. I have almost every blend, plus the Pine Pollen and Matcha, and my husband and I take (we rotate them) them daily. We use them as preventative medicine, We use them AS medicine. We use them for cellular health, anti-aging, energy and vitality. We have pretty much dived into the studies and literature on these amazing blends, and we are so grateful to Gavin for providing a healing path for literally any ailment or condition. My husband is a doctor, and he is all-in on the science and results we have experienced. I’m 50. I don’t look 50. I have energy, I’m never sick, and it’s due to the blends, and some time-restricted eating. I also try to stay on a pretty healthy, low-sugar, active lifestyle eating, but trust me, that doesn’t always happen. My vitality is not due to food and exercise alone. We have so many blend favorites but if I have to call out a few, Trinity, Nebula, Peel, Spice and Shilajit are in constant rotation. The newest blends are pretty much blowing my mind. The Stomach Reset Combo… wow.. Paraslayer and Helico have completely rid me of stomach ailments, and along with Purge (!!!!! this stuff is NEXT LEVEL) without getting too TMI, let’s just say that Purge does what the name states. The detoxing purge is real. Treat the Purge with respect and follow the dosing guidelines! We are forever customers and have started our kids on the some of the blends, as well. Do yourself and your health a favor and get yourself a sample pack. Or whatever you are able to start out with. Do some research, (Interstellar is always happy to answer questions and guide you to best blend choice), and get these blends.

              5. Rated 5 out of 5

                Katharina FInkmann (verified owner) – July 20, 2021

                Dear Gavin,
                First Thank you so much. I have been taking the blends for a few years in the hopes of healing my Eczema. It was relieved, not completely healed. I have been on the Paraslayer and Helico for the past couple of weeks. The Eczema is completely healed. Gone. Also I am highly allergic to Wasp Stings (and many other things) A couple of days ago I arrived home, grabbed the storm door and got stung by a wasp on my pointer finger. Besides it hurting, I thought for sure I would have to go to the Hospital. I went in, put alcohol on it and a band aide and waited. No sickness, no throwing up, no swelling. I give credit to the blends. Trying Purge on my next week off in August. Thank you so much.xoxo

              6. Rated 5 out of 5

                Tracy McCulloch – August 19, 2021

                Over the past few years, I made a decision to heal myself from the inside. I basically felt I was just existing. Everyone else around me saw the sports coach, holistic therapist and all I saw was the broken woman from childhood abuse. I set goals and have always been a high achiever, but it always took a dip due to emotional stress, anxiety and eventually weight gain. So I was on a rollercoaster. I had been following Gavin on Facebook for a few years and finally plucked up the courage to find out more about Interstellar Blends. Firstly as always, my first goal was to lose weight quickly as it was prohibiting me from doing all the things I love. My self-esteem was low and I was perimenopausal so after reading the testimonials and being directed to the support group, I was sold. So many amazing results, advice, guidance and support. It was a no-brainer. and PURGE was ordered. I have tried many things in my time to lose weight quickly and always thought dry fasting was the only answer, which is amazing but very difficult to adhere to regularly. Purge had me dropping over 2kg the first day and not only that, it highlighted major stomach issues. To enable continuing with purge without feeling like vomiting, I was advised if I still felt like this after a week to use the stomach reset protocol i.e., Helico and Paraslayer (to rid me of the parasites that were in my gut, which most people have and don’t realise). So here I am 2 weeks down the line taking PURGE with no adverse side effects and happy as can be seeing the weight fall off (even whilst having a light meal yesterday I lost 1.5kg). Nothing compares to ‘PURGE’.

                With my orders, Gavin generously gives samples for free and my first one was Supernova. This blend gives you energy (all day) without the feeling of irritation or worry that your heart is popping out of your chest. I love this blend and will never be without it. I am hooked on the blends because they are ‘life-changing. This being the case I ordered the July Special with 19 samples. Life was becoming so much more fun. In particular, one blend that stood out for me was ‘Trinity’., another blend I will not do without, ever. It gave me back my life with more confidence, completely eradicated my anxiety and just gave me that happy, glowing feeling every single day. Furthermore, the samples allowed me to experiment with my families ailments. Firstly, my daughter’s eczema which after only 2 days is less noticeable, with less itching and my partner’s legs and hands aches and pains from heart surgery also eased in such a short space of time with ‘PEEL and SPICE’. I am so grateful for the impact these blends have had on our well-being as a family.

                In conclusion, these products enhance every aspect of your life and provide what we are all looking for in life, Happy Days. Thank you, Gavin.

                Tracy McCulloch

              7. Rated 5 out of 5

                Jennifer Parra – August 27, 2021

                This amazing combo (thank you Gavin!) has giving me my life back! I’ve been suffering from a very stubborn IBS flare up for probably over a year and nothing was helping. Everything I ate hurt me which was frustrating and exhausting to say the least. I always had to plan my meals very carefully especially when they revolved around a social event which was also very annoying and not always easy. Needless to say, I was miserable! Then, my sister told about this combo and how it was helping a lot of people with similar issues and decided to give it a shot! I’m SOOO glad I did! I’m beyond grateful for these blends, Gavin and my sister for suggesting that I try them! I decided to do two rounds with this combo (minus purge both times) and now I just keep feeling better and better and back to normal as I can now eat and enjoy food again without having to constantly worry if I’ll have to spend all night in the bathroom (sorry TMI) or spend days at a time in pain.

                So in conclusion, if you are like me and are suffering from stomach issues please don’t hesitate to try these blends and reset your stomach ASAP!! You will NOT be disappointed and, like me, you can start to enjoy life again!!

                Thanks again Gavin!

                ~ Jennifer Parra

              8. Rated 5 out of 5

                India Houston – December 29, 2021

                The Stomach Reset combo is unlike any other! Purge specifically has been a lifechanger for me. My mother claims my intestinal issues may have derived from being premature and the medicines given at birth…I say it’s from the SAD diet given growing up (McDonald’s and other crap); nevertheless, I suffered chronic constipation all my life. Never able to “go” without some type of laxative. Had barium treatments but no issue was ever seen. (Of course not!) Sluggish insides…and I felt sluggish.

                Now when Gavin mentioned the release of Purge earlier this year, I knew for a FACT that this product was designed for me and opted for the Stomach Reset combo because I knew I needed an entire gastric reset! Paraslayer and Helico were much needed added bonuses. Especially since without a doubt I knew that I was infested with Parasites. Let me say that my first time trying PURGE is an experience. Do not underestimate it! Follow Gavin’s instructions. Keep a fresh, wet, warm rag (that you are willing to part with) or some Dude Wipes because your butt will need it!!! Stay by the toilet & do not have any plans especially if you are doing a Challenge.

                Since taking all three, specifically PURGE, the brain fog that has plagued me for so long is lifted. My stomach pudge has minimized. The focus and clarity is amazing. Being able to go #2 and feeling clean internally, it’s indescribable. I cannot see myself not having these products. Name a better trio?! I can’t!

              9. Rated 5 out of 5

                Valerie Cade (verified owner) – January 9, 2022

                Imagine a lady, fairly healthy, age 82 who all of a sudden had diarrhea and was losing weight like crazy due to eating a bad steak; for six weeks ~ just shy of going to the hospital when she then tried Gavin’s Stomach Re-Set Combo. After one week of taking everything as directed, even upping purge near the end, she turned the corner and was able to rid herself of the pain and diarrhea. To quote her: “I don’t think I’d have made it to my 83rd without this Stomach Re-Set!” We are so thankful that we could quickly get this to her and in fact, I’ve made the decision to have this on hand should anyone else be in the same boat (or is that toilet bowl :)! Thank you Gavin!

              10. Rated 5 out of 5

                Amber Wippel (verified owner) – February 1, 2022

                This one is a long story that I’ll try to keep short. About two years ago my husband starting complaining of pains in his stomach. Around the same time I thought I had a UTI. My husband went to the doctor and they told him his back was hurt and he needed PT. I was told that I needed antibiotics, which obviously never cleared up my issue. Our health kept declining and I struggled to keep myself above water. Trying to keep myself on a schedule, along with a hard headed man wasn’t there easiest of tasks. Looking back, we made mistakes.
                Fast forward to about a month ago. I had done a lot of research to nail down our issues and began to think that we had the same issue, but it manifested differently. I knew it was either yeast or parasites. 🥴 I had helico from a previous order and stated my case to my husband. He was tired, so he gave in quickly and got on board. Within two days I noticed white specs in my feces. (I know. TMI) I was low key excited to see that because it meant I was on to something. 🤷🏼‍♀️ Two years of pain, this girl was exhausted. I immediately ordered the entire bundle because I only had two weeks for each of us left in the first batch.
                We are on week 3 now. Eating within a 3-4 hour window, helico, paraslayer and purging every few days to once a week.
                I swear to everyone, our pain is completely gone. If you’ve been diagnosed with IC, fatty liver, or whatever else they think sounds fun to say, do your own research. Clean your gut. I will literally do 2-3 cleanses a year, along with take this daily. This will NEVER EVER happen again. Cheers everyone and good luck on your healing journeys.

              11. Rated 5 out of 5

                Geraldine (verified owner) – April 24, 2022

                I’d been suffering with severe pain in my left side, lower ribs, for about two years sporadically.
                I had also developed gastritis and then inflammation along my hypochondrium area.

                I was in severe pain and I lost 21lbs due to my stomach hurting if I ate too much. My appetite diminished dramatically and I began to feel weak and I didn’t want to move very much.
                I have to admit that I was in a state of fear at this time.. I was definitely thinking the worst case scenario and of course that doesn’t help.

                Although I am a life long ‘avoider’ of Doctors, I opted to go for a diagnosis.
                The Doctor decided it was probably a ‘peptic ulcer’ which had also traveled down into the duodenum. She took bloods and also requested a hospital appointment to check stomach, spleen, pancreas and liver. This was because I have no other symptoms like heartburn or coughing.

                Anyway, I decided on my own treatment. I contacted Gavin who suggested the stomach combo along with the ‘liver sample.’ This was about two months ago.

                I was so relieved to receive the package and start on the treatment.
                I started with Hyliobactor, paraslayer and the liver sample. I admit, I was apprehensive about taking Purge after reading the comments!! Lol!

                Within four days the pain in my stomach subsided significantly. Over the following two weeks or so, I started to feel more grounded in my body and take an interest in life again. My energy improved a hundredfold as did my sociability.
                Now I have no pain!!
                What I noticed in this healing! If it was a peptic ulcer(s) they have gone completely. There is no pain or tenderness in my stomach or duodenum, which I could feel in the mid abdomen. (Hyliobactor)
                I started to notice lots of little white specks in my stool – probably parasitic eggs! Still taking paraslayer until this is gone completely.
                The liver blend. Amazing! I developed a fungal nail last year and most of my finger nail peeled off. Liver blend has almost cured this! Liver governs nails, tendons, bone, teeth. The nail is almost fully grown back.
                Purge.. Well I decided to try it. It does it’s job! So I’m taking that every couple of night’s now, just one little spoonful. It keeps everything moving..

                As regards the hospital, I received a date for late May! Good job I don’t rely on those services to keep me healthy!
                Massive thanks for the unending support of Gavin and his team.

              12. Rated 5 out of 5

                Tina (verified owner) – August 23, 2022

                Wow where do I start. I started taking interstellar blends at the end of 2021 and nothing in words can describe how they have levelled up my mind, body, spirit and changed my life more in more ways than I could ever imagine. Life is just amazing & I am thankful for Gavin everyday. I am completely off all medication & I just love life so much. Before blends, I was pretty much a walking zombie; constantly getting sick , health issues, on and off medication, I yearned to feel ‘normal’ and I can finally say I am at that point right now and more. Let me give you a summary of some of my favourite blends:

                TRINITY : Before meeting Trinity I was a complete daily mess of anxiety & depression. I would have several panic / anxiety attacks a day & I still remember waking up with my heart feeling like it was off the charts and completely dreading the day. I didn’t want to do anything, I had such a negative outlook on life & was in constant victim mode. I’ve done a complete 180 on Trinity, she’s made the biggest impact on me & I could never live without it again. I don’t have anxiety anymore & I wake up so excited to welcome what the day holds for me. I am so full of gratitude for being alive, I love life so much! Everyone around me constantly describes me as a ray of sunshine. Trinity has helped me fix my relationship with myself, and of course that trickles into my relationships and daily life.

                PLUSH : I am so thankful for Plush as the last medication for me to get off was the contraceptive pill. Like many girls , I was put on it when I was a teenager for acne, supposedly caused by ‘hormone issues’ and had been struggling to get off it for the better part of 10 years. Whenever I tried to get off it, the acne would come back full force , mood swings, my periods super irregular. In May this year, I started on Plush and that was the last time I was on the pill. My acne has NOT come back at all, my periods are regular now, I don’t have any PMS symptoms and I finally feel like my body is a part of me. In a sense I finally feel like myself , I love my body and self now and that’s the best I can describe it. ALSO, I have always looked younger all my life , I am currently 27 and would get mistaken for 20 – 23 all the time. But now new people I meet are shocked I am even over the age of 17- 18! I believe this is because Plush has cleared up old acne scars & sun damage/ pigmentation has also lightened up over the last few months. My face also seems more lifted then it did before Plush as if my skin is producing a lot of collagen again – before Plush I noticed my jowls had began to start drooping, in which I assumed the normal ageing process was starting , but now that’s gone too!

                SPICE & PEEL : All my life I struggled with allergies, I felt like my body was allergic to everything that was part of the earth. I was constantly on a cycle of having hay fever, eczema and hives & one day I realised I had none of these… for months which had never happened before. I don’t remember the last time I touched an anti-histamine pill nor be covering myself in steroid cream. I don’t wake up sneezing or with a blocked nose, I don’t come back with rashes anymore when I go hiking or bush walking. Any cuts I get or bruises heals FAST within days. It’s also eliminated all inflammation I would experience from allergies as well.

                REWIRE : This has to be my favourite blend on par with Trinity for eliminating distractions. Although never being professionally diagnosed due to my refusal to be on medication, I know I have what they call “ADHD”. Rewire, just shuts down the constant chatter in my mind and makes me get things done! I don’t procrastinate nor zone out anymore, and tasks don’t feel like heavy chores. It has stopped me from thinking about food all the time, kept me on strict 22/2 sometimes even longer, eliminated my shopping and nicotine addiction & I have even become the best performer in my team at work. People are sometimes baffled at how I am so efficient, whilst producing top quality work & how great my attention to detail is sometimes. Anything from time management to money management is great now. I understand new concepts so so easy now – currently undertaking a couple courses & it baffles me how I feel like I’m on the ‘limitless’ pill at times. Things just click!

                STOMACH RESET COMBO : And lastly, a homage to Helico , Paraslayer & Purge. To sum it up before introducing this trio, for as long as I could remember, I was struggling with constant food intolerances, insane bloating , gut and digestion issues. Sometimes I would eat & I would automatically throw up, or be in digestion pain for the whole day / night. This trio cured it all. It did take 2 – 3 months or so to clear everything up as my issues were very much in the deep end , but just like my other past health issues, I can’t believe how i am ‘normal’ now. Food makes me so happy now & I am just so grateful I have a beautifully working digestive system now.

              13. Rated 5 out of 5

                Kristen King – October 29, 2022

                Let’s just start by saying if you’re not ready to be your best version in this life stay away. I’ve been on blends for over a year now and I am currently taking 21 different blends but I do have some favorites. They include trinity, nebula, rewire, paraslayer (forever), helico, victorious and now the spaceborn. My whole family takes these blends including my 3 dogs. The clarity, sharpness, balance, and overall happiness we feel on these blends is out of this world.
                Let’s talk about the stomach reset which was the first combo I bought. I had no idea at the time but hellooooo parasites, I didn’t realize I had so many! Wow! It took me down lots of parasite rabbit holes. I’m convinced now they are the root of all disease. I’ve also read ingredients on other companies that sell parasite meds (cellcore) and Interstellars matched plus many more. It’s a win-win!!
                I tell anyone who wants to listen about the blends. It’s become our families Healthcare policy as I’m not interested in our shitty so called Health system in the US, it lies, steals, and kills! My morning coffee is now my favorite time of the day, it’s like I’m putting on my armor for the day!! Thank you Gavin, your blends are truly amazing and life changing. You have a customer for life! ❤️

              14. Rated 5 out of 5

                Antunes (verified owner) – May 23, 2023

                So, it took me quite a while to get around to writing this review because I really wanted to give these herbs a proper test before sharing my thoughts here. Let me tell you, I’ve been dealing with this annoying cough for years now. I’ve seen countless doctors who all told me it was my stomach acid causing the coughing after meals and at bedtime. Their solution? Pop some pills to “manage” it. But honestly, I wasn’t too thrilled about going down that route.

                So, I decided to give this combo a shot instead. And let me tell you, within just two weeks, I started noticing some serious improvements! My coughing reduced by a solid 50%. I kept following Gavin’s advice and took it with some Kefir. Fast forward a couple of months, and guess what? No coughing at all! I was seriously blown away.

                Then I got a bit careless as I was running out of the supply, so I stopped taking the herbs. And you know what happened? Yep, my cough gradually crept back in. That’s when I realized that these herbs were really doing wonders for my GI issues and reflux.

                Oh, and let me tell you about the “purge”. I read in the reviews that it’s better to start slow, so I waited two weeks after taking Helico and Paraslayer before giving Purge a shot. I took 1/4 of a teaspoon as I felt that lower amounts wasnt working. And boy, did it work! After a few trips to the toilet, I saw some seriously nasty parasites coming out. The other times I tried the purge, nothing quite as horrifying came out, so I guess it had cleaned myself out pretty well the first time around!

                Honestly, if you’re struggling with stomach problems, I totally recommend giving this combo a go. It’s been a game-changer for me in terms of tackling my cough and getting my GI health back on track.

                Thanks Gavin for everything!

              Add a review Cancel reply

              Your email address will not be published. Required fields are marked *

              Related products

              • INTERSTELLAR SHILAJIT

                INTERSTELLAR SHILAJIT

                Rated 5.00 out of 5
                $99.00
                Select options This product has multiple variants. The options may be chosen on the product page
              • INTERSTELLAR BLEND ALZ NEUROPROTECTOR 200:1 CONCENTRATION

                ALZ (Neuroprotector)

                Rated 5.00 out of 5
                $275.00
                Select options This product has multiple variants. The options may be chosen on the product page
              • SUPER TONIC HAIR (Hair & Scalp Health)

                SUPER TONIC HAIR (Hair & Scalp Health)

                Rated 5.00 out of 5
                $275.00
                Select options This product has multiple variants. The options may be chosen on the product page
              • TRINITY (Top Seller! Obliterates Anxiety, Depression & Stress)

                TRINITY (Top Seller! Obliterates Anxiety, Depression & Stress)

                Rated 5.00 out of 5
                $275.00
                Select options This product has multiple variants. The options may be chosen on the product page
              • On Sale
                SPICE & PEEL 20:1 COMBO - Save 33%!

                SPICE & PEEL 20:1 COMBO – Save 33%!

                Rated 5.00 out of 5
                $150.00 Original price was: $150.00.$100.00Current price is: $100.00.
                Select options This product has multiple variants. The options may be chosen on the product page
              • APIGENIN

                APIGENIN

                Rated 5.00 out of 5
                $275.00
                Select options This product has multiple variants. The options may be chosen on the product page
              © 2025 Interstellar Blends | All Rights Reserved
              Privacy Policy Terms and Conditions
               interstellar herbs, interstellar blend, anti-aging herbs, longevity supplements, intermittent fasting benefits, herbal blends for health, nootropic formulas, herbal remedies for anxiety, skin rejuvenation supplements, anti-wrinkle natural products, detox supplements, herbal support for mental clarity
              interstellar herbs, interstellar blend, anti-aging herbs, longevity supplements, intermittent fasting benefits, herbal blends for health, nootropic formulas, herbal remedies for anxiety, skin rejuvenation supplements, anti-wrinkle natural products, detox supplements, herbal support for mental clarity interstellar herbs, interstellar blend, anti-aging herbs, longevity supplements, intermittent fasting benefits, herbal blends for health, nootropic formulas, herbal remedies for anxiety, skin rejuvenation supplements, anti-wrinkle natural products, detox supplements, herbal support for mental clarity
                   interstellar herbs, interstellar blend, anti-aging herbs, longevity supplements, intermittent fasting benefits, herbal blends for health, nootropic formulas, herbal remedies for anxiety, skin rejuvenation supplements, anti-wrinkle natural products, detox supplements, herbal support for mental clarity    interstellar herbs, interstellar blend, anti-aging herbs, longevity supplements, intermittent fasting benefits, herbal blends for health, nootropic formulas, herbal remedies for anxiety, skin rejuvenation supplements, anti-wrinkle natural products, detox supplements, herbal support for mental clarity    
                ✕

                Login

                Lost your password?

                Create an account?